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ABSTRACT 
 
 
RENAL BASOLATERAL TRANSPORT OF 
GLUCURONIDES AND OTHER ORGANIC ANIONS 
IN RAT IN VITRO MODELS 
by Sarah L. Miles 
Glucuronidation is a common Phase II biotransformation reaction that increases the 
hydrophilicity, and thus elimination, of toxins, xenobiotics, and endogenous compounds.  
Previous studies suggest that the kidney can secrete glucuronide conjugates, but the renal 
transport mechanisms for glucuronide secretion have not been determined.  Based on the 
chemical nature of glucuronide metabolites, it is hypothesized that organic anion transporter 
(OAT) proteins along the basolateral membrane of the renal proximal tubule promote renal 
accumulation of glucuronide conjugates. The purpose of this study was to develop a rat renal 
proximal tubule model which demonstrates OAT activity and by which the contribution of OAT in 
the renal accumulation of glucuronide metabolites could be assessed.  In the current study two in 
vitro models were established; freshly isolated renal proximal tubules (IRPTs), and renal cortical 
slices (RCSs) from the male Fischer 344 rat.  These models demonstrate time-, temperature- and 
probenecid-sensitive uptake of prototypical OAT1 and OAT3 substrates fluorescein (FL) and 14C-
p-aminohippuric acid (PAH), and the prototypical OAT 3 selective substrate 3H-estrone sulfate 
(ES).  Accumulation of 14C-4-acetamidophenyl-β-D-glucuronide (AG) was found to be time-
dependent, but not temperature- or probenecid-sensitive in IRPTs.  In the RCSs, AG uptake was 
time-dependent, but only minimally temperature- and probenecid-sensitive.  
Accumulation/inhibition studies with FL, PAH, ES and AG indicate very limited interaction 
between AG and OAT.  PAH uptake was not affected by other glucuronides (i.e. testosterone 
glucuronide, methylumbelliferyl glucuronide) in IRPTs or RCSs.  Studies using RCSs from 
Sprague-Dawley rats yielded comparable results to those found in Fischer 344 rat.  In all models, 
accumulation of 14C-AG was not inhibited by excess unlabeled AG.  These results suggest that in 
these rat models, AG does not appear to be a substrate for renal basolateral membrane OAT 
proteins; that the contribution of OAT in the basolateral membrane transport of AG (and 
potentially other glucuronide metabolites) is minimal; and accumulation of AG does not appear to 
be a protein carrier-mediated process.  Thus, rat renal proximal tubular cells do not appear to 
facilitate the accumulation of glucuronide conjugates, and thus do not appear to contribute to the 
renal secretion of glucuronide conjugates. 
iv 
DEDICATION 
 
I wish to dedicate this work to my family.  To my husband, Dan, I am forever 
thankful for your friendship, love, continual support and endless patience through 
this long journey. To my father and mother for their years of support, 
encouragement and listening, I would not have finished this without you.  
 
 
v 
 
ACKNOWLEDGMENTS 
 
I would like to express my sincerest gratitude to my mentor and advisor, Dr. Gary 
O. Rankin.  His support, guidance, and optimism throughout this project have been 
the key to its completion.  I am also grateful to Dr. Gruetter, Dr. Niles, and Dr. 
Valentovic who have been instrumental in helping to shape and mold this project 
as decisions about direction needed to be made.  I would like to extend special 
thanks to Dr. Lawrence H. Lash who provided his expertise in the renal cortical cell 
isolation technique which was later adapted for use in this project. To Dr. Carlotta 
E. Groves, for providing her expertise in renal organic anion transport and aiding in 
data analysis, her assistance is deeply appreciated. 
Special thanks to technicians John Ball, Dianne Anestis and Carla Cook for their 
training and support throughout this project.  
I would also like to acknowledge and express my deepest appreciation to Dr. Eliza 
Robertson.  Her friendship and moral support during these years have been a 
blessing. Thanks for everything. 
vi 
 
TABLE OF CONTENTS 
 
 
ABSTRACT .......................................................................................................................... iii 
DEDICATION ........................................................................................................................iv 
ACKNOWLEDGMENTS ......................................................................................................v 
TABLE OF CONTENTS......................................................................................................vi 
LIST OF FIGURES ............................................................................................................ viii 
LIST OF TABLES................................................................................................................xii 
LIST OF SYMBOLS / NOMENCLATURE ................................................................... xiii 
CHAPTER I .............................................................................................................................1 
INTRODUCTION......................................................................................................................1 
1.1 Glucuronides and renal organic anion transport...............................................1 
1.2 Hypothesis................................................................................................................2 
1.3 Selection of animal species and in vitro models ...............................................2 
CHAPTER II............................................................................................................................4 
REVIEW OF LITERATURE ......................................................................................................4 
2.1 Glucuronides............................................................................................................4 
2.2 Role of the Kidney in Organic Anion Excretion ...............................................16 
2.3 Organic Anion Transporter Proteins involved .................................................26 
in Renal Secretion of Organic Anions......................................................................26 
2.4 Renal Transport of Prototypical Organic Anions ............................................46 
2.5 Summary ................................................................................................................53 
CHAPTER III.........................................................................................................................55 
METHODS ............................................................................................................................55 
3.1 Animals ...................................................................................................................55 
3.2 Materials .................................................................................................................55 
3.3 Equipment ..............................................................................................................57 
3.4 Isolation of Renal Proximal Tubules (IRPT) ....................................................58 
3.5 Characterization of proximal tubules.................................................................60 
3.6 Toxicity experiments in IRPTs............................................................................65 
3.7 IRPT model characterization for organic anion transport (OAT) .................67 
3.8 14C-Acetamidophenyl-β-d-glucuronide (AG)  
accumulation studies in IRPTs..................................................................................76 
3.9 Western blot analysis for OAT1 and OAT3 in IRPTs and HK2 cells ..........78 
vii 
3.10 Accumulation studies with OAT substrates in 
renal cortical slices (RCS)..........................................................................................80 
3.11 14C-acetamidophenyl-β-D-glucuronide (AG)  
accumulation studies in RCS ....................................................................................83 
3.12 14C-AG accumulation studies in RCSs from male Sprague-Dawley rat ..85 
3.13 Statistics ...............................................................................................................86 
CHAPTER IV ........................................................................................................................87 
RESULTS .............................................................................................................................87 
4.1 Studies Using Isolated Renal Proximal Tubules (IRPTs) .............................87 
4.2 Studies in Renal Cortical Slices (RCS)...........................................................131 
CHAPTER V .......................................................................................................................151 
DISCUSSION ......................................................................................................................151 
5.1 Characterization of IRPTs .................................................................................151 
5.2 Toxicity Studies ...................................................................................................151 
5.3 OAT1 and OAT3 studies in IRPTs ..................................................................153 
5.4 Acetamidophenyl glucuronide accumulation in IRPTs ................................155 
5.5 OAT1 and OAT3 studies in RCSs ...................................................................157 
5.6 Acetamidophenyl glucuronide accumulation in RCSs.................................159 
5.7 Interaction of glucuronide metabolites with OAT1 and OAT3 
in IRPTs and RCSs ...................................................................................................161 
5.8 Conclusion............................................................................................................162 
5.9 Future Directions.................................................................................................164 
Bibliography ......................................................................................................................167 
Appendix ............................................................................................................................185 
Curriculum Vitae ..............................................................................................................202 
viii 
 
LIST OF FIGURES 
 
Figure 2.1 Mechanism of glucuronidation……………………………………..……p. 6 
Figure 2.2 Formation of acetaminophen and diclofenac glucuronides………..…p. 8 
Figure 2.3 Role of glucuronidation in the activation of xenobiotics to toxic           
metabolites……………………………………………………………………………p. 13 
Figure 2.4 Structure of the renal nephron………………………………...……….p. 20 
Figure 2.5 A simplified overview of proximal tubular function………………...…p. 21 
Figure 2.6 Model of organic anion transporters in the renal proximal tubule…..p. 25 
Figure 3.1 Schematic diagram of renal cortical tissue before and after Percoll 
density centrifugation………………………………………………………………..p. 61 
Figure 4.1 Freshly isolated renal proximal tubules from male Fischer 344 rat...p. 89 
Figure 4.2 Percent LDH release from IRPTs treated with AG…………………..p. 91 
Figure 4.3 Percent LDH release from IRPTs treated with APAP……………….p. 92 
Figure 4.4 Percent LDH release from IRPTs treated with DC…………………..p. 93 
Figure 4.5 Effect of AG on nucleotide levels in IRPTs……………………………p. 94 
Figure 4.6 Effect of APAP on nucleotide levels in IRPTs………………………..p. 95 
Figure 4.7 Effect of DC on nucleotide levels in IRPTs…………………………...p. 96 
Figure 4.8 Time-dependent accumulation of FL in IRPTs…………………...…p. 100 
ix 
Figure 4.9 The effect of temperature on FL accumulation in IRPTs…………..p. 101 
Figure 4.10 The effect of probenecid on FL accumulation in IRPTs…………..p. 102 
Figure 4.11 IC50 determination of probenecid for FL uptake in IRPTs………...p. 103 
Figure 4.12 The effect of ouabain on FL accumulation in IRPTs…………...…p. 104 
Figure 4.13 The effect of benzylpenicillin on FL accumulation in IRPTs…...…p. 105 
Figure 4.14 The effect of dehydroepiandrosterone sulfate on FL accumulation in 
IRPTs………………………………………………………………………………..p. 106 
Figure 4.15 The effect of acetamidophenyl glucuronide on FL accumulation in 
IRPTs………………………………………………………………………………..p. 107 
Figure 4.16 The effect of probenecid on PAH accumulation in IRPTs………..p. 110 
Figure 4.17 IC50 determination of probenecid for PAH uptake in IRPTs………p.111 
Figure 4.18 The effect of acetamidophenyl glucuronide on PAH accumulation in 
IRPTs………………………………………………………………………………..p. 112 
Figure 4.19 The effect of testosterone glucuronide (TG), methylumbelliferyl 
glucuronide (MUG) and acetamidophenyl glucuronide (AG) on PAH accumulation 
in IRPTs…………………………………………………………………………….p. 113 
Figure 4.20 The effect of temperature on estrone sulfate accumulation in 
IRPTs………………………………………………………………………………...p.116 
Figure 4.21 The effect of probenecid on estrone sulfate accumulation in 
IRPTs…..……………………………………………………………………………p. 117 
Figure 4.22 The effect of self-inhibition on estrone sulfate accumulation in 
IRPTs………………………………………………………………………………..p. 118 
x 
Figure 4.23 The effect of acetamidophenyl glucuronide on estrone sulfate 
accumulation in IRPTs……………………………………………………………p. 119 
Figure 4.24 Time-dependent accumulation of acetamidophenyl glucuronide in 
IRPTs…………………………………………………………………………….…..p.123 
Figure 4.25 The effect of temperature on acetamidophenyl glucuronide 
accumulation in IRPTs……………………………………………………………..p. 124 
Figure 4.26 The effect of probenecid on acetamidophenyl glucuronide 
accumulation in IRPTs……………………………………………………………..p. 125 
Figure 4.27 The effect of self-inhibition on acetamidophenyl glucuronide 
accumulation in IRPTs……………………………………………………………..p. 126 
Figure 4.28 The effect of estrone sulfate on acetamidophenyl glucuronide 
accumulation in IRPTs……………………………………………………………..p. 127 
Figure 4.29 The effect of D-saccharic acid 1,4-lactone on acetamidophenyl 
glucuronide accumulation in IRPTs……………………………...……………….p. 128 
Figure 4.30 Western blot analyses for OAT1 and OAT3…...............................p. 130 
Figure 4.31 Mannitol accumulation in RCSs…………………………………….p. 133 
Figure 4.32 The effect of probenecid on PAH accumulation in RCSs………...p. 135 
Figure 4.33 The effect of testosterone glucuronide (TG), methylumbelliferyl 
glucuronide (MUG) and acetamidophenyl glucuronide (AG) on PAH accumulation 
in RCSs……………………………………………………………………………...p. 136 
Figure 4.34 Time-dependent accumulation of ES in RCSs…………………….p. 138 
xi 
Figure 4.35 The effect of probenecid and temperature on ES accumulation in 
RCSs……………………………………………………………………………...…p. 139 
Figure 4.36 Time-dependent accumulation of acetamidophenyl glucuronide in 
RCSs……………………………………………………………………………...…p. 142 
Figure 4.37 The effect of temperature and probenecid on AG accumulation in 
RCSs………………………………………………………………………………...p. 143 
Figure 4.38 The effect of p-aminohippuric acid and estrone sulfate on AG 
accumulation in RCSs…...………………………………………………………...p. 144 
Figure 4.39 The effect of self-inhibition on AG accumulation in RCSs………..p. 145 
Figure 4.40 The effect of temperature and probenecid on AG accumulation in 
RCSs from Sprague-Dawley rat…………………………………….………….…p. 148 
Figure 4.41 The effect of p-aminohippuric acid on AG accumulation in RCSs from 
Sprague-Dawley rat………………………………………………………………..p. 149 
Figure 4.42 The effect of self-inhibition on AG accumulation in RCSs from 
Sprague-Dawley rat……………………………………………………………….p. 150 
xii 
 
LIST OF TABLES 
Table 1. Types of glucuronides formed from various chemical substrates………p. 9  
Table 2. Properties of basolateral OAT transporters in renal proximal                               
tubules.................................................................................................................p. 28 
Table 3. PAH substrate specificities for basolateral OAT transporters…………p. 33 
Table 4. Substrate specificity of various compounds in selected OAT 
isoforms……………………………………………………………………………….p. 49 
Table 5. Substrate specificity of probenecid in selected OAT isoforms……...…p. 52 
Table 6. Biochemical characteristics of IRPTs from male F344 rat……………..p. 89 
 
 
xiii 
 
LIST OF SYMBOLS / NOMENCLATURE 
 
 
ACE – angiotensin-converting enzyme 
ADP – adenosine diphosphate 
AG – acetaminophen glucuronide/acetamidophenyl glucuronide 
AMP – adenosine monophosphate 
ANOVA- analysis of variance 
AP – alkaline phosphatase 
APAP- acetaminophen 
ATP – adenosine triphosphate 
AZT - azidothymidine 
BLMV – basolateral membrane vesicle 
BSP - bromosulfopthalein 
BSA – bovine serum albumin 
cAMP – cyclic adenosine monophosphate 
cGMP – cyclic guanosine monophosphate 
CHO cells – Chinese hamster ovary cells 
CLCR- creatinine clearance 
CLREN – renal clearance 
COS7 -  
DBSP – dibromosulophthalein 
DEXA – dexamethasone 
DHEAs- dehydroepiandrosterone sulfate 
DC – diclofenac 
DT – distal tubule 
E2-17βG – β-estradiol 17β-D-glucuronide 
EGF – epidermal growth factor 
ERK – extracellular signal regulated kinase 
xiv 
ES – estrone sulfate 
F344 – Fischer 344 rat 
FL - fluoresceine 
fu – unbound fraction of drug 
GFR – glomerular filtration rate 
GSH – glutathione 
HB -   
HeLa cells – immortal cell line derived from human cervical carcinoma 
HEK293 cells – human embryonic kidney cell line 
HK – hexokinase 
HK2 – immortalized human kidney cell line 
HX – hypophysectomized 
IRPT(s)- isolated renal proximal tubule(s) 
IC50 – inhibitory concentration (50% inhibition) 
KH – Krebs Henseleit  
LDH – lactate dehydrogenase 
LLC-PK1 – Porcine kidney proximal tubule cell line 
LSC – liquid scintillation counter 
MAPK – mitogen activated protein kinase 
MEK – mitogen activated extracellular-regulated kinase kinase 
MN - mannitol 
mRNA – messenger ribonucleic acid 
MRP2/cMOAT – multidrug resistance transporter  
MUG – methylumbelliferyl glucuronide 
NaDC – sodium dicarboxylate exchanger 
NLT – novel liver transporter 
NKT – novel kidney transporter 
NPT – sodium dependent inorganic phosphate transporter 
NSAID – nonsteroidal anti-inflammatory drug 
OA – organic anion 
xv 
OAT – organic anion transporter 
OATP – organic anion transporting polypeptide 
OK – opossum kidney  
PAH – para-aminohippurate / para-aminohippuric acid 
PB – probenecid 
PG – benzylpenicillin, penicillin G 
PGE2 – prostaglandin E2 
PGF2(α) – prostaglandin F2(α) 
PKA – protein kinase A 
PKC – protein kinase C  
PMA – phorbol 12-myristate 13-acetate 
PT – proximal tubule 
RBF – renal blood flow 
RCS – renal cortical slices 
SD – Sprague-Dawley 
SE – standard error 
SL – D-saccharic acid 1,4-lactone 
T3 – Triiodothyronine 
TEA - tetraethlyammonium 
TG – testosterone glucuronide 
UDP – uridine diphosphate 
UDPG – UDP-glucose 
UDPGA – UDP-glucuronic acid 
UGT – UDP glucuronosyltransferase 
URAT – urate transporter 
UTP – uridine triphosphate 
 
 
 
 
 
 1 
 
 
CHAPTER I 
 
Introduction 
 
1.1 Glucuronides and renal organic anion transport 
 
Glucuronidation is a major Phase two biotransformation reaction that 
increases the hydrophilicity, and thus elimination of toxins, xenobiotics and 
endogenous compounds.  While the liver is the primary site of glucuronidation, 
this reaction also takes place in other organs including the kidney.  Until recently, 
glucuronidation has been considered a detoxification pathway. However, recent 
findings have shown that certain reactive glucuronide conjugates have the 
potential for covalent binding within tissues.  Many drugs are metabolized to 
glucuronide conjugates with potential for inducing toxic reactions.  Several 
analgesics (such as diclofenac, sulindac, and ibuprofen) which are metabolized 
to glucuronide conjugates have been shown to cause various forms of renal 
toxicity.  However, the mechanism of nephrotoxicity for these metabolites has not 
been fully established.   
Results from previous studies suggest that the renal proximal tubule (PT) 
has the ability to secrete glucuronide conjugates. Currently, the transport 
mechanisms within the kidney for glucuronide conjugate transport have not been 
established.  Because of the anionic nature of the glucuronide metabolite, the 
primary transporters of interest are the organic anion transporter (OAT) proteins 
(specifically, OAT1 and OAT3).  The major site of localization of these 
transporters in the kidney is along the basolateral membrane of the PT.  While 
OAT transporters exist on the luminal membrane of the PT as well, the 
basolateral OATs are more likely to be of major importance in the role of 
glucuronide secretion by the kidney.  These OAT proteins transport  organic 
2 
anions (OAs) from the blood into the proximal tubular cells as the initial step in 
secretion.  This initial transport step in secretion is of importance in determining 
how renal proximal tubular cells contribute to the accumulation of glucuronide 
metabolites within the kidney cells. The second step in glucuronide secretion 
involves efflux across the luminal membrane into the luminal fluid.  The luminal 
membrane also contains numerous transporters, both from the OAT family, as 
well as others such as multidrug resistance transporters (MRP) which direct the 
efflux of compounds out of the cell and into the luminal fluid for removal from the 
kidney. With increased understanding of the role of the basolateral OATs to 
glucuronide accumulation, we may better understand the role of these 
metabolites in the potential renal toxicity of compounds which are metabolized to 
glucuronide conjugates.                 
 
1.2 Hypothesis 
 
It is hypothesized that the first step of renal secretion of glucuronide 
conjugates involves organic anion transporters along the basolateral membrane 
of the PT.     
  
1.3 Selection of animal species and in vitro models 
 
 The Fischer 344 rat was chosen as the primary animal model in this study 
due to the fact that the rat shares numerous similar anatomical and physiological 
characteristics similar to humans as well as metabolic pathway similarities, 
allowing for comparisons in absorption excretion and distribution of 
pharmacologic compounds (Kacew and Festing, 1996).  Additionally, the Fischer 
344 rat strain is an inbred strain which remains genetically consistent for many 
generations.  This provides greater data uniformity.  Sprague-Dawley (SD) rats 
were chosen as a secondary animal model for comparison to the Fischer 344 rat 
because the SD rat has been indicated to demonstrate renal secretion of 
3 
acetaminophen glucuronide (AG) (Galinsky and Levy, 1981).  Freshly isolated 
renal proximal tubules (IRPTs) were chosen as a study model because this in 
vitro model provides an enriched population of PT segments where cells are able 
to maintain communication and metabolism.  Access to the basolateral 
membrane of the PT and the contribution of this portion of the kidney to the 
secretion of compounds can be separated from other components of the kidney 
in this model.  Most importantly, one can study the handling of molecules by the 
basolateral membrane of the PT without having to consider a significant 
contribution of the apical membrane.  Isolation of PT fragments involves 
enzymatic collagenase digestion of the cortical tissue.  Once separated from the 
cortical tissue, tubules collapse and access to the luminal membrane is not 
available.  This is important because it enables the separation between secretion 
(basolateral) and reabsorption (luminal) processes of the PT.  Renal cortical 
slices (RCSs) were chosen as a secondary in vitro model to assess glucuronide 
secretion. The use of RCSs also allows for access to the basolateral membrane 
without significant interference from the apical membrane since in this model, 
again, the lumens of the tubules collapse.  The RCS model is useful in addition to 
the IRPT model in that it provides a heterogeneous cell population, the 
orientation of the cortical nephron is maintained, cellular communication and 
metabolism is maintained and no enzymatic digestion is required in the 
establishment of the model (all cellular proteins should be undamaged by any 
enzymatic digestion). Both IRPTs and RCSs have frequently been used as in 
vitro models to study renal transport of xenobiotics in various animal models.   
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CHAPTER II 
 
Review of Literature 
 
2.1 Glucuronides 
 
2.1.1  Glucuronidation and its Role in Bioactivation 
 Glucuronidation is a major Phase II drug-metabolizing reaction.  The 
glucuronidation pathway is catalyzed by UDP-glucuronosyltransferases (UGTs). 
Currently, there are approximately 20 distinct UGTs known in both humans and 
rats.  This superfamily of UGT proteins is divided into 2 families (UGT1, UGT2) 
based on sequence homologies.  UGTs, which catalyze the conversion of 
hydrophobic substrates to hydrophilic glucuronides are found in hepatic and extra 
hepatic tissues. This superfamily yields a range of isozymes, each possessing 
different physical and catalytic properties (Mulder et al., 1990).  Most vertebrates 
are capable of generating UGT-directed glucuronides from a number of 
structurally divergent substances (Tukey and Strassburg, 2000).  Conservation in 
exon/intron organization is maintained in rodents as several UGT2 genes have 
been characterized and shown to contain the same exon/intron branch points 
(Haque et al., 1991; Makenzie and Rodbourn, 1990). The human UGTs range 
from 529 to 534 amino acids in length, with several highly conserved domains 
that are important for membrane targeting and activity.  UGT activity has also 
been shown to be inducible.  Several xenobiotics cause the induction of UGT and 
are broken down into two major classes; (1) the polycyclic aromatic hydrocarbon 
induced UGT and (2) the Phenobarbital induced (PB) UGT (Mulder et al., 1990). 
These compounds result in an increase in UGT enzyme protein as a result of 
increased mRNA levels.  Due to the overlapping substrate specificity of UGTs, 
5 
the glucuronidation of some aglycones may be induced by more than one 
inducer.   
 Glucuronidation involves the transfer of the glucuronic acid group from 
UDP-glucuronic acid (UDPGA) to an acceptor group on a substrate by the 
enzyme UGT (Fig. 2.1). UDPGA is a highly water-soluble compound.  The 
formation of UDPGA involves a two step reaction in the cytosol.  UDPGA is 
synthesized from the precursors glucose-1-phosphate and uridine triphosphate 
(UTP) to form UDP-glucose (UDPG).  UDPG is oxidized by UDPG 
dehydrogenase to UDPGA.  UDPGA must be synthesized in the cell where 
glucuronidation takes place since it is not likely to be taken up by intact cells 
(Mulder et al., 1990). 
Glucuronidation is a microsomal reaction which takes place in the smooth 
endoplasmic reticulum and serves as an important step in converting lipophillic 
substrates into hydrophilic glucuronide metabolites.  Glucuronide metabolites are 
then eliminated from the body through the bile and urine.  The mechanism of 
glucuronidation is an SN2 reaction, the acceptor group of the substrate attacking 
the C1 carbon of the pyranose ring to which uridine diphosphate (UDP) is 
attached in an α-glycosidic bond (Fig. 2.2).  The resulting glucuronide has the β-
glycosidic configuration. Glucuronides can be formed through hydroxyl (alcoholic, 
phenolic), carboxyl, sulfuryl, carbonyl, and amino (primary, secondary, and 
tertiary) linkages (Mulder et al., 1990; Tukey and Strassburg, 2000). Examples of 
various chemical substrates (shown as functional groups) that undergo 
glucuronidation are shown in Table 1.   The reactivity of a given substrate will 
depend on the structure, due to both electronic and steric factors (Mulder et al., 
1990). In addition to structural requirements, substrates for glucuronidation must 
also be sufficiently lipid soluble. The thickness or bulkiness of the substrate 
molecule is important in determining which UDPGT forms will glucuronidate a 
given substrate (Mulder et al., 1990).  Extensive analysis of specific catalytic 
activities attributed to recombinant UGT proteins has demonstrated broad 
overlap of substrates targeted for glucuronidation.  
6 
  
Figure 2.1 Mechanism of glucuronidation.  Glucuronidation involves the transfer of 
the glucuronic acid group from UDP-glucuronic acid (UDPGA) to an acceptor group on a 
substrate by the enzyme UDP-glucuronosyltransferase.  It is synthesized in the cytosol from the 
precursors glucose-1-phosphate and uridine triphosphate (UTP) to form UDP-glucose (UDPG).  
UDPG is oxidized by UDPG dehydrogenase to UDPGA and transported into the smooth 
endoplasmic reticulum.  The mechanism of glucuronidation is a SN2 reaction, the acceptor group 
of the substrate attacking the C1 carbon of the pyranose ring to which UDP is attached in a α-
glycosidic bond. The resulting glucuronide has the β-glycosidic configuration. Glucuronide 
metabolites are then eliminated from the body through the bile and urine    
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While the liver is one of the primary sites of glucuronidation based on 
UDPGT activity, UDPGT is also localized in the kidney, mainly in the proximal 
tubular cells (Mulder, 1990; Tukey and Strassburg, 2000).  It has been reported 
that in the rat, the kidney lacks some of the major UDPGT activities present in 
the liver (Lucier and McDaniel, 1977), in particular testosterone (Lucier and 
McDaniel, 1977) and morphine (Rush et al., 1983).  In humans, UDPGT activity 
is present in the kidney, where bile acids are readily conjugated (Matern et al., 
1984; Parquet et al., 1985)   High levels of glucuronidation also occur in the 
intestinal mucosa.  In the rat intestine, the major UDPGT enzyme present is the 
planar phenol UDPGT, which is the major xenobiotics-metabolizing form 
(Hartiala, 1973; Koster et al., 1986).  Most other organs and tissues also possess 
glucuronidation activity, although it may be very low (Mulder et al., 1990).  
 It is important to note that the kidney has the potential to come in contact 
with glucuronides formed at both extrarenal sources such as the liver and small 
intestine, as well as at intrarenal sources by conjugation of the parent xenobiotic 
within the PT cell. Until recently, glucuronidation has been accepted to be a 
detoxification reaction that terminated the biological activity of both endogenous 
compounds as well as xenobiotics.  As opposed to the previously accepted 
detoxification mechanism, some glucuronides (particularly those of the acyl 
classification) are now understood to be potentially reactive intermediates (Smith 
et al., 1990; Van Breemen and Fenselau, 1986; Hyneck et al., 1988).  Many of 
these reactive glucuronide metabolites have been shown to covalently bind to 
tissue and serum proteins, and will be discussed in greater detail in the next 
section. 
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Figure 2.2.  Formation of acetaminophen and diclofenac glucuronides.  
Conjugation of acetaminophen with glucuronic acid leads to the formation of an                   
ethereal glucuronide moiety, while conjugation of diclofenac with glucuronic acid 
leads to the formation of an acyl glucuronide moiety.  Both conjugates are readily 
excreted in the urine.   
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Table 1.  Types of glucuronides formed from various chemical substrates. 
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2.1.2 Toxicity Associated with Glucuronides 
 
As shown in Fig 2.2, glucuronidation of a hydroxyl group results in an 
ether-type glucuronide while glucuronidation of a carboxy group results in an 
ester-type (acyl) glucuronide.  While it has previously been accepted that 
glucuronidation was a detoxification mechanism, in the past several years, many 
published reports have indicated that some acyl glucuronides are potentially 
reactive intermediates that undergo not only hydrolysis and intramolecular acyl 
migration, but also bind reversibly to proteins in vivo and in vitro (Faed, 1984; van 
Breemen and Fenselau, 1985; Spahn-Langguth and Benet, 1992).  Acyl 
glucuronides have been found to be electrophiles, reacting with sulfhydryl and 
hydroxyl groups resulting in covalent binding of the molecule to tissue and 
plasma proteins (Stogniew and Fenselau, 1982).  
Covalent binding to protein can occur by two mechanisms, the first being 
nucleophillic displacement where a protein functional group reacts at the 
carboxylic (acyl) carbon of the acyl glucuronide leaving the protein irreversibly 
bound to the drug moiety and releasing glucuronic acid (Fig 2.3).  The second 
mechanism is via an acyl migration by which the aglycone migrates from the 1-
hydroxyl group of the glucuronic acid to the 2,3 and 4-hydroxyl groups of the 
glucuronic acid portion. The aldehyde group of the ring open tautomer then 
condenses with a lysine group on the protein to form an imine. At the completion 
of the reaction, the irreversibly bound product still contains a glucuronic acid 
which acts as a covalent link between protein and drug (Fig. 2.3).  In spite of the 
presence of glucuronic acid in other types of glucuronides (N-, S-, C-, or ether 
glucuronides) they do not undergo acyl migration and therefore no ring opening 
and aldehyde formation are possible.  Covalent binding to protein has been 
found for a number of compounds forming acyl-glucuronide metabolites. Studies 
have demonstrated that in vivo binding to plasma proteins of tolmentin (Hyneck 
et al., 1988), fenoprofen (Volland et al., 1991), diflunisal and probenecid 
(McKinnon and Dickinson, 1989) is correlated with exposure to the reactive acyl 
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glucuronide metabolites of these xenobiotics. Clofibric acid was also shown to 
irreversibly bind to rat liver tissue in vivo in a dose dependent manner (Sallustio 
et al., 1991).  King and Dickinson (1993) have further demonstrated the covalent 
binding of difluinisal via its acyl glucuronide metabolite to plasma proteins, as 
well as kidney, small intestine and large intestine tissues of rat, with such binding 
increasing with the duration of dosing.  Other studies have demonstrated 
irreversible covalent binding of suprofen to renal tissue of rat (Smith and Liu, 
1995). This study by Smith and Liu (1995) further demonstrated that enhanced 
exposure of a particular organ to reactive acyl glucuronides due to excretion by 
or metabolism within the organ may result in enhanced covalent binding to 
tissues within that organ.  McGurk et al. (1996) also demonstrated irreversible 
binding of mefenamic acid via its acyl glucuronide metabolite to human serum 
albumin as well as cellular proteins in culture. Mefenamic acid, a nonsteroidal 
anti-inflammatory drug (NSAID) commonly used to relieve pain, has been 
implicated in several cases of nephrotoxicity including acute renal failure and 
tubulointerstitial nephritis (Woods, 1981; Jenkins et al., 1988).  
Covalent binding of reactive acyl glucuronide metabolites to cellular 
constituents can result in acute toxicity, hypersensitivity reactions, mutagenesis 
or carcinogenesis, although binding can occur without any harmful effects (Faed, 
1984).  From studies reported in the literature, there is evidence that antibodies 
occur in the blood of patients at low levels following administration of 
acetylsalicylic acid and valproic acid (Amos et al., 1971; Williams et al., 1992). An 
immunological mechanism may be the basis for anaphylactic reactions as well as 
organ toxicity, since covalent binding may be followed by antigen-antibody 
formation.  Thus, acyl glucuronides may act as haptens, which upon binding to 
proteins become immunogens and induce antibody production (Zia-Amirhosseini, 
1994).   
It is important to note that an unacceptably high incidence of significant 
adverse drug reactions has been reported for NSAIDs of the aryl-alkyl acid class.  
Six of the 25 drugs removed from the U.S. and British market between 1964 and 
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1983 because of severe toxicity were acid compounds, five of which were 
NSAIDs (Spahn-Langguth and Benet, 1992).  All six of these drugs 
(benoxaprofen, ticrynafen, ibufenac, zomepirac, indoprofen and aclofenac) are 
metabolized by humans to acyl glucuronides, i.e., reactive intermediates (Bakke 
et al., 1984).  For zomepirac, the common NSAID toxicities of gastric irritation, 
nephritis, and acute renal failure were not a major factor in its withdrawl from the 
market. Removal was rather due to a high incidence of anaphylactic or 
anaphylactoid reactions (Corre and Rothstein, 1982; O’Brien and Bagby, 1984). 
Case reports have also described such reactions for tolmentin (Rossi and Knapp, 
1982), sulindac, ketoprofen, acetylsalicylic acid and ibuprofen (O’Brien and 
Bagby, 1984). Additionally, in 1987, suprofen was withdrawn from the market due 
to cases of unexplained acute renal toxicity (Strom et al., 1989; Hart et al., 1987).  
Furthermore, disease states which compromise the excretion of acyl 
glucuronides may enhance exposure of the body to these reactive metabolites 
and lead to increased irreversible binding to tissue proteins. Whether such 
enhanced exposure with subsequent covalent binding is a causative factor 
observed in toxicity to that organ (where binding occurs) is still unknown.  
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Figure 2.3.  Role of glucuronidation in the activation of xenobiotics to toxic                  
metabolites.  Covalent binding to protein can occur by two mechanisms, the first being 
nucleophillic displacement where a protein functional group reacts at the carboxylic (acyl) carbon 
of the acyl glucuronide leaving the protein irreversibly bound to the drug moiety and releasing 
glucuronic acid.  The second mechanism is via an acyl migration by which the aglycone migrates 
from the 1-hydroxyl group of the glucuronic acid to the 2,3 and 4-hydroxyl groups of the 
glucuronic acid portion. The aldehyde group of the ring open tautomer then condenses with a 
lysine group on the protein to form an imine. In this mechanism the glucuronic acid acts as a 
bridge between the acyl residue and the protein becoming part of the adduct. 
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2.1.3 Renal Formation of Glucuronide Conjugates 
 
 Immunohistochemical studies conducted in human and rat indicate that 
the highest concentration of renal UDPGTs is in the PT (Lock and Reed, 1998).  
Renal glucuronide formation has been confirmed in studies using perfused 
kidneys from both rats and humans for a number of phenols (4-
dimethylaminophenol, p-nitrophenol, paracetamol) (Elbers et al., 1980; Diamond 
and Quebbemann, 1981; Emslie et al., 1981). Renal glucuronidation varies for 
different species and substrates.  For example, in humans clearance of 
indomethacin occurs primarily by renal glucuronidation (Moolenaar et al., 1992). 
Vree and Van der Ven (1999) have shown that the acyl glucuronide metabolite of 
furosemide is also formed in part by the kidney tubules in humans. However, 
human renal synthesis of acetaminophen glucuronide from acetaminophen is 
negligible (Morris and Levy, 1984).   In rat, it has been found that acetaminophen 
glucuronide is synthesized from acetaminophen by the kidney and secreted into 
the urine (Newton et al., 1982; Li et al., 2004). Li et al. (2004) demonstrated that 
8.66 ± 2.99 % of the administered dose of acetaminophen appeared in the urine 
as the glucuronide conjugate.  This is in close agreement with Hart et al. (1980), 
who demonstrated in isolated perfused rat kidney that 10% of paracetamol 
appeared in the urine as the glucuronide conjugate.  It has also been 
demonstrated that estradiol-17β-D-glucuronide (E2-17βG) is also formed within 
the kidney and undergoes tubular secretion (Kanai et al., 1996).   It can be seen 
that the kidney has the ability to contribute to the glucuronidation of numerous 
compounds.  Thus total renal clearance of glucuronide conjugates must consider 
the renal contribution to glucuronide metabolites found in the urine. When the 
liver and the kidneys metabolize a drug into identical products and the kidney 
excretes these products in the urine, the differences in metabolic pathways are 
not detectable. Therefore, there is the potential for the resulting calculation of 
renal clearance (CLRE) to be too high (Vree et al., 1992).   
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2.1.4 Renal Handling of Glucuronide Conjugates 
 
 It has been well established that the kidney has the ability to efficiently 
excrete glucuronide conjugates (Braun et al.,. 1957; Schachter and Manis, 1958: 
Yuan, 2002).  While glucuronide conjugates can enter the proximal tubular filtrate 
via glomerular filtration, it has also been indicated that the kidney has the ability 
to secrete glucuronides (Duggin and Mudge, 1975; Galinsky and Levy, 1981; 
Watari et al., 1983; Somogyi et al., 1993; Van Crugten et al., 1991; Schachter 
and Manis, 1958).  Since glucuronide conjugates in general are ionized at 
physiological pH and are highly polar chemical species, glucuronides are subject 
to a diffusional barrier in their movement across biological membranes (Evans, 
1996). Glucuronide conjugates are generally acidic compounds and are generally 
more hydrophilic than their parent aglycones. Most glucuronide conjugates have  
pKa values of between 3-4, regardless of the pKa of the parent compound (Smith 
and Williams, 1966). Therefore, at physiological pH they are almost entirely 
ionized and are highly polar.  Given their polarity, movement of glucuronide 
conjugates between the primary site of formation (hepatocytes), the systemic 
circulation, and target cells (renal proximal tubular cells in this discussion) may 
be restricted by their limited ability to passively diffuse across membrane barriers 
and may depend on carrier-mediated transport systems that are present in the 
cellular membranes. The movement of glucuronide conjugates across 
membranes has only recently begun to be investigated. Cellular transport of 
glucuronide conjugates has primarily been studied in the hepatocyte, the primary 
site of glucuronide formation (Sallusito et al., 2000). It has been shown that 
glucuronide metabolites are substrates for organic anion transporting polypeptide 
(oatp) transporters and multispecific organic anion transporter (OAT) proteins in 
the basolateral (sinusoidal) membrane of the hepatocyte (Sallusito et al., 2000). 
Sallusito et al. (2000) demonstrated that the sinusoidal uptake of gemfibrozil acyl 
glucuronide occurs against a 50 fold concentration gradient and is inhibited by 
the organic anion dibromosulophthalein (DBSP), a substrate for the oatp/OATP 
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transporter proteins.  Additionally the uptake of bilirubin acyl glucuronide into rat 
hepatocyte sinusoidal membrane vesicles is saturable, temperature dependent, 
trans-stimulated, osomotically sensitive, electrogenic, Na+ independent and 
competitively inhibited by bromosulfopthalein (BSP), another substrate for 
oatp/OATP proteins (Adachi  et al., 1990).  
While the hepatic handling of glucuronide conjugates has begun to be 
investigated, currently very little is known about how the kidney secretes 
glucuronide conjugates, and more specifically, what transport protein(s) along the 
basolateral membrane of the PT cells are involved in transporting glucuronide 
conjugates from the blood across the basolateral membrane and into the PT 
cells.  The kidney possesses several of the same OAT proteins as those found in 
hepatocytes (Kusuhara et al., 1999; Sekine et al., 1998). Isern et al. (2001) 
showed that Oatp1 expressed in Xenopus oocytes transports estradiol-17-β-
glucuronide (Km ~ 5 µM).  Multispecific organic anion transporter 3 (hOAT3), has 
also been shown to mediate the transport of estradiol-17-β-glucuronide (Cha et 
al., 2000).  These and other OAT proteins in the kidney may potentially contribute 
to the renal secretion of glucuronide conjugates along the renal PT.   
  
2.2 Role of the Kidney in Organic Anion Excretion 
 
2.2.1 Renal Excretion 
 
 Maintenance of fluid and electrolyte homeostasis is a critical function of 
the kidney.  The kidney also plays an important role in the elimination of 
numerous xenobiotics and endogenous compounds.  Three processes are 
involved in the renal handling of drugs; glomerular filtration, tubular reabsorption 
and tubular secretion.   The functional units of the kidney, the nephrons (Fig 2.4), 
determine the degree of renal elimination of compounds through a balance of 
filtration, reabsorption and secretion (Fig. 2.5). 
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Renal clearance (CLREN) is defined as the hypothetical volume of plasma 
from which a substance is completely removed per unit of time (usually one min) 
in one pass through the kidney.  Clearance of a compound depends on 
glomerular filtration rate (GFR), the rate of tubular secretion and the rate of 
tubular reabsorption of that compound.   
Glomerular filtration is passive filtration of the blood as the blood flows 
through the glomeruli of the kidney.  The extent to which a drug or drug 
metabolite is filtered depends on the molecular size and protein binding.  GFR is 
determined or estimated by measuring the clearance of a filtered substance that 
is not reabsorbed, metabolized or secreted and is calculated as: 
Clearance * Plasma concentration = Urine concentration * Urine volume 
GFR= Urine concentration* Urine volume/ Plasma concentration 
 If ClREN depends only on filtration,  
ClREN = GFR * fu 
where fu is the unbound fraction of drug and GFR is the glomerular filtration rate 
(normal human GFR = 125 ml/min). When this number is compared to renal 
blood flow (1200 ml/min) it can be seen that only ~25% of blood is filtered at the 
glomerulus.   
The pores within the capillary endothelium and the ultrafiltration 
membrane of the glomerulus allow only small molecules (less than 400 – 600 A 
in diameter or about 5 kDa molecular weight) to be filtered into the tubular fluid. 
Large molecules such as most proteins, and therefore the drugs bound to them, 
cannot pass through the glomerulus, leaving only small, unbound compounds to 
be filtered at the glomerulus. General kidney function can also greatly affect 
glomerular filtration. Glomerular filtration is generally estimated by measuring 
creatinine clearance (CLCR).  Creatinine is an endogenous compound that is 
freely filtered at the glomerulus and is not protein bound (fu = 1). Therefore, for 
creatinine 
ClCR = GFR 
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However, it is important to note that measures of renal drug clearance using 
CLCR do not account for tubular secretion or reabsorption of drugs (Perri et al.,  
2003).  An additional problem with using creatinine to estimate GFR is that, 
although freely filtered by the glomerulus, creatinine is also secreted in small 
amounts by the renal tubules.  The extent of tubular secretion varies from one 
individual to another, as does renal function, which may introduce large errors in 
individuals with impaired renal function.  Another more accurate measure of GFR 
can be obtained through the measurement of inulin clearance.  Inulin is a 
polymer of fructose which is freely filtered at the glomerulus and is neither 
reabsorbed nor secreted by the renal tubules.  It is metabolically inert and 
cleared only by the kidney.  
Tubular reabsorption also affects the renal clearance of a compound. The 
tubular epithelium is the site of reabsorption of many substances, with molecules 
being reabsorbed (by transport or diffusion) across the luminal membrane of the 
tubules from the filtrate into the intracellular cytoplasm.  From there, the 
molecules can pass across the basolateral membrane (by transport or diffusion) 
back into the plasma.  As solutes are reabsorbed from the tubular lumen, water 
follows.  While GFR is about 120 ml/min, reabsorption of solutes and water along 
the proximal, distal, and collecting ducts of the kidney is so extensive that only 1 
– 2 ml/min of the filtered water is eliminated as urine.  Reabsorption is important 
for many endogenous substances (e.g., glucose) as well as some xenobiotics.  
Compounds may be reabsorbed either by passive diffusion, if the compound is 
lipid soluble and nonionized, or by carrier-mediated transport if it is a charged 
molecule. It is important to note that the pH of the tubular lumen can also affect 
reabsorption by affecting the ratio of drug in non-ionized and ionized form.  With 
tubular reabsorption, the clearance of a compound may then seem smaller than 
expected by glomerular filtration alone (Perri et al., 2003).   
  The third process of tubular function is secretion.  Tubular secretion can 
effectively increase the renal clearance of a compound (as compared to 
glomerular filtration alone) by actively secreting a compound into the proximal 
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tubular lumen.  Secretion involves transport of drugs against a concentration 
gradient, thereby concentrating the compound in the tubular lumen. This 
transport mechanism is energy dependent and involves carrier-mediated 
transport by way of cotransporter and/or counter transporter proteins along the 
tubular epithelia. The rate of tubular secretion depends solely on the protein 
transporters involved.  Saturation of these transport mechanisms, and 
competition between compounds that use them, may affect the rate of drug 
elimination, and can thereby lead to drug interactions (Perri et al., 2003).  While 
some drug interactions may be beneficial, acting to prolong the duration of action 
of a beneficial drug by decreasing its elimination via the kidney (e.g., probenecid 
treatment prevents the elimination of penicillin in the urine), this same 
mechanism can also lead to the accumulation of a toxic compound in the body.   
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Figure 2.4. Structure of the renal nephron.  
         The proximal tubule is divided into three sections; S1 (proximal convoluted), S2         
                      (proximal convoluted) and S3 (proximal straight).  The S1 portion of the nephron is 
                       nearest the glomerulus, with the S3 segment nearest the Loop of Henle.     
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Figure 2.5.  A simplified overview of proximal tubular function.   
                   The proximal tubule plays an important role in the elimination of biotransformation  
                       products through a balance of filtration, secretion and reabsorption.   
 
2.2.2 Drug Elimination by the Kidney 
 
While all portions of the nephron can contribute to the elimination of 
compounds from the kidney, the PT is the portion of the nephron that plays the 
most significant role in drug elimination. To accomplish this elimination, the 
kidney possesses numerous transport proteins that are primarily localized to the 
proximal tubular epithelial cells of the nephron.  Many of these transporters utilize 
adenosine triphosphate (ATP) or transmembrane ion gradients to drive 
movement of substrate compounds across the cell membrane in either a 
secretory or reabsorptive direction.  The structural requirements for interaction of 
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drugs with renal transport mechanisms normally include either an electronegative 
(anionic) or an electropositive (cationic) charge, and a hydrophobic backbone. In 
the kidney, only a few uptake systems for organic anions have been proposed 
that interact with a variety of xenobiotics (Ullrich et al., 1997; Pritchard and Miller, 
1993).  These systems primarily include the multispecific organic anion transport 
proteins (OAT1 and OAT3). These and other systems will be discussed in 
greater detail in later sections. Despite the increasing knowledge of the molecular 
identity of individual transport proteins, and transporter substrate specificities, the 
overall knowledge regarding the role of these transporters in the renal handling of 
drugs and their metabolites is limited.  
  
2.2.3 Tubular Secretion of Organic Anions 
 
 Tubular secretion of xenobiotics, especially organic anions, has been 
extensively studied (Pritchard and Miller, 1993; Moller and Sheikh, 1982; 
Brendayan, 1996). Organic anions are weakly acidic compounds that are ionized 
at physiological pH.  A major system for net tubular secretion of hydrophobic 
organic anions exists in the PTs of almost all vertebrates. Mechanisms of organic 
anion transport in the kidney PTs have been studied over the past several 
decades.  In addition to in vivo experiments, studies have also used tissue slices, 
isolated tubules, perfused tubules, cultured cells, membrane vesicles and 
peritubular capillary perfusion to study how the kidney handles various 
xenobiotics (Moller and Sheikh, 1982; Pritchard and Miller, 1993).  The results of 
these studies indicate that the secretion of organic anions from the blood into the 
urine is accomplished sequentially.  Tubular secretion involves a molecule (e.g., 
an organic anion) first passing from the blood into the interstitial fluid and then 
across the basolateral membrane into the renal tubular cells.  Once inside the 
tubular epithelial cells, the molecule is then moved from the cell across the 
luminal membrane and into the tubular lumen for excretion in the urine.  To 
accomplish secretion, two distinct transporters are required; one at the 
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basolateral membrane of the cell (to accept organic anions from the blood into 
the cell), and one at the apical membrane (luminal membrane) to excrete organic 
anions from the cell into the tubular fluid (urine).   
When organic anion secretion was studied in isolated perfused renal PTs 
from various species, the steady-state concentration of organic anions (OA) in 
the tubule lumen was found to be greater than that in the peritubular bathing 
medium and the concentration in the cell was greater than in either the lumen or 
the peritubular bathing medium (Dantzler, 2002).  Because the inside of the cell 
is negatively charged (-70 mV) as compared to the lumen (-3 mV), and the 
peritubular fluid (0 mV), and because OA are negatively charged at physiological 
pH and do not appear bound inside the cells, this pattern of OA accumulation is 
compatible with transport into the cells against an electrochemical gradient at the 
basolateral membrane, with movement from the cell into the lumen down an 
electrochemical gradient (Dantzler, 2002).  Membrane permeability studies in 
various models have shown that (1) the permeability of the luminal membrane for 
efflux of OAs is greater than that of the basolateral membrane; (2) backflux of 
OAs across the epithelium from lumen to the peritubular fluid is small; and (3) 
any backflux that does occur crosses the cells from the luminal membrane 
across to the basolateral membrane (Dantzler, 2002).  In the renal PT, the 
general direction of movement of OAs is in a secretory direction.  This involves 
transporters along the basolateral membrane, as OAs must move against an 
electrochemical gradient to enter the cell. However, once inside the cell, OAs 
move easily across the luminal membrane for excretion in the urine.  Any OAs 
that move back across the basolateral membrane (back flux) generally are those 
reabsorbed from the luminal fluid and are intended to be returned to the general 
circulation by crossing the basolateral membrane and reentering the blood.   
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2.2.4 Transport of organic anions across the basolateral membrane  
 
 The first step in tubular secretion of OAs is the uptake from blood across 
the basolateral membrane of epithelial cells in the PT.  Transporter-mediated 
systems have been shown to play a significant role in endogenous and 
exogenous OA uptake in the PT.  Entry of OAs along the basolateral membrane 
of proximal tubular cells is of primary importance because it leads to the entry of 
potentially reactive compounds into the proximal tubular (PT) cell.  As these 
compounds accumulate within the cells, potentially toxic reactions can result.  
Several transporters from the OAT family have been localized to the basolateral 
membrane of renal PT cells (Fig 2.6). These transporters include the 
multispecific organic anion transport proteins 1, 2 and 3 (OAT1, OAT2 and 
OAT3). The model organic anion used for studying OAT transport is p-
aminohippurate (PAH).  PAH is nearly completely removed from the blood 
entering both kidneys and by calculating the rate of PAH clearance, can be used 
to approximate renal blood flow.  PAH is extensively protein bound and must 
enter the luminal fluid via secretion.  In general, transepithelial renal secretion of 
a wide range of hydrophobic OAs involves transport into the cell of the PTs 
against an electrochemical gradient at the basolateral membrane by 
countertransport for α-ketoglutarate moving down its electrochemical gradient 
(Fig 2.6).  This step is the dominant rate limiting step in the secretory process.  In 
the following sections, each transporter contributing to the basolateral uptake of 
OAs into the proximal tubular cells will be discussed in detail and is shown in 
Figure 2.6.   
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Figure 2.6 Model of organic anion transporters in the renal proximal tubule.      
 Uptake of organic anions (OA-) across the basolateral membrane is mediated by the 
classic sodium-dependent organic anion transport system, which includes α-ketoglutarate 
(α-KG2-)/OA- exchange via the multispecific organic anion transporter (OAT1) and 
sodium-ketoglutarate cotransport via the Na+/dicarboxylate cotransporter (NaDC3). A 
second sodium-independent uptake system for OA- has been identified only in human 
proximal tubules (OAT2) and is not a dicarboxylate exchanger.  OAT3 has been shown to 
transport bulky OA- and has recently been demonstrated to be a dicarboxylate 
exchanger.  Intracellular accumulation of substrates of both transport systems has been 
demonstrated in both mitochondria as well as vesicles of unknown origin.  The apical 
(brush-boarder) membrane contains various transport systems for efflux of OA- into the 
lumen or reabsorption from the lumen into the cell.  The multidrug resistance transporter, 
MRP2, mediates primary active luminal secretion.  The organic anion transporting 
polypeptide, OATP1, and the kidney-specific OAT-K2 and OAT-K1 might mediate 
facilitated OA- efflux but could also be involved in reabsorption via an exchange 
mechanism. URAT1 functions as an exchanger mediating reabsorption of uric acid, but 
can also transport OAs.  OAT4 is present only in human kidney, and its mechanism is 
unknown.  The human type I sodium-dependent inorganic phosphate transporter, NPT1, 
originally thought to function primarily in the reabsorption of  phosphate from the 
glomerular filtrate, has since been determined to transport organic anions  
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2.3 Organic Anion Transporter Proteins involved 
in Renal Secretion of Organic Anions 
 
2.3.1 Organic anion transporter 1 (OAT1) 
 
Previously referred to as the PAH transporter (Lu et al., 1999), OAT1 is 
the first of 5 members of the OAT family.  OAT1 through OAT5 are all members 
of the Slc22a (amphiphillic solute transporter) family, which is a subset of the 
major facilitator superfamily (Koepsell and Endou, 2004).  Sequencing of various 
OAT1 clones reveals regions coding for 546 (mouse; Lopez-Nieto et al., 1997), 
550 or 563 (hOAT1 short isoform; Hosoyamada et al., 1999; Race et al., 1999; 
long isoforms; Hosoyamada et al., 1999;), or 551 (rat; Sekine et al., 1997; Sweet 
et al., 1997; rabbit; Bahn et al., 2002) amino acids.  Compared to hOAT1 (100%), 
homologies decrease in order in comparison to hOAT1; rabbit (91.3%)>rat 
(90.6%)>pig (89.6%)>mouse (87.9%)>>flounder (55.9%)>>C. elegans (28.1) 
(Burckhardt and Burckhardt, 2003). In the human, OAT1 appears in four splice 
variants; OAT1-1, OAT1-2, OAT1-3, and OAT1-4.  Preliminary findings show no 
difference between OAT1-1 and OAT1-2 with respect to transport whereas OAT 
1-3 and OAT 1-4 appear to be nonfunctional (Buttler et al., 2001).  Membrane 
topology models of OAT1 predict 12 putative transmembrane domains. Four 
consensus sequences for N-glycosylation are present in the large extracellular 
loop between the first and second transmembrane domains and four protein 
kinase C phosphorylation sites are predicted in a large intracellular loop between 
the sixth and seventh transmembrane domains (Burckhardt and Burckhardt, 
2003).  Studies using mouse OAT1 demonstrate that a large portion of the 
protein remains in the intracellular compartment, suggesting that glycosylation of 
OAT1 is involved in the sorting of the OAT1 protein to the plasma membrane.  
Immunoblot analysis using polyclonal antibodies against hOAT1 shows a single 
protein band with molecular mass of 80-90 kD in human kidney cortex extract. 
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This size is decreased to 60 kD following deglycosylation (Cihlar et al., 1999).  In 
the rat kidney a single 77 kD protein band is detected with rOAT1 antiserum 
(Nakajima et al., 2000). The predicted molecular weight of hOAT1 and rOAT1 
from amino acid sequence is 60 kD.  These heavier molecular weights suggest 
that OAT1 is a glycosylated protein (Sekine et al., 2000). 
Physiologically, OAT1 mediates the first step in the renal excretion of 
many anionic drugs (e.g. antibiotics, anti-viral drugs, NSAIDs, diuretics, 
angiotensin converting enzyme (ACE) inhibitors, angiotensin II antagonists, anti-
neoplastic agents, anti-epileptic agents) and endogenous anions (e.g. cyclic 
nucleotides, dicarboxylates, prostanoids, neurotransmitter metabolites) and acts 
in parallel with other OA transporting proteins along the basolateral membrane in 
the PT (Sekine et al, 2000).  OAT1 is one of the primary transporters for OAs 
along the basolateral membrane of the renal PT.  The contribution of OAT1 in OA 
secretion in numerous models has been thoroughly studied and characterized. 
Molecular properties of OAT1 are summarized in Table 2. 
 
2.3.1.1 Cloning and Tissue Distribution 
 
 Molecular cloning of organic anion transport proteins from a number of 
species has greatly advanced the knowledge of organic anion transport.  OAT1 
(Slc22a6) was first identified by expression cloning from the kidneys of mouse 
and initially identified as NKT (novel kidney transporter, Lopez-Nieto et al., 1997).  
Later, OAT1 was identified in rat (OAT1, Sekine et al., 1997; ROAT, Sweet et al., 
1997), and flounder (fOAT1, Wolff et al., 1997). The human ortholog was cloned 
in 1998 by Reid et al.  (hOAT1, 1998) and later by four other laboratories 
(hOAT1, Hosoyamada et al.,1999; Race et al.,1999; Cihlar et al., 1999; PAHT, 
Lu et al.,  1999). Additional orthologs of OAT1 have also been identified in rabbit 
(Bahn et al., 2002) and pig (Hagos et al., 2002).  The term “OAT1” is used to 
refer to all orthologs, and the species from which the ortholog was derived is  
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generally indicated by a lower case letter designation preceding OAT1 (i.e. 
rOAT1 for rat OAT1) (Burckhardt and Burckhardt, 2003). 
 Northern blot analysis has revealed that OAT1 is highly expressed in the 
cortex of the kidney of the human (Cihlar et al., 1999; Hosoyamada et al., 1999; 
Lu et al., 1999; Race et al., 1999), rat (Buist et al., 2002; Kobayashi et al., 2002a; 
Sekine et al., 1997; Sweet et al., 1997), and mouse (Lopez-Nieto et al., 1997). 
Besides kidney, OAT1 has also been detected to some degree in brain, liver, 
skeletal muscle, and placenta and possibly retina (Burckhardt and Burckhardt, 
2003). In SD rats, Buist et al. (2002) found that the amount of OAT1 mRNA in the 
kidney steadily increased after birth, reaching a maximum around 30 days.  After 
30 days, mRNA levels decreased in females but remained constant in males.  
This indicates that there is a gender difference in OAT1 expression in adult SD 
rats. Kobayashi et al. (2002a) however, did not find a gender difference in the 
expression of OAT1 in 35-day old Wistar rats.  The potential for gender and 
species difference in OAT1 expression must therefore be considered when 
studying transport of organic anions and other compounds in various in vitro and 
in vivo systems from different rat strains.    
 Immunohistochemical analysis of OAT1 protein has shown that OAT1 is 
localized to the basolateral membrane of proximal tubular cells in humans 
(Hosoyamada et al., 1999; Motohashi et al., 2002) and rat (Kojima et al., 2002; 
Tojo et al., 1999).  The proximal tubule, which is comprised of three sections (S1, 
S2, S3) shows varying amounts of OAT1 expression in each section. It has been 
demonstrated that, in rat, OAT1 is primarily expressed in the S2 portion of the 
proximal tubule (Tojo et al., 1999) with the S1 and S3 segments showing only 
weak expression of the OAT1 protein (Kojima et al., 2002).  Protein labeling for 
the OAT1 protein in the human PT has shown varying results, either showing 
S1=S2=S3 (Motohashi et al., 2002) or labeling only in the S1 and S2 portions 
(Hosoyamada et al., 1999).  Cerrutti et al. (2002) demonstrated, using Western 
blot studies, that OAT1 protein in basolateral membrane vesicles (BLMV) from 
female Wistar rats at 110-130 days of age was present at only 40% of the level 
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found in BLMV from male rats. Kobayashi et al. (2002a), however, did not find a 
gender difference in expression of OAT1 in male and female Wistar rats at 7 
weeks of age. Protein analysis has revealed that the amount of OAT1 protein can 
potentially be different in male and female rats (possibly depending on age as 
well), and this may contribute to gender differences in the pharmacokinetics of 
anionic drugs.  
 
 2.3.1.2 OAT1 Substrates; Characterization and Specificity 
 
 Cloned OAT1 has been expressed in Xenopus laevis oocytes, COS7 
cells, LLC-PK1 cells, HeLa cells, CHO cells, and in immortalized mouse PT cells.  
More than 150 substrates have been tested with the cloned and heterologously 
expressed OAT1 from human, rat, mouse, flounder and C. elegans, 
demonstrating a wide range of compounds that are substrates for OAT1 
(Burckhardt and Burckhardt 2003). 
 OAT1 demonstrates wide substrate selectivity including endogenous 
substances such as cyclic nucleotides (cAMP, cGMP), prostaglandins (PGE2), 
and uric acid, and numerous structurally unrelated drugs such as NSAIDs 
(acetylsalicylate, indomethacin, salicylate), N-acetylcysteine conjugates, antiviral 
drugs (acyclovir, cidofovir, zidovudine), diuretics (acetazolamide, bumetanide, 
ethracrynic acid, furosemide), antibiotics (benzylpenicillin, cephaloridine, 
tetracycline), uricosuric drugs, antineoplastic drugs (methotrexate) and 
ochratoxin A.  The prototypical substrate for OAT1 is PAH (Miller and Pritchard 
1997). Fluorescein (FL) also shows the same transport properties as PAH and is 
thus used as a prototypical substrate for OAT1 as well (Dantzler, 2002). 
Numerous studies have been conducted using PAH as a marker substrate for 
OAT1 uptake.  Studies using various classes of substrates tested on PAH 
transport have been used to establish the structural requirements for substrates 
interacting with the PAH transporter (Burckhardt and Burckhardt 2003).  It has 
been determined that the structural requirements for OAT1 substrates include: 
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1. Substrates must have a hydrophobic domain of 4-10 Å 
2. An increase in the strength of the negative charge (decrease in pKa) 
favors the interaction with the PAH transporter. 
3. A full ionic charge is not necessary (uncharged polarized molecules 
can interact with OAT provided they are hydrophobic enough) 
4. Electron withdrawing side groups (Cl, Br, NO2) increase affinity for 
OAT1 (Burckhardt and Burckhardt 2003) 
Binding of substrates to the transporter most likely involves hydrophobic 
interactions and the formation of hydrogen bonds.  The negatively charged 
molecules may bind to oppositely charged amino acid residues of OAT1.  
Because hydrogen bonds are relatively weak, release of substrates after 
translocation into the cell is easier.  The formation of hydrogen bonds enables a 
transporter to interact with molecules from various chemical classes, indicating 
that hydrogen bonds may play a key role in polyspecific transporters (Burckhardt 
and Burckhardt, 2003). While OAT1 proteins from various species show similar 
function, it has been demonstrated that there are species differences in substrate 
specificity of the various isoforms.  It has been shown that rOAT1 has the ability 
to transport the compound methotrexate (Sekine et al., 1997; Uwai et al., 2000) 
while hOAT1 does not (Lu et al., 1999).  It is important to note also, that OAT1 
transport is not strictly limited to OAs.  While the prototypical organic cation 
tetraethylammonium (TEA) was not transported by rOAT1 (Uwai et al., 1998; 
Sekine et al., 1997; Sweet et al., 1997) and did not inhibit other isoforms of OAT 
(hOAT1: Cihlar et al., 1999; Islinger et al., 2001; fOAT1; Wolff et al., 1997), OAT1 
has been shown to transport cimetidine, a weak base which forms a cation 
(fOAT1: hOAT1: Burckhardt et al., 2003).  Cimetidine has also been shown to 
inhibit PAH accumulation in intact rat kidney (Ullrich et al., 1993).   
 OAT1 is thought to be the classic sodium-dependent organic anion 
transporter along the PT.  Characterization of OAT1 transport has been carried 
out in various expression models using uptake experiments utilizing radiolabeled 
PAH.  Summary of transport and Km values for PAH transport are listed in Table 
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3.  Uptake of labeled PAH was found to be saturable, with Km values ranging 
from 3.9 to 430 µM (Burckhardt and Burckhardt, 2003).  In rOAT1 expressing 
models, Km values for PAH uptake ranged from 11-85.1 µM where as in hOAT1 
expressing models, Km for PAH uptake ranged from 3.9-22 µM (Table 3).   
 Transport by OAT1 involves transport against an electrochemical gradient 
in exchange for α-ketoglutarate (or other dicarboxylates such as glutarate) 
(Pritchard and Miller, 1996) (Fig. 2.5).  OA exchange for dicarboxylate has been 
demonstrated in several OAT1 clone models (Lu et al., 1999; Apiwattanakul et al, 
1999; Cihlar and Ho, 2000).  The α-ketoglutarate concentration is maintained by 
metabolic production within the cell, and also by Na+ coupled uptake of α-
ketoglutarate into PT cells via the Na+-dicarboxylate exchanger (NaDC3) (Fig. 
2.5).  This inside to outside concentration difference of Na+ provides the driving 
force for the uptake of organic anions against negative membrane potential.  
Preloading cells with glutarate has been shown to increase the uptake of PAH by 
OAT 1 (human: Cihlar et al., 1999; Ho et al., 2000; Lu et al., 1999; Motojima et 
al., 2002; rat: Cihlar et al., 1999; Pombrio et al., 2001; Sekine et al., 1997; Sweet 
et al., 1997).  Coexpression of OAT1 with the Na+-dicarboxylate exchanger also 
demonstrated an increase in PAH uptake with dicarboxylate present outside of 
the cell (thus available as substrate for the dicarboxylate exchanger; Sekine et 
al., 1997; George et al., 1999).   Sodium that is transported into the cell by the 
Na+-dicarboxylate exchanger is removed by the membrane bound Na+/K+-
ATPase to maintain the sodium gradient across the basolateral membrane, thus 
classifying OAT1 as a tertiary active transporter.   
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Table 3 PAH  substrate specificities for basolateral OAT transporters 
     
Transporter Species 
Expression 
system 
Transport (+/-) 
or Km (µM) References 
     
hOAT1 Human Oocyte + Race et al. 1999 
   3.9 Islinger et al. 2001 
   4.0 Cihlar et al. 1999 
   9.3 
Hosoyamada et al. 
1999 
     
  CHO cells 15.4 Cihlar and Ho, 2000 
    Ho et al. 2000 
     
  HeLa cells 5.0 Lu et al. 1999 
     
  Mouse PTC 15.8 Takeda et al. 2000 
   20.1 Takeda et al. 2001 
     
  OK cells 22.0 Motojima et al. 2002 
     
rOAT1 Rat Oocyte 11.0 Pombrio et al. 2001 
   14.3 Sekine et al. 1997 
   31.0 Uwai et al. 2000 
   70.0 Sweet et al. 1997 
     
  LLC-PK1 47.0 Nagata et al. 2002 
   59.5 Hasegawa et al. 2002 
     
  Mouse PTC 43.2 Takeda et al. 1999 
   85.1 Sugiyama et al. 2001 
     
     
hOAT2 Human EcR293 + Sun et al. 2001 
  LLC-PK1 + Morita et al. 2001 
     
rOAT2 Rat Oocyte + Sekine et al. 1998 
     
     
hOAT3 Human Oocyte 87.2 Cha et al. 2001 
     
rOAT3 Rat Oocyte 64.7 Kusuhara et al. 1999 
   278.0 Feng et al. 2001 
  LLC-PK1 + Hasegawa et al. 2002 
   - Nagata et al. 2002 
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 2.3.1.3 Regulation  
  
 The mechanism responsible for the basolateral uptake of OAs is well 
understood. However, the cellular regulation of OA transporters has only recently 
begun to be studied.  Physiological studies have established the regulation of 
organic anion transport by hormones, kinases, growth factors and even 
substrates (Terlouw et al., 2003).  OAT1 proteins possess several potential 
phosphorylation sites for protein kinases, suggesting that phosphorylation of one 
or more of these sites may play a role in OAT1 regulation (Sekine et al., 2000).  
Studies carried out in various OAT expression models have all implicated that 
protein kinase C (PKC) may play a role in the regulation of this transport system 
(Shuprisha et al., 2000).  Early studies on the activation of PKC by phorbol esters 
in isolated PTs from rabbit revealed conflicting data.  Hohage et al. (1994) 
demonstrated that activation of PKC revealed a stimulation of PAH uptake, 
where Gekle et al. (1999) found that PKC activation by phorbol esters caused an 
inhibition of PAH uptake.  Studies using stauorosporine, a PKC inhibitor, 
reversed the stimulation or inhibition by phorbol esters, indicating that PKC has 
the ability to regulate OAT activity.  Stimulation of PKC by phorbol esters has 
also been shown to inhibit the uptake of FL in killifish tubules (Miller, 1998) and 
inhibit PAH transport across both the basolateral and luminal membranes in 
opossum kidney (OK) cells (Sauvant et al., 2001; Takano et al., 1996).  PKC 
activation by parathyroid hormone has also been shown to cause an inhibition of 
PAH transport in OK cells (Nagai et al., 1997).  These studies in conjunction with 
others indicate inhibition of OAT1 by activation of PKC (human: Lu et al., 1999; 
rat: Uwai et al., 1998; mouse: You et al., 2000).  Thus, while the definitive role of 
PKC in activation or inactivation of OAT1 via phosphorylation remains to be fully 
elucidated, it is evident that PKC plays an important role in the regulation of 
OAT1 protein in the renal PT. 
 While studies have shown a relationship between PKC activation and 
inhibition of OAT1 transport, it has not been determined whether PKC regulation 
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involves a decrease in membrane expression by internalization of membrane 
transporters or by inhibition of recruitment of transporters to the membrane.  In 
studies conducted on mouse OAT1, activation of PKC led to a decrease in Vmax 
with no change in Km, indicating internalization of active transporters (You et al., 
2000).  Interestingly, PKC was not shown to directly phosphorylate the mOAT1 
protein, suggesting PKC may actually phosphorylate an OAT1 regulatory protein 
that is responsible for internalization/inhibition of OAT1.  Wolff et al. (2003) has 
demonstrated that PKC-induced hOAT1 downregulation is achieved through 
carrier retrieval from the cell membrane and does not involve phosphorylation of 
the hOAT1 protein. 
As described previously, OAT1 is a tertiary active transport carrier.  
Therefore, inhibition of uptake via OAT1 can also be accomplished through 
regulation of either the Na+/K+-ATPase or NaDC3.  Treatment of flounder PTs 
with phorbol esters is thought to inhibit OA uptake via OAT1 by inhibition of 
Na+,K+-ATPase (Halpin and Renfro, 1996) because PKC activation has been 
shown to partially deactivate renal Na+,K+-ATPase (Bertorello and Aperia, 1989).  
Studies by Rover et al. (1998) indicate that PKC did not affect transport mediated 
by the basolateral NaDC3 in rabbit. 
 Of additional interest is regulation via epidermal growth factor (EGF).  
EGF is an endogenous compound that is important in normal tubulogenesis, and 
has been shown to enhance the basolateral uptake of OAs in opossum kidney 
(OK) cells (Sauvant et al., 2001).  This activation is believed to be via the 
mitogen-activated protein kinase (MAPK) pathway because EGF stimulates both 
OA uptake and phosphorylation of extracellular signal-regulated kinase 1 and 2 
(ERK1/2).  Both OA uptake and ERK1/2 phosphorylation was prevented by 
inhibition of mitogen activated extracellular signal-regulated kinase kinase (MEK) 
(Sauvant et al., 2001)  Sauvant et al. (2004) also showed in OK cells that EGF 
stimulates basolateral OA transport.  They demonstrated that activation is 
through ERK1/2, arachidonic acid, phospholipase A2, and generation of 
prostaglandins.  EGF activates adenylate cyclase and protein kinase A (PKA), 
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stimulating OA uptake.  Thus, this demonstrates another cellular mechanism for 
regulation of OAT1 activity in the PT cell. 
 Triiodothyronine (T3) or dexamethasone (DEXA) pretreatment in rats has 
been shown to increase renal PAH excretion (Bahn et al., 2003).  Stimulation 
was accompanied by increased protein synthesis in the renal cortex in both 
cases.  Increased OAT1 mRNA levels following T3 or DEXA treatment indicate 
that OAT1 expression can also be regulated by T3 and DEXA.  
 There are indications that a number of physiological factors help regulate 
basolateral organic anion transport in mammals.  However, there are still many 
details regarding the pathways involved in OAT regulation that remain to be 
clarified, as well as questions about the actual physiological significance of 
regulation that remain unanswered.   
 
2.3.2 Organic Anion Transporter 2 (OAT2) 
 
 In humans, OAT2 (SLC22A7) appears to participate in the renal handling 
of organic anions.  OAT2 has been shown to share 42% amino acid sequence 
identity to OAT1.  OAT2 is quite possibly only a minor contributor to organic 
anion secretion along the basolateral membrane of the PT, as it has only been 
localized to that membrane in the human kidney.  However, since information on 
OAT2 is limited, its full contribution to OA handling has not been elucidated.   
Molecular properties of OAT2 are summarized in Table 2. 
  
 2.3.2.1 Cloning and Tissue Distribution 
 
OAT2 was the first member of the OAT family to be cloned.  In 1994, a 
gene product was cloned from rat liver and named novel liver transporter (NLT).  
It has sequence motifs similar to a major facilitator superfamily and was cloned 
but not characterized (Simonson et al., 1994).  Later, it was recloned and 
identified as polyspecific organic anion transporter and renamed OAT2 (Sekine 
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et al. (1998a).  Two splice variants of hOAT2 have been reported (hOAT2A and 
hOAT2B) but the sequences have not been determined (Sun et al., 2001).  
Studies of the OAT2 proteins have shown that rOAT2 is a protein of 535 amino 
acids (Simonson et al., 1994) and mOAT2 has 540 amino acids (Kobayashi et 
al., 2002b).  The two splice variants of hOAT2 (2A and 2B) have 546 and 538 
amino acids respectively (Sun et al., 2001). The protein structure has been 
predicted to contain 12 transmembrane spanning domains.  The large first 
extracellular loop between the first and second transmembrane helix of rOAT2 
and mOAT2 contains two potential sites for N-glycosylation.  Two potential sites 
for phosphorylation by protein kinase A (PKA) and protein kinase C (PKC) have 
been reported for rOAT2 and six potential sites for PKC phosphorylation have 
been reported for mouse OAT2 (Burckhardt and Burckhardt, 2003). 
Expression of mRNA of hOAT2 has been detected in the liver and kidney 
(liver>kidney) (Sekine et al., 1998a; Sun et al., 2001). Immunohistochemical 
analysis revealed that hOAT2 is localized to the basolateral side of the PT in 
kidney (Enomoto et al., 2002a; Khamdang et al., 2002). In male rats the OAT2 
transcript was also found in the liver with little expression in the kidney (Sekine et 
al, 1998b; Simonson et al, 1994; Sun et al., 2001). Immunofluorescence 
localization by Kojima et al. (2002) demonstrated the presence of rOAT2 in the 
renal cortex and medulla. The expression level of rOAT2 was much lower 
compared to that of rOAT1 and rOAT3 (Kojima et al., 2002).  rOAT2 has been 
shown to be localized on the apical side of the medullary thick ascending limbs of 
Henle’s loop, and cortical and medullary collecting ducts, whereas rOAT2 was 
not detected in the proximal tubular cells (Kojima et al., 2002). Gender 
differences in OAT2 expression have also been shown (Buist et al., 2002; 
Kobayashi et al., 2002a).  Female rats show a higher expression of OAT2 in the 
kidneys compared to male rats.  This gender difference appears at the onset of 
estrogen production in female rats, suggesting that hormones may play a role in 
regulation of renal OAT2, but not hepatic OAT2 (Kobayashi et al., 2002a).  
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It is important to note that immunohistochemistry studies have yielded 
results that differ for human and rat, as well as gender differences in expression.  
Immunohistochemistry has shown that localization of OAT2 varies between 
humans and rats, and this must be taken into consideration when studying and 
comparing the effects of certain compounds that may be substrates for OAT2.  
With varying levels of expression of OAT2, different organs from different species 
may respond differently to therapeutic or toxic compounds.  Gender differences 
present the same problems when studying the effects of certain xenobiotics, as 
males or females may be more or less susceptible to certain drug effects, thus 
confounding any comparison that might be made between males and females. 
Both of these points become additionally important in considering the contribution 
of OAT2 in the secretion of OA along the basolateral membrane of the renal PT.  
While studies in humans may show transport of a compound, studies in rats may 
yield significantly different results, and results in male study models may yield 
varying results from those found in females.      
 
2.3.2.2 OAT2 Substrates; Characterization and Specificity 
  
The substrate selectivity of OAT2 and OAT1 appear to be similar, 
however, the transport efficacy for each substrate is different.  The transport of 
PAH by hOAT2 occurs at much lower levels than by hOAT1 (Sekine et al., 1997).  
When expressed in Xenopus laevis oocytes, hOAT2 demonstrated uptake of 
organic anions such as salicylate, acetylsalicylate, PGE2, methotrexate, 
dicarboxylates and PAH (Sekine et al., 1998a).  hOAT2 has been shown to 
transport PGF2α in a time- and concentration-dependent manner (Enomoto et al., 
2002a).  Khamdang and colleagues (2002) have also documented transport of 
cephaloridine by hOAT2 and its contribution to the renal excretion of this 
antibiotic.   Studies conducted with rat OAT2 have shown that rOAT2 mediates 
the transport of PGF2α with an affinity similar to that of hOAT2 (Takeda et al., 
2002).      
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 In the kidney (as well as liver) rOAT2 mediates saturable uptake of 
salicylate from the blood in a sodium independent manner, like that of OAT1 
(Sekine et al., 1998a). Salicylate uptake however, was not trans-stimulated by 
intracellular glutarate (Sekine et al., 1998a).  When OAT2 was expressed in LLC-
PK1 cells, transport of α-ketoglutarate was not found (Morita et al., 2001). This 
indicates that OAT2 does not function as a dicarboxylate exchanger, exchanging 
an extracellular OA against intracellular α-ketoglutarate.  PAH transport was also 
not inhibited by dicarboxylates further supporting this conclusion (Burckhardt and 
Burckhardt, 2003). Summary of transport and Km values for PAH transport are 
listed in Table 3.  Wolff (unpublished results: Burckhardt and Burckhardt, 2003) 
has indicated that OAT2 shows low affinity for PAH, concluding that if OAT2 is 
present in the basolateral membrane of PT cells, it is unlikely to contribute much 
to organic anion secretion.  Human OAT2 is also only weakly inhibited by 
probenecid, the prototypical inhibitor of the OAT proteins.  Enomoto et al. (2002) 
have determined that the Ki value of probenecid for human-OAT2-mediated 
organic anion uptake is 766 µM.  Khamdang et al. (2003) demonstrated this point 
by showing that cephaloridine induced nephrotoxicity was not reversible in 
human OAT2-expressing S2 cells when treated with 1mM probenecid, but 
nephrotoxicity could be reversed in S2 human-OAT1 and S2 human-OAT3 cells 
by treatment with probenecid.      
 
 2.3.2.3 Regulation 
  
Hormonal regulation of rOAT2 has been studied. Findings have shown 
that there is an increase in OAT2 mRNA levels in male rat kidney following 
castration, with subsequent decrease in levels following post castration treatment 
with testosterone (Kudo et al., 2002; Kobayashi et al., 2002a).  However, this 
increase is minimal and does not approach the levels seen in female kidney.  
Administration of estrogen to castrated males provided conflicting results in 
mRNA levels of OAT2 (increase: Kudo et al., 2002; decrease: Kobayashi et al., 
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2002a).  This indicates that sex steroids do not apper to be the primary mediator 
of the gender difference in OAT2 expression in rats.  Buist et al. (2003) and 
Kobayashi et al. (2002a) were able to demonstrate in hypophysectomized (HX) 
rats, a marked decrease in OAT2 mRNA in female rats, while the levels of OAT2 
in HX male rats was not altered.  Continuous infusion of growth hormone (GH) 
(female pattern) significantly increased OAT2 mRNA in HX rats compared with 
untreated rats (Buist et al., 2003).  This demonstrated that the female pattern of 
growth hormone secretion is at least partially responsible for the elevation of 
OAT2 in the female rat kidney compared with male kidney. Other mechanisms of 
regulation (e.g., PKC) have not been determined. 
 
2.3.3 Organic Anion Transporter 3 (OAT3) 
 
 OAT3 (SLC22A8) has also been shown to participate in the renal 
excretion and reabsorption of anionic drugs.    The OAT3 protein contains 536 
amino acids for rOAT3, 537 for mOAT3, and either 543 or 568 for hOAT3.  Rat 
OAT3 is 49% and 39% identical to rOAT1 and rOAT2, respectively. Human 
OAT3 is 51% and 36% identical to hOAT1 and hOAT2 respectively (Burckhardt 
and Burckhardt, 2003).  The expressed OAT3 protein is predicted to have 12 
transmembrane domains with a large, putatively extracellular loop located 
between the first and second transmembrane domain.  The OAT3 protein 
contains four potential sites for N-glycosylation.  Rat OAT3 contains three 
potential PKC phosphorylation sites, while hOAT3 contains eight potential 
phosphorylation sites (Burckhardt and Burckhardt, 2003). There is no 
experimental data available on the topological organization of OAT3 prevailing 
within the membrane. 
Due to OAT3 presence in the basolateral membrane of the PT, it can play 
an important role in the renal excretion of organic anions. Physiologically, OAT3 
also mediates the first step in the renal excretion of many anionic drugs and 
endogenous anions, acting in parallel with other OA transporting proteins along 
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the basolateral membrane in the PT.   Molecular properties of OAT3 are 
summarized in Table 2.  
 
2.3.3.1 Cloning and Tissue Distribution 
 
 OAT3 was first cloned from rat kidney (rOAT3: Kusuhara et al., 1999).  
The human homolog, hOAT3 was later cloned by Race et al. (1999).  Cha et al. 
(2001) cloned the functional hOAT3 from human kidney based on sequences 
derived from rOAT3.  OAT3 has also been cloned from rabbit (Dantzler and 
Wright, 2003). 
 Northern blot analysis showed that rOAT3 is actually most abundantly 
expressed in the liver, followed by the kidney, while hOAT3 transcripts are 
expressed abundantly in the kidney and at lower levels in the brain and skeletal 
muscle (Race et al., 1999; Kusuhara et al., 1999). Studies by Buist et al. (2002) 
however, have shown rOAT3 to be most abundant in the kidney, rather than the 
liver.  Levels of renal OAT3 in rat have been shown to increase after birth and 
reach maximum levels by 14 days.  Similar levels were detected in male and 
female animals (Buist et al., 2002).  In human kidneys, it is important to note that 
mRNA levels for OAT3 are nearly three times higher than that for OAT1 
(Motohashi et al., 2002).  In rat kidney, OAT1 has been found to be more highly 
expressed in the kidney than OAT3, with OAT3 being expressed predominantly 
in the liver (Dresser et al., 2000; Kusuhara et al., 1999).  This indicates that 
OAT3 may play a more significant role in OA transport in the human kidney than 
OAT1.  
 OAT3 has been localized to the basolateral membrane of the renal PT in 
both rat (Hasegawa et al., 2002) and human (Cha et al., 2001). Kojima et al. 
(2002) have shown that rOAT3 is present at the basolateral membrane in all 
sections of the PT (S1, S2, S3), as well as in the thick ascending limbs, the distal 
tubules, and the collecting ducts. Interestingly, in the human kidney, OAT3 
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appears to be confined to the basolateral membrane of the PTs where it is co-
localized with OAT1 (Motohashi et al., 2002).   
 
2.3.3.2 OAT3 Substrates; Characterization and Specificity 
 
 Characterization of OAT3 transport conducted in Xenopus laevis oocytes 
showed PAH uptake by rOAT3 (Cha et al., 2001; Kusuhara et al., 1999). 
Summary of transport and Km values for PAH transport for OAT3 are listed in 
Table 3.  Results from additional studies have indicated that rOAT3 does not 
transport PAH, but rather suggest that the affinity of rOAT3 for PAH is lower than 
that of rOAT1 (Sugiyama et al., 2001; Nagata et al., 2002).  This is apparently 
true for hOAT3 as well.  Studies by Cha et al (2001) indicate a 4-10 fold higher 
Km for PAH transport by hOAT3 compared to hOAT1 (87.2 µM and 9 µM 
respectively).  Rat OAT3 also demonstrated a higher Km for PAH transport than 
rOAT1 (65 µM and 14 µM respectively (Cha et al., 2001), suggesting that OAT1 
and OAT3 transporters would have different contributions in tubular secretion.     
 Rat OAT3 has been shown to transport several other OAT substrates, 
including benzylpenicillin, cimetidine (cation), 17β-estradiol-D-17β-glucuronide 
(E217βG), estrone sulfate, indoxyl sulfate, ochratoxin A and pravastatin.     
hOAT3 has been shown to transport azidothymidine (AZT), cAMP, cimetidine, 
dehydroepiandrosterone sulfate (DHEA-S), estradiol glucuronide, estrone sulfate, 
methotrexate, ochratoxin A, PGE2, PGF2α, salicylate, taurocholate, urate, and 
valacyclovir (Burckhardt and Burckhardt, 2003).  OAT3 can be distinguished from 
OAT1 by its ability to transport sulfate and glucuronide conjugates of steroid 
hormones.  For this reason an estrogen conjugate, estrone sulfate (ES), has 
been used as the prototypical OAT3 substrate.  OAT3 also shows interaction with 
cimetidine (a cationic drug) whereas OAT1 does not (Cha et al., 2001, Feng et 
al., 2001).  This indicates that OAT3 does not discriminate between organic 
anions and cations as sharply as OAT1 (Burckhardt and Burckhardt, 2003).   
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 The mechanism of transport of OAT3 has recently been redefined.  OAT3 
was originally shown to function as a uniporter, and not as an anion exchanger in 
the manner of OAT1 transport (exchange of an OA for a dicarboxylate).  
Kusuhara et al. (1999) found that estrone sulfate (ES) transport by rOAT3 could 
not be trans-stimulated by unlabeled ES, PAH, or ochratoxin A.  Cha et al. (2001) 
reported similar results for hOAT3.  These findings lead to the conclusion that 
OAT3 did not function as an anion exchanger like OAT1.  However, up to this 
point, no studies had been conducted to determine the contribution of internal α-
ketoglutarate or glutarate to OAT3 transport.  It has been demonstrated that 
hOAT3 has the ability to interact with glutarate (Cha et al., 2001), indicating the 
potential for OAT3 to interact with dicarboxylates.  Recent findings however, 
have shown that OAT3 does function as a dicarboxylate exchanger in the same 
mechanism as OAT1.  Sweet et al. (2003) demonstrated that ES transport by 
rOAT3 expressed in Xenopus laevis oocytes was significantly trans-stimulated by 
preloading cells with glutarate (a dicarboxylate).  Additionally, it was shown that 
when OAT3 was coexpressed with the Na+/dicarboxylate exchanger, ES 
transport was significantly inhibited by the presence of Li+ or methylsuccinate, 
and by the exclusion of Na+ from the preloading medium, all of which act to 
inhibit the Na+/dicarboxylate exchanger. These results indicate that OAT3 
functions as an OA/dicarboxylate exchanger that couples OA uptake indirectly to 
the sodium gradient.  Similar results were also found in rat renal cortical slices 
(Sweet et al., 2003).  Bakhiya et al. (2003) have also shown that hOAT3 
functions as an OA/dicarboxylate exchanger similar to OAT1.   
 
2.3.3.3 Regulation 
 
 Treatment of rOAT3 expressing mouse proximal tubular cells with the 
phorbol ester, phorbol 12-myristate 13-acetate(PMA), a PKC stimulator, inhibited 
the uptake of ES in a dose and time-dependent manner (Takeda et al., 2000b).  
Inhibition of PKC by chelerythrine chloride reversed the effects of PMA.  These 
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results indicated that PKC activation downregulates rOAT3 mediated organic 
anion transport. Inhibition was determined to be due to the internalization of 
transporters, or to an inhibition of translocation of preformed transporters to the 
membrane.   
 Rat OAT3 also appears to undergo some regulation by testosterone. In 
male rats, OAT3 is much more highly expressed in the liver, than in female rats 
(renal expression is the same in males and females). Kobayashi et al. (2002a) 
demonstrated that after castration, OAT3 levels in the liver of male rats decrease, 
and testosterone treatment restored normal male levels.  Additionally, HX 
increased OAT3 mRNA in female liver indicating a role for growth hormone in the 
female pattern of OAT3 expression as well (Kobayashi et al., 2002a; Buist et al., 
2003).   
 
2.3.4 Luminal Transport of Organic Anions 
  
 As mentioned previously, the secretion of OAs can be divided into two 
processes (1) uptake of OA across the basolateral membrane into PT cells and 
(2) efflux of the OA out of the cell into the tubule lumen across the luminal 
membrane.  Far less is known about the mechanisms involved in OA transport 
into the tubular lumen than is known about basolateral transport of OAs.   
Movement of OAs across the luminal membrane during the transepithelial 
secretory process occurs down an electrochemical gradient.  Since the luminal 
membrane appears to be highly permeable to substances with low lipid 
solubilities, this transport must be carrier-mediated.  At the luminal membrane, 
the efflux carriers differ among various species.   
Currently, several OA transporters have been identified at the luminal 
membrane of renal proximal tubular cells (Figure 2.6). The luminal membrane 
may contain organic anion uniporters or “channels” (Burckhardt and Pritchard, 
2000). These luminal uniporters have been identified in several animal species 
including; flounder, rat, rabbit, and pig.  A second type of transporter found at the 
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luminal membrane includes organic anion/Cl- (OH-, HCO3-) antiporters, found in 
dog and rat.  A third type of transporter found in the luminal membrane is an 
organic anion/α-ketoglutarate antiporter (human, cow).  A fourth type of OA 
transporter localized to the luminal membrane is an ATP-driven organic anion 
transporter (Burckhardt and Burckhardt, 2003). Several specific transporters 
have been identified in the luminal membrane of the PT.  Human type I sodium-
dependent inorganic phosphate transporter, NPT1, a sodium phosphate 
cotransporter, expressed in HEK293 cells by Uchino et al. (2000), was shown to 
facilitate secretion of PAH and urate.  OAT4 was cloned from human cDNA (Cha 
et al., 2000) and shown to be localized at the luminal membrane (Babu et al., 
2002). However, the contribution of OAT4 to the efflux of OAs across the 
basolateral membrane is uncertain, as it has not been show to transport PAH 
(Cha et al., 2000).   URAT1 has also been cloned, based on its sequence 
homology to OAT4 (Enomoto et al., 2002a) and has been shown to function as 
an antiporter, exchanging urate against either chloride or certain monovalent 
organic anions.  As with OAT4, PAH does not appear to be a substrate for 
URAT1 and thus does not contribute to PAH secretion. Multidrug resistance 
transporter 2 (MRP2) is mainly responsible for the ATP-dependent translocation 
of sulfated or glucuronidated compounds such as glutathione S-conjugates, 
bilirubin glucuronide, 17-β-glucuronosyl estradiol, and glutathione disulfide (Konig 
et al., 1999; Keppler et al., 1997). In human and rat, MRP2 has been located in 
the proximal tubular cell at the luminal membrane (Schaub et al., 1997, 1999), 
and has been shown to transport PAH (Van Aubel et al., 2000b).  A kidney 
specific transporter, termed rOAT-K1 was also cloned from rat kidney (Saito et 
al., 1996) and has been shown to transport methotrexate, but not PAH.  rOAT-K1 
does not share any significant sequence identity with OAT isoforms and is 
therefore thought to belong to a different gene family. A second kidney specific 
transporter, rOAT-K2 was also identified from rat kidney (Masuda et al., 1999), 
and has been shown to transport methotrexate, folate, taurocholate and PGE2. 
PAH has been shown to interact only weakly with rOAT-K2. Rat OAT-K1 and 
46 
OAT-K2 have been identified at the luminal membrane in the kidney (Masuda et 
al., 1997, 1999; Tojo et al., 1999; Hasegawa et al., 2002). OATP1 transporters 
have also been localized to the luminal membrane in the S3 segment of the renal 
PT (Bergwerk et al., 1996) where it meditates uptake of OAs from the luminal 
fluid into the proximal tubular cell.  OATP3 is thought to be a multispecific anion 
transporter that accepts many types of organic anions including taurocholate and 
other bile acids as substrates (Echkardt et al., 1999; Burchkardt and Wolf, 2000). 
The driving force for OATP3 is considered to be reduced glutathione (Li et al., 
1998).  Isern et al. (2001) demonstrated that mouse OATP1 mediates sodium-
independent uptake of the anionic steroid conjugates dehydroepiandrosterone 
sulfate (Km ~ 8 µM) and estradiol-17-glucuronide (Km ~ 5 µM). Rat OATP1 gene 
expression was much higher in the kidneys of male rats than female rats (Kato et 
al., 2002).   
 
2.4 Renal Transport of Prototypical Organic Anions 
 
2.4.1 Renal Transport of Para-aminohippuric Acid (PAH) 
 
 PAH is the prototypical substrate for OAT1 at the basolateral membrane of 
the renal PT cell (Km values presented for various systems in Table. 2).  OAT3 
has also been shown to transport PAH (Table 3). At the basolateral membrane, 
PAH uptake against its concentration gradient is coupled to dicarboxylate (most 
often α-ketoglutarate) exchange (Pritchard, 1988; Burckhardt and Wolf, 2000; 
Sekine et al, 2000) and is indirectly coupled to Na+ uptake (Shimada et al., 1987; 
Pritchard 1988). PAH does not appear to interact with  luminal transport proteins 
in the kidney including hOAT4 (Cha et al, 2000), urate transporter (URAT1; 
Enomoto et al., 2002a), rOATP1 or rOATP2 (Sugiyama et al., 2001).  PAH shows 
only limited affinity for NPT1 (Uchino et al., 2000) and MRP2 (Leier et al., 2000).  
At the luminal membrane, PAH is transported by either an anion exchanger 
which transports many organic and inorganic anions such as urate, lactate, OH-, 
47 
and Cl- as substrates (Kahn et al., 1983; Kahn and Aronson, 1983; Guggio et al., 
1983; Steffens et al., 1989; Ohoka et al., 1993) or a membrane potential 
sensitive system (Martinez et al., 1990; Werner et al., 1990; Ohoka et al., 1993).  
In dog and rat renal brush-border membrane vesicles, an anion antiporter 
exchanged PAH or urate against OH-, HCO3- CL-, lactate acetoacetate or 
monovalent succinate (Burckhardt et al., 2001).  Studies conducted by Ulrich and 
Rumrich (1997) using PAH preloaded rat proximal tubular cells, demonstrated 
that luminal PAH transport in the rat PT in situ is insensitive to electrical potential 
and therefore may occur by anion exchange. The main driving force for luminal 
PAH influx in rat nephrons in situ may be the intracellular PAH concentration, as 
the electrical potential difference seems not to be important.  
 Currently, the molecular identity of the antiporters and/or uniporters 
involved in PAH secretion across the luminal membrane is unknown.  Of the 
cloned OATP transporter proteins known to be located in the luminal membrane 
of the kidney PTs, oatp1 and OAT-K1 do not transport PAH.  This excludes these 
transporters as candidates for PAH antiporters or uniporters.  OAT-K2 was only 
weakly inhibited by PAH, but transport of labeled PAH has not been 
demonstrated. NPT1 had been shown to display low affinity uptake of labeled 
PAH (Km of 2.7 mM).  MRP2 has been shown to be a luminal transporter of 
PAH; however there may be luminal PAH transporters that have not yet been 
identified.  
 
2.4.2 Renal transport of Estrone-3-Sulfate (ES) 
 
 ES is the prototypical substrate for OAT3 (see Table 4 for Km values in 
various systems). Studies by Sweet et al. (2002) have indicated that OAT3 is not 
the only basolateral transport protein responsible for ES uptake.  ES transport by 
OAT3 has not been shown to be trans-stimulated by unlabeled ES (Cha et al., 
2001) Interaction of ES with other basolateral transporters has also been 
demonstrated.  ES has been suggested to interact with URAT1, as ES cis-
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stimulated uptake of urate by URAT1 (Enomoto et al., 2002).  There has been 
conflicting results regarding the interaction of ES with MRP2.  Sasaki et al. 
(2002) demonstrated that ES was not a substrate of MRP2, yet ES stimulated the 
transport of other substrates of MPR2.   Of particular importance, Sweet et al. 
(2002) determined that ES did not interfere with PAH transport by OAT1, thus 
enabling the use of ES to determine the contribution of OAT3 in a system in 
comparison to the contribution of OAT1 to a substrate’s transport by the OAT 
system.  At the luminal membrane, in humans, ES appears to be transported by 
OAT4 (Cha et al., 2000), and stimulates efflux of substrates by the luminal 
transporters URAT1 and MRP2.   
 
2.4.3 Renal Transport of Fluorescein (FL) 
 
 FL has been used in several studies as a model OAT substrate. FL 
accumulates in proximal tubular cells of the kidney (Terlouw et al., 2000). FL is 
thought to be transported into the cytoplasm of PTs by a basolateral mechanism 
similar to the classical organic anion system (Sullivan et al., 1990). In isolated 
non-perfused proximal S2 segments from rabbit, Sullivan et al. (1990) found a 
Km for FL transport of 10 µM.  Masereeuw et al. (1994) determined that FL 
uptake in isolated proximal tubular cells from rat was concentration dependent, 
saturable and probenecid sensitive, with an apparent Km of 59 ± 15 µM.  Dose 
dependent inhibition of FL uptake by PAH indicated that FL uptake is regulated 
by the PAH transport system, and therefore, FL is a suitable substrate for 
studying this system.  It has also been demonstrated that FL transport in isolated 
S2 segments of rabbit PT is stimulated by increased intracellular α-ketoglutarate 
levels, suggesting FL transport is carried out in the same manner as PAH 
transport (Sullivan and Grantham, 1992; Nikiforov, 1995). 
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Table 4. Substrate specificity of various compounds in selected OAT isoforms   
Compound Transporter Expression system 
Transport 
(+/-) or 
Km (µM) 
Inhibition 
(+/-) or 
IC50 (µM) References 
      
benzylpenicillin hOAT1 Oocyte  + Hosoyamada et al. 1999 
    + Islinger et al. 2001 
  HeLa cells  - Lu et al. 1999 
  Mouse PTC  + Jung et al. 2001 
      
 rOAT1 Oocyte + 1680.0 Jariyawat et al, 1999 
    + Islinger et al. 2001; 
    + Sekine et al. 1997 
  LLC-PK1   418 Hasegawa et al. 2002 
    800.0 Nagata et al. 2002 
      
 rOAT2 LLC-PK1  + Morita et al. 2001 
      
 hOAT3 Oocyte  + Cha et al. 2001 
  Mouse PTC  + Jung et al. 2001 
      
 rOAT3 Oocyte  + Deguchi et al. 2002 
    + Kusuhara et al. 1999 
  LLC-PK1 82.6 82.6 Nagata et al. 2002 
    52.8 Hasegawa et al. 2002 
      
DHEA-S hOAT2 EcR293 -  Sun et al. 2001 
      
 hOAT3 Oocyte + + Cha et al. 2001 
      
Estrone Sulfate hOAT3 Oocyte 3.1  Cha et al. 2001 
  Mouse 2.2  Takeda et al. 2001 
   7.5  Takeda et al. 2000 
    + Babu et al. 2002 
      
 rOAT3 Oocyte 2.34  Kusuhara et al. 1999 
   33  Feng et al. 2001 
    + Feng et al. 2001  
     Deguchi et al. 2002 
  Mouse PTC 618  Takeda et al. 2002 
  LLC-PK1  9.1 Nagata et al. 2002 
      
Fluorescein hOAT1 Oocytes  + Islinger et al. 2001 
  CHO cells +  Cihlar and Ho. 2000 
  HeLa cells  + Lu et al. 1999 
 ? rabbit S2 segments 10  Sullivan et al. 1990 
 ? rat isolated PT cells 59  Masereeuw et al. 1994 
      
Paracetamol rOAT1 Oocytes  2099 Apiwattanakul et al. 1999 
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FL transport in isolated S2 segments of rabbit PT is inhibited by probenecid and 
PAH (IC50 6 µM and 141 µM respectively: Sullivan and Grantham, 1992). While 
specific transport proteins have not been identified in the efflux of FL into the 
luminal fluid, efflux at the luminal membrane of isolated perfused rabbit PTs has 
been found to be a saturable process and, therefore, suggested to be a carrier-
mediated process (Shuprisha et al., 2000).    
 
2.4.4 Inhibition of Renal Organic Anion Transport by Probenecid  
 
 Probenecid is a highly lipid soluble benzoic acid derivative.  Probenecid 
has been used as the prototypical inhibitor of organic anion transport across 
epithelial barriers.  This becomes extremely important in the renal PT where it 
inhibits the secretion of drugs and drug metabolites.  Probenecid was used 
originally in medicine to prolong the action of penicillin and prevent its loss in the 
urine (Insel, 1996).  Probenecid has been shown to function as an inhibitor of 
OAT1, OAT3, MRP, URAT1, NPT1, and OATP transporters (see Table 5 for 
inhibitory values and references).  Probenecid inhibits renal secretion of the 
glucuronide conjugates of NSAIDs such as naproxen, ketoprofen, indomethacin 
and causes plasma concentrations of these compounds to increase (Insel, 1996).  
Macdonald et al. (1995) also demonstrated in humans that co-administration of 
probenecid with diflunisal greatly reduces the renal clearance of diflunisal 
glucuronides (both acyl and ether). Dickinson (1993) also found a 70% reduction 
in the renal clearance of both diflunisal glucuronide conjugates.  Vree et al. 
(1993a) have suggested that probenecid may be glucuronidated in the kidney 
and that it may inhibit renal glucuronidation of such drugs as nalidixic acid (Vree 
et al., 1993b) and indomethacin (Vree et al., 1994).  The role of probenecid, 
particularly in vivo, can be complicated as it can inhibit the secretion and 
formation of glucuronide conjugates, as well as the secretion of other organic 
anions. 
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2.4.5 Renal Secretion of Acetaminophen Glucuronide (AG)  
  
Studies on renal tubular secretion of acetaminophen glucuronide have 
offered confounding results.  The liver is the primary site of acetaminophen 
glucuronidation, however, extrahepatic glucuronidation has also been found (Li et 
al., 2004).  It has been shown that serum protein binding of acetaminophen 
glucuronide in humans is less than 10% (Duggin and Mudge, 1975; Morris and 
Levy, 1984), and therefore, AG is readily available for glomerular filtration.  Renal 
clearance of acetaminophen glucuronide in many instances was determined after 
administration of acetaminophen (Morris and Levy, 1984; Galinsky and Levy, 
1981; Duggin and Mudge, 1975) and conjugate clearance values must then be 
considered as estimates of conjugate renal clearances. It has been 
demonstrated that the kidney has the ability to glucuronidate acetaminophen 
(Ross et al., 1980; Hart et al., 1980; Newton et al., 1982; Emslie et al., 1981; Li et 
al., 2004).  When acetaminophen is administered, renal glucuronidation of 
acetaminophen to AG with subsequent efflux into the tubular lumen cannot be 
separated from secretion.   
Several studies have been conducted to determine the renal secretion of 
acetaminophen glucuronide.  In 1975, Duggin and Mudge found in dog, that AG 
at low plasma concentrations (~20 µg/ml), appears to undego tubular secretion 
via an active transport process. At higher plasma concentrations of AG (~90 
µg/ml), it was found that AG appeared to be reabsorbed.  It was also found that 
net tubular AG secretion was not probenecid sensitive, while secretion of the 
sulfate conjugate of acetaminophen was probenecid sensitive (Duggin and 
Mudge, 1975).  Renal secretion of AG was also demonstrated in rat by Galinsky 
and Levy (Sprague-Dawley rats: 1981) and Watari et al. (Wistar rats: 1983).  
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Table 5. Substrate specificity of probenecid in selected OAT isoforms  
      
Compound Transporter Expression system 
Transport 
(+/-) or Km 
(µM) 
Inhibition 
(+/-) or IC50 
(µM) References 
      
      
Probenecid hOAT1 Oocytes  + Cihlar et al. 1999 
    + 
Hosoyamada et al. 
1999 
    + Islinger et al. 2001 
    + Pombrio et al. 2001 
    + Race et al. 1999 
  CHO cells  6.3 Cihlar et al. 1999 
    6.5 Ho et al. 2000 
    7.4 Mulato et al. 2000 
  HeLa cells  + Lu et al. 1999 
  Mouse PTC (S2)  4.29 Jung et al. 2001 
    12.1 Takeda et al. 2001 
  OK cells  + Motojima et al. 2002 
      
 rOAT1 Oocyte - + Uwai et al. 1998 
    + Cihlar et al. 1999 
    + Mulato et al. 2000 
    + Pombrio et al. 2001 
    + Sekine et al. 1997 
    + Sweet et al. 1997 
    + Tsuda et al. 1999 
    + Uwai et al. 2000 
    + Wada et al. 2000 
      
 hOAT2 Mouse PTC (S2)  766 Enomoto et al. 2002b 
      
 rOAT2 LLC-PK1  + Morita et al. 2001 
      
 hOAT3 Oocyte  + Cha et al. 2001 
  Mouse PTC (S2)  4.9 Jung et al. 2001 
    9 Takeda et al. 2001 
      
 rOAT3 Oocyte  + Feng et al. 2001 
     Kusuhara et al. 1999 
    1.68 Deguchi et al. 2002 
  LLC-PK1  4.43 Nagata et al. 2002 
    20 Sugiyama et al. 2001 
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In contrast to these findings, Morris and Levy (1984) found that on 
average, renal clearance of AG did not exceed creatinine clearance in human 
subjects, suggesting that AG does not undergo appreciable tubular secretion.  
This lack of secretion, however, may be due to a balance between secretion and 
reabsorption.  It has also been suggested in studies in dog, that AG is completely 
filtered at the glomerulus and does not undergo secretion (Heckman et al., 1986). 
 There are many factors that determine renal secretion of AG. It has been 
reported that the kidney has the potential to secrete AG, and this secretion is 
most likely via the organic anion transport pathway.  However, to date, all studies 
have been conducted in whole animals, or whole organ systems.  Currently there 
is no information at the cellular level about the renal handling of AG, or other 
glucuronide conjugates.  
 
2.5 Summary 
 
 Glucuronidation is an important biotransformation process that can lead to 
the formation of both inert and reactive metabolic metabolites.  Toxicity 
associated with glucuronide conjugates has primarily been associated with the 
glucuronide metabolites of carboxylic acid containing compounds.  
Glucuronidation of carboxylic acids leads to the formation of acyl glucuronides 
which have been shown to be reactive intermediates.  Acyl glucuronides have 
been shown to become covalently bound not only to serum proteins, but also 
within various tissues of the body.  This covalent binding can lead to toxicity and 
hypersensitivity reactions.  Currently, there is little knowledge about how the 
kidney handles glucuronide metabolites, and whether transport of reactive acyl 
glucuronide metabolites has any implications for the nephrotoxicity of certain 
compounds, particularly NSAIDs which have been shown to form acyl 
glucuronide metabolites.  Glucuronide conjugates are organic anions, carrying a 
negative charge at physiological pH.  The renal PT, which is the primary site of 
xenobiotic secretion in the kidney, possesses several organic anion transport 
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proteins along the basolateral membrane that facilitate uptake of organic anions 
from the blood into the proximal tublular cells. Table 2 provides a brief summary 
of the characteristics of these OAT transporters.   The kidney has been shown to 
demonstrate transport of several organic anions including PAH, fluorescein, and 
estrone sulfate.  Tables 4 and 5 provide a list of various OAT substrates with Km 
values.  These OAT proteins (principally OAT1 and OAT3) may be responsible 
for the transport of glucuronide conjugates in the kidney. However, information 
on renal handling of glucuronide conjugates by basolateral OAT proteins in the 
kidney is currently lacking.  Since information on renal glucuronide handling is 
extremely limited, this project was designed to investigate the transport of a 
prototypical glucuronide, acetamidophenyl glucuronide (AG).  To study the 
transport of AG by the kidney, rat in vitro models were used to gain insight into 
how the kidney may secrete glucuronide metabolites with emphasis on the 
basolateral organic anion transport system.    
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CHAPTER III 
 
Methods 
 
3.1 Animals 
 
 Male Fischer 344(F344; 175-200 g) and Sprague-Dawley rats (SD; 200-
250 g) were obtained from Hilltop Lab Animals, Inc. (Scottdale, PA) and were 
placed in standard plastic cages prior to use.  Animals were maintained under 
controlled ambient temperature (21-23ºC), humidity (40-55%) and light cycle 
(lights on 0600-1800 h) with free access to food (Purina Rat Chow) and water at 
all times.  Animals were allowed a minimum of 5 days to acclimatize to the 
animal facilities prior to tissue collection.  
 
3.2 Materials 
  
4-Acetamidophenyl-ring-UL14C β-D-glucuronide sodium salt (AG; specific 
activity: 48.8 mCi/mmol ), was purchased from Sigma Chemical Co. (Saint Louis 
MO) (Cat.  no. A 1329).  p-[Glycyl-14C]-aminohippuric acid (PAH; specific activity: 
52.7 mCi/mmol) (Cat no. NEC 563), D-[1-3H(N)]-mannitol (MN; specific activity:17 
Ci/mmol) and [6,7-3H(N)]-estrone sulfate, ammonium salt (ES; specific activity: 
46 Ci/mmol) (Cat no. NET 1012 and NET 203, respectively) were purchased 
from Perkin Elmer Life and Analytical Sciences (Boston, MA).  All other 
chemicals not listed were purchased from Sigma Chemical Co (St. Louis, MO) or 
Fisher Scientific (Agawam, MA) and were of highest purity available. 
 
4-Acetamidophenol (acetaminophen, APAP): Aldrich: A7302 
p-Acetamidophenyl β-D-glucuronide: Sigma: A4438 
Adenosine 5’-triphosphate: Sigma: A2383 
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Bovine Serum Albumin (BSA): Sigma: A4503 
Brilliant Blue G250 (Coomassie blue): Fisher: BP100-25 
Collagenase IV: Sigma: C9891 
Dehydroepiandrosterone sulfate: Sigma: D5297 
Deoxyribonuclease 1 (DNase 1): Sigma: DN 25 
Diclofenac: Sigma: D6899 
ECL™ Western Blotting Detection Reagents (Amersham Biosciences, RPN2106)† 
Estrone-3-sulfate: Sigma: E 0251 
Fluorescein: Sigma: F6377 
Heparin: Sigma: H3393 
HK-2 human kidney, PTCs, transformed (ATCC, CRL-2190) 
Hyperfilm™ ECL high performance chemiluminescence film (Amersham Biosciences, 
RPN2114K) †  
Methylumbelliferyl glucuronide: Sigma: M9103 
Nicotinamide adenine dinucleotide phosphate: Sigma: N0505 
OAT1 antibodies, affinity pure (Alpha Diagnostic International, OAT11-A) 
OAT3 antibodies, affinity pure (Alpha Diagnostic International, OAT31-A) 
Ouabain: Sigma: O3125 
p-aminohippuric acid: Sigma: A1422 
Pentobarbital: Sigma: P3761 
Penicillin G (Benzylpenicillin): Sigma: P3020 
Percoll ®: Sigma: P1644 
Probenecid: Sigma: P8761 
D-Saccharic acid 1,4-lactone: Sigma: S0375 
Scintiverse II: Fisher: SX12-4 
Soy bean trypsin inhibitor: Sigma: T9003 
Testosterone glucuronide: Sigma: T8157 
Triton X-100: Fisher: BP151 
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Endo H (endoglycosidase H) (New England Biolabs, P0702S) 
 
3.3 Equipment 
 
Located in VA Research Building: 
Masterflex peristaltic pump 
Osmette S osmometer 
Mettler analytical balance 
Corning pH meter 
Dubnoff metabolic shaking incubators 
Sorvall® Microspin 12 Centrifuge  
 
Common facilities VA Research Building: 
Beckman J6 MI refrigerated centrifuge 
Beckman Avanti J25 ultracentrifuge 
Beckman Optimal XL-100K Ultracentrifuge, Rotor SW 60 Ti 
Beckman Avanti centrifuge, rotor J14 
Phase contrast microscope 
Beckman UV/Vis spectrophotometer 
Perkin Elmer HTS 7000 bioassay reader-fluorescent microplate reader 
Wallac 1409 liquid scintillation counter 
Forma Scientific BioFreezer (-80) 
IEC Centra CL2 Centrifuge 
 
Medical Education Building: 
Sorvall® RC 5B Refrigerated Superspeed Centrifuge, SS-34 rotor 
Sorvall® MC5B Centrifuge 
Beckman 126 HPLC 
Trans-Blot Electrophoretic Transfer Cell (BioRad)† 
Micromax RF Centrifuge, International Equipment Company 
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† All reagents and equipment for Western blot analysis were kindly provided by Dr. 
Kelley Kiningham. 
  
3.4 Isolation of Renal Proximal Tubules (IRPT) 
 
Male F344 rats were anestisized (pentobarbital sodium, 50mg/kg, i.p.) and 
renal proximal tubule (IRPT) fragments were isolated following the procedure 
described by Gesek et al. (1987) and modified by Aleo et al. (1991).   Additional 
modifications were made, initiating renal retrograde perfusion by the procedure of 
Jones et al. (1979).  The level of anesthesia was assessed using the toe pinch 
and corneal reflex methods.  The peritoneal cavity was opened by a midline 
incision and 0.2 ml heparin (0.2% w/v in 0.9% saline) injected into the femoral 
vein.  Ligatures were placed under the lower abdominal aorta (below the renal 
arteries), the coeliac and superior mesenteric arteries, and the upper abdominal 
aorta (as high in the abdominal cavity as possible). The ligature was then tied 
around the upper aorta, and the rat was sacrificed by bilateral pneumpthorax 
exsanguination.  The celiac, mesenteric and lower abdominal arteries were then 
ligated.  A small incision was made in the lower abdominal aorta above the 
ligature and a cannula (blunted 19 x 7/8 butterfly infusion set) inserted and tied in 
place.  Retrograde perfusion was then initiated with the kidneys in situ with 75 ml 
of oxygenated (95% O2 /5% CO2) Perfusion buffer A (see appendix for buffer 
composition) at 12 ml/min for 3 min at 37ºC.  The kidneys were transferred to a 
beaker containing continuously oxygenated Perfusion buffer A from which the 
buffer was being withdrawn to provide a recirculating system.  After initial 
perfusion, cannulated kidneys were transferred to Perfusion buffer B (see 
appendix for buffer composition) for an additional 3 min (also continuously 
oxygenated).  Following perfusion, kidneys were removed from the perfusion 
apparatus, decapsulated, and cortical tissue dissected away from the medulla, 
minced, and placed in a 50 ml plastic beaker with 25 ml of oxygenated 
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collagenase containing Incubation buffer (see appendix for composition).  
Digestion of cortical tissue was initiated at 37ºC in a shaking water bath (60 rpm) 
with continuous oxygenation.  After 15 min, solid kidney tissue was allowed to 
settle in the beaker and freed PTs (PTs) remaining in suspension in the 
incubation buffer were removed by transfer pipette and placed in a 50 ml 
centrifuge tube.  The suspension was centrifuged at 50 x g for 2 min at 4º C in a 
Beckman J6MI centrifuge (JS 4.2 rotor).  The supernatant was removed and 
reserved for further cortical tissue digestion and the pellet was resuspended in 
oxygenated ice cold 1x Krebs-Henseleit (KH) buffer (see appendix for 
composition) and kept on ice.  The remaining tissue was digested with an 
additional 25 ml of Incubation buffer for additional 5 min intervals until cortical 
tissue was completely digested.  Total incubation time was typically 25 min.  PTs 
were removed at the end of each 5 min interval, centrifuged as described and 
combined.  The total pellet was then rinsed three times by resuspension in 25 ml 
ice cold 1x KH buffer and centrifugation at 50 x g for 2 min.  The final PT pellet 
was then resuspended in 10 ml 1x KH buffer. This suspension of PT tubules was 
then divided in half and each 5 ml resuspended in polycarbonate round bottom 
centrifuge tubes each containing 30 ml oxygenated 45% Percoll solution (see 
appendix for compositon). A 5 ml 100% Percoll cushion was then injected into 
the bottom of each tube using a transfer pipette (Fig. 3.1A).  PTs were then 
centrifuged at 17,000 x g for 10 min at 4º C in either a Beckman Avanti ™ 
Ultracentrifuge (JA 14 rotor) or a Sorvall® RC 5B superspeed centrifuge (SS 34 
rotor) (allowed stopping without brake).  Following centrifugation PTs formed a 
uniform layer above the cushion layer (Fig. 3.1B).  This layer was removed using 
a transfer pipette, and rinsed three times in 1x KH buffer at 500 x g for 5 min  at 
4º C in a Beckman J6MI centrifuge (JS 4.2 rotor).  PTs were then resuspended in 
oxygenated Transport buffer #1 (see appendix for composition) at a 
concentration of 1.0 mg protein/ml for all assays. Protein content was determined 
by the Bradford (1976) method using BSA as the standard and expressed in mg 
protein/ml.  
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3.5 Characterization of proximal tubules 
 
Following isolation of PTs, biochemical and visual characterization of the 
isolated PTs was done to determine the purity of the isolated material.  Analysis 
was conducted immediately following tubule isolation from the renal cortical 
tissue (pool sample), and again following Percoll density gradient enrichment (PT 
sample).  Tubules were analyzed for alkaline phosphatase (AP), a brush border 
enzyme found only in the proximal tubular segment of the nephron and for 
hexokinase (HK), a cytosolic enzyme present in highest concentrations in the 
distal portion of the nephron.  In addition to enzymatic characterization, lactate 
dehydrogenase (LDH) release was analyzed to determine the viability of tubules 
both before (pool sample) and after Percoll enrichment (PT sample).  LDH is a 
cytosolic enzyme that is released due to cell death or damage.    
 
3.5.2 Biochemical characterization of proximal tubules 
 
Alkaline phosphatase (AP): AP activity was measured 
spectrophotometrically using Sigma Diagnostics Kit 104, based on the procedure 
of Bessey et al (1946).  This assay is a quantitative colorimetric determination of 
AP and absorbance was measured on a Beckman DU® 530 Life Science UV/Vis 
spectrophotometer at 410 nm (10 mm cuvet).  This procedure depends on the 
hydrolysis of p-nitrophenyl phosphate by the alkaline phosphatase enzyme 
yielding p-nitrophenol and inorganic phosphate.  When made alkaline, p-
nitrophenol is converted to a yellow complex that is readily measured at 400-420 
nm.  The intensity of the color is proportional to the phosphatase activity.   For 
comparison purposes, AP activity was expressed in nmol p-nitrophenol 
liberated/min/mg protein. 
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                   17,000 x g 
 
                                   
 
                100%                                                     100% 
 
                  A                                      B 
Figure 3.1. Schematic diagram of renal cortical tissue before and after 
Percoll density centrifugation. (A) Renal cortical tissue was resuspended in 30 ml of 
45% Percoll solution with a 5 ml 100% Percoll cushion injected into the bottom of the tube.  
Before separation, all digested cortical tissue was equally distributed in the 45% Percoll solution.  
(B) Following centrifugation at 17,000 x g for 10 min. PTs formed a uniform layer above the 100% 
Percoll cushion.  This layer was then removed by transfer pipette and represents the purified PTs 
used in uptake studies. Glomeruli, distal tubule (DT) fragments and individual cells were primarily 
found at the top of the Percoll gradient.  The PT layer has minimal contamination by short DT 
fragments and individual cells as determined by enzymatic and visual characterization.   
 
 
To determine AP content, 50 µl of sample or water (blank) was added to a 
tube containing  0.5 ml 221 alkaline buffer solution and 0.5 ml stock substrate 
solution (warmed to 37 º C) (see appendix for buffer and substrate composition), 
mixed and incubated for 5 min at 37 º C.  After 5 min, 10 ml 0.05 N NaOH was 
added to each tube and mixed.  Absorbance of the sample vs. blank was then 
read at 410 nm and AP units determined from a calibration curve.  Four drops of 
concentrated HCl were then added to each tube (both sample and blank) and 
absorbance of sample vs. blank read at 410 nm and AP activity determined from 
the calibration curve.  To determine the final value for AP activity, the AP activity 
value following HCl treatment was subtracted from the original AP activity value 
for each sample, yielding the corrected AP activity for each sample.  This final 
62 
value was then multiplied 3x to account for using only a 5 min incubation rather 
than a 15 min incubation as directed by the assay protocol.  This decreased 
incubation time was used because tubules had such high concentrations of AP. 
 
Calibration curve for alkaline phosphatase: 
1 2 3 4
 Tube 
No.
 Diluted p-
Nitrophenol 
solution (mL)
NaOH 0.02 N 
(mL)
Alkaline 
Phosphatase 
Activity Sigma 
Units/mL
1 1.0 10.0 1.0
2 2.0 9.0 2.0
3 4.0 7.0 4.0
4 6.0 5.0 6.0
5 8.0 3.0 8.0
6 10.0 1.0 10.0  
 
 
To create the calibration curve, the solutions indicated in columns 2 and 3 
were pipetted into numbered tubes, and absorbance of each read immediately at 
410 nm using 0.02 N NaOH as reference.  The calibration curve was constructed 
by plotting absorbance vs. units in column 4.  
 
Hexokinase (HK): Hexokinase activity was measured by the method of 
Joshi and Jagannathan (1966).  This is a spectrophotometric kinetic assay 
measured at 340 nm.  To determine the HK activity in IRPT samples, 0.1 ml of a 
1 mg protein/ml IRPT suspension was mixed with 0.01 ml 10 % (v/v) Triton-X 
100, 0.5 ml substrate solution, 0.5 ml NADP+, 2.88 µl G6PDH (at 600 units/ml), 
7.12 µl H2O, and 0.5 ml ATP in 10 mm pathlength 4.5 ml polystyrene disposable 
cuvette (see appendix for composition of all substrates and chemicals).  The total 
reacting volume (1.62 ml) was then mixed and the change in absorbance was 
measured immediately for 3 min.  The hexokinase assay is based on the 
following reactions: 
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Glucose + ATP + H2O           Glucose-6-phosphate + ADP + Pi 
Glucose 6-phosphate + NADP+         6-phosphoglucose + NADPH + H+ 
 
 Hexokinase activity was calculated as follows: 
HK activity = A340 min-1/ [6.22 x 103 mol-1L)(103 ml-1)]x 109 nmol mol-1 x 16.2) 
                                = 2604.5 nmol  x ∆ ABS/min 
For comparison purposes activity was expressed in nmol NADP+ 
reduced/min/mg protein.   
 
Visual characterization: Visual appearance of isolated material was 
determined using a Nikon inverted Diaphot-TMD phase contrast microscope, with 
100x magnification.   Using a transfer pipette, a small amount of PT suspension 
was placed on a microscope slide and visualized for PT content following Percoll 
separation.   
  
3.5.2 Protein content analysis- Bradford method 
 
Protein content was measured by the Bradford (1976) method using 
bovine serum albumin (BSA) as the standard.  To determine the amount of 
protein in initial IRPT isolates from Percoll separation, a 100 µl aliquot was 
removed and diluted in 400 µl H2O in a glass Wheaton Tissuemizer.  The PT 
suspension was homogenized and 25 µl of PT homogenate was analyzed for 
total protein content and calculated from a standard curve. Each 25 µl aliquot 
was placed in a 13x100 mm tube to which 25 µl of H2O was added for a total 
reacting volume of 50 µl.  Bradford reagent (2.5 ml) was then added to each 
tube, mixed on a vortex and allowed to incubate at room temperature.   The 
remaining IRPT isolate from the Percoll separation was then diluted to a 1 mg 
protein/ml concentration with the appropriate amount of transport buffer for 
toxicity and uptake studies.  The protein content in toxicity and uptake study 
samples was determined by analyzing either a 10 or 25 µl aliquot of IRPT 
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suspension from each flask and the amount of protein calculated from a standard 
curve, following a freeze thaw cycle of each sample to rupture the cell 
membranes.  Each sample aliquot was brought to a final reacting volume of 50 µl 
with the appropriate amount of H2O before the addition of Bradford reagent.  The 
concentration curve was made using 1 and 2 mg protein/ml stock solutions of 
BSA.  A 2 mg protein/ml solution of BSA was made by diluting 20 mg BSA/ 10 ml  
distilled H2O and a 1 mg protein/ml solution was made by making a 1:1 dilution of 
a portion of the 2 mg protein /ml solution.  Protein standards for the assay were 
prepared as described below (in duplicate) in 13x100 mm tubes: 
Protein Stock Volume stock Volume water Amount of Protein
2 mg/ml 30 µl 20 µl 60 µg
2 mg/ml 25 µl 25 µl 50 µg
2 mg/ml 20 µl 30 µl 40 µg
1 mg/ml 30 µl 20 µl 30 µg
1 mg/ml 20 µl 30 µl 20 µg
1 mg/ml 10 µl 40 µl 10 µg
1 mg/ml 5 µl 45 µl 5 µg
 
Bradford dye reagent (2.5 ml; see appendix for composition) was then added to 
each tube, mixed on a vortex and absorbance read at 595 nm using a Stasar III 
spectrophotometer (once mixed on a vortex, tubes were allowed to sit at room 
temperature for a minimum of 2 min, maximum of 1 hour). The absorbance of 
sample aliquots was measured in the same manner.    
 
3.5.3 Lactate dehydrogenase (LDH) assay 
 
 LDH release was analyzed by a spectrophotometric kinetic assay (Sigma 
Diagnostics® Lactate dehydrogenase (LD-L) kit (procedure No. 228-UV) 
measured at 340 nm. This assay is based on the reaction: 
  
Lactate + NAD+        LDH       Pyruvate +NADH + H+ 
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Formation of NADH results in an increase in absorbance at 340 nm. The 
rate of increase in absorbance is directly proportional to LDH activity in the 
sample. 
 
LDH release was assayed upon completion of enzymatic isolation of renal 
cortical tissue (pool sample), Percoll enrichment of cortical tissue (PT sample) or 
following incubation of IRPTs with a test compound.  At this time, a 0.5 ml PT 
sample was taken and centrifuged to separate the “media” from “tissue” portion 
of the sample.  The supernatant was decanted and reserved as the media 
sample.  The remaining pellet (tissue sample) was homogenized in 1.0 ml of 10% 
Triton-X 100 to release intracellular LDH.  The amount of LDH activity was then 
determined for both the tissue and media portions of the sample and LDH 
release into the media was expressed as percent of total. 
 
3.6 Toxicity experiments in IRPTs 
 
All toxicity experiments were conducted by placing 3-4 ml of tubule 
suspension in 25 ml polycarbonate Erlenmeyer flasks. Flasks were then placed 
in a shaking water  bath incubator at 37ºC and sealed with a serum bottle stopper 
with an inlet and outlet for gas flow (95% O2/5% CO2). The atmosphere was 
equilibrated with shaking for 20 min in initial experiments but was shortened to 5 
min in later experiments as shorter preincubations appeared to decrease 
variability between treatments.  All assays were run in duplicate or triplicate 
depending on yield of tubule material. 
 
3.6.1 Toxicity studies with acetaminophen (APAP), acetamidophenyl-β-D-
glucuronide (AG), and diclofenac (DC) 
 
 Assays were run in duplicate for each treatment and time point.  Toxicity 
was assessed by both increased lactate dehydrogenase (LDH) release and 
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alterations nucleotide levels (ATP, ADP, AMP).  After preincubation, flasks 
containing 3.0 ml of PT suspension were treated with 30.0 µL distilled H2O 
(control), 20 or 50mM APAP, AG or DC for a final concentration of 200 or 500 µM 
APAP, AG or DC.  After addition of compound, oxygenation stoppers were 
replaced and shaking resumed at 100 rpm for 15, 30, or 60 min.  At the end of 
each time point, 1.0 ml was removed for nucleotide analysis, and 0.5 ml removed 
and placed in a second 1.5 ml centrifuge tube for LDH analysis (as described in 
section 3.5.3). 
 
3.6.2 Nucleotide (ATP, ADP, AMP) isolation 
 
Following incubation with control (H2O) or test compound 1.0 ml from each 
flask was removed and placed in a labeled 1.5 ml centrifuge tube and centrifuged 
for 10 min at maximum speed in a tabletop Sorvall Microspin centrifuge.  The 
supernatant was discarded, and 300 µl 0.9% saline added to each pellet.  Each 
pellet was mixed on a vortex to resuspend PTs and 50 µl removed for protein 
analysis.  Perchloric acid (3M, 125 µl) was added to the remaining 250 µl of PTs 
in each sample tube and mixed on a vortex to precipitate proteins.  Following 
addition of perchloric acid, sample tubes were kept on ice for 5 min, mixed on a 
vortex and centrifuged for 10 min at maximum speed. A 300 µl aliquot of 
supernatant was then removed from each sample tube, placed on ice in a clean, 
labeled 1.5 ml centrifuge tube, and the pH adjusted to approximately 7.0 with 6N 
KOH (volume of KOH recorded).   All sample tubes were kept on ice for the 
duration of nucleotide isolation. Following pH adjustment the tubes were 
centrifuged for 10 min at 2000 x g in a Sorval MC12V centrifuge.  The 
supernatant was prepared for HPLC analysis by filtration (Millipore HV .45 µm 
syringe filter) of 200 µl of supernatant, 200 µl distilled H2O, and air pushed 
through the filter into a clean labeled 1.5 ml centrifuge tube.  Each filtered sample 
was frozen at -80º C until analyzed.   
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 Levels of ATP, ADP and AMP were determined using an HPLC method 
adapted from Lash et al. (1995).  A 100 µl aliquot of extracted nucleotide sample 
was injected into a Beckman 126 model HPLC with a 100 µl injection loop. The 
mobile phase was a gradient of two solutions: Solvent A: 100 mM potassium 
phosphate, pH 6.0, and Solvent B: methanol. The gradient was 7.5 min at 100% 
A; 7.5 min linear gradient to 90% A; 15 min linear gradient to 75% A; 0.5 min 
linear gradient to 100% A and a 10 min re-equilibration at initial conditions.  The 
flow rate of the mobile phase was 1.3 ml/min. The column was a Radial-Pak C18 
cartridge (8 mm x 10 mm) (Waters Inc.; Milford, MA).  The wavelength for 
detection was 254 nm.  Adenine nucleotide concentrations were calculated from 
standard curves of ATP, ADP and AMP (0.94 - 9.4 nM), and expressed as 
nmol/mg protein. 
Preparation of nucleotide standards: 
Each standard sample for ATP, ADP and AMP was prepared in 1 ml of H2O. 
  2.07 mg ATP (3.75 mM) 
  1.60 mg ADP (3.75 mM) 
  1.30 mg AMP (3.75 mM) 
Each standard was diluted 1:10 for a final concentration of 0.376 mM.  A final 1.0 
ml standard of each was made by adding 250 µl of 1:10 dilution to yield a final 
standard concentration of 0.094 µmol/ml.   
   
3.7 IRPT model characterization for organic anion transport (OAT) 
 
 Currently, there is limited quantitative information on the ability of the F344 
rat kidney to transport classical organic anion transport (OAT) substrates.  To 
verify that this model carried out organic anion transport, tubules were treated 
with various compounds that have been shown to be transported by the organic 
anion transporting proteins in the proximal tubular basolateral membrane in the 
kidney in other animal models.  For these studies, the compounds selected to 
characterize this model were fluorescein (FL) (OAT 1 and 3), p-aminohippuric 
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acid (PAH) (OAT 1 and 3), and estrone sulfate (ES) (OAT 3).  Both uptake and 
inhibition studies were conducted to show the presence and function of OAT in 
this system. 
All uptake experiments were conducted by placing 3 ml (FL uptake 
experiments) or 4 ml (radioisotope experiments) of tubule suspension in 25 ml 
polycarbonate Erlenmeyer flasks. Flasks were then placed in a shaking water  
bath incubator at 37ºC and sealed with a serum bottle stopper with an inlet and 
outlet for gas flow (95% O2/5% CO2). The atmosphere was equilibrated with 
shaking for 20 min in initial FL experiments but was shortened to 5 min in later FL 
experiments as the longer time appeared to decrease variability between 
treatments. Preincubation for all radioisotope studies was carried out for 5 min.  
FL assays were conducted in duplicate or triplicate depending on tubule yield, 
and all radioisotope experiments were conducted in duplicate. 
 
3.7.1  Accumulation and quantification of FL in IRPTs 
 
Uptake and accumulation of 4 µM fluorescein (FL) in IRPTs was used to 
assess the presence and function of OAT transport in this model.  Each 
experiment is described in detail following this section.  This section primarily 
describes the quantification of FL content from each PT suspension sample 
following treatment. 
In the experiments described in this section, to determine the amount of 
FL accumulation in IRPTs, 1.0 ml of PT suspension was removed from each 
flask at the end of the given time point and placed on ice in 5.0 ml ice cold 
Transport buffer #1 in a 15 ml centrifuge tube to stop FL uptake.  PT suspension 
samples were immediately centrifuged at 2500 x g for 2 min.  The supernatant 
from each sample tube was discarded and PT pellets were then rinsed again in 5 
ml ice cold buffer and pellets frozen in an inverted position to allow excess buffer 
to drain from the PT material.  PT pellets were ruptured either by freeze/thaw 
(frozen at – 20 º C for approximately 12 hours with subsequent addition of 1.5 ml 
69 
distilled water), or by homogenization with a Techmar Tissuemizer to release 
intracellular (cytosolic) FL.  After disruption, material was centrifuged at 2500 x g 
for 5 min to pellet cellular debris.  Cytosolic FL content in the supernatant was 
determined using a Perkin Elmer HTS 7000 bioassay fluorescence microplate 
reader (485 nm excitation, 538 nm emission).  Triplicate 100 µl aliquots were 
taken from each sample and placed in a 96 well plate.  To determine the FL 
content of each sample, samples were compared against standards of 4.0, 3.2, 
2.4, 1.6, 0.8, 0.4, 0.2, and 0.0 µM FL and corrected for background untreated PT 
fluorescence.  FL values were then converted to nmol/mg protein.  An additional 
1.0 ml was removed from each flask for protein determination using the Bradford 
(1976) method.    
 
3.7.1.1 Time-dependent accumulation of FL in IRPTs 
 
Time-dependent accumulation of FL was measured to assess the 
temporal aspects of OAT transport function in this model, and also to determine 
the best time points for subsequent assays.  Following preincubation as 
previously described in section 3.6, 30 µl of 400 µM FL was added to each flask 
containing 3 ml of PT suspension for a final concentration of 4 µM FL.  Tubules 
were then incubated at 37ºC in a shaking water bath (100 rpm) for 15, 30, 45, 60, 
and 120 seconds.   At the end of each time point, samples were assayed for FL 
content as described in section 3.7.1.   
 
3.7.1.2 The effect of temperature on FL accumulation in IRPTs 
 
Temperature dependent accumulation of FL by IRPTs was used as a 
marker for active, carrier protein-mediated uptake along the tubular basolateral 
membrane in this model.  Cellular transport of molecules requires temperatures 
closer to physiological levels (37ºC); accumulation of FL at cold temperatures 
(4ºC) will allow the distinction between basolateral protein-mediated transport, 
70 
and non-specific binding to tubular proteins or passive diffusion.  Tubules were 
preincubated at either 4ºC or 37ºC.  Following preincubation, 4 µM FL was added 
to each flask and incubated as previously described at 4ºC or 37ºC for 2 min. At 
the end of the 2 min incubation period, samples were assayed for FL content as 
described in section 3.7.1. 
 
3.7.1.3 The effect of probenecid on FL accumulation in IPRTs and 
determination of the IC50 for probenecid accumulation in IRPTs  
 
Probenecid is used as the typical inhibitor of organic anion transport (both 
OAT 1 and OAT 3) (Insel, 1996).  To determine the effect of probenecid (and 
thus the contribution of OAT) on FL accumulation in this model, 3 ml of IRPTs at 
1 mg protein/ml were incubated for 2 min at 37ºC in a shaking water  bath (100 
rpm) with 4 µM FL alone or co-incubated with 4 µM FL and 1 mM probenecid.  At 
the end of the 2 min incubation period, samples were assayed for FL content as 
described in section 3.7.1. 
To determine the inhibitory concentration that provides half maximal 
inhibition (IC50) for probenecid on FL accumulation in this model, 3 ml of IRPTs at 
1 mg protein/ml were incubated for 2 min at 37ºC in a shaking water  bath (100 
rpm) in the presence of increasing concentrations of probenecid (5-250 µM).  At 
the end of the 2 min incubation period, samples were assayed for FL content as 
described in section 3.7.1.  
 
3.7.1.4 The effect of ouabain on FL accumulation in IRPTs 
 
Ouabain is an inhibitor of the sodium/potassium ATPase, the energy 
driving force for OAT 1 transport along the basolateral membrane in renal PTs. 
To determine the effect of ouabain, and thus the contribution of OAT 1 to FL 
accumulation in this model, 3 ml of IRPTs at 1 mg protein/ml were incubated for 
2 min at 37ºC in a shaking water  bath (100 rpm) with 4 µM FL alone or in the 
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presence of 100 µM ouabain.  Ouabain was added to tubules 10 min prior to the 
addition of FL to insure adequate inactivation of sodium/potassium ATPase.  Due 
to the light sensitivity of ouabain, all incubations were conducted in the dark.  At 
the end of the 2 min incubation period, samples were assayed for FL content as 
described in section 3.7.1. 
 
 3.7.1.5 The effect of benzylpenicillin (PG) on FL accumulation in IRPTs 
 
PG has been shown to be a relatively selective inhibitor of rOAT3 
(Hasegawa et al. 2002).  To determine the contribution of OAT 3 in the 
accumulation of FL in this model, 3 ml of IRPTs at 1 mg protein/ml were 
incubated for 2 min at 37ºC in a shaking water  bath (100 rpm) with 4 µM FL 
alone or in the presence of 1 mM PG. At the end of the 2 min incubation period, 
samples were assayed for FL content as described in section 3.7.1. 
 
3.7.1.6 The effect of dehydroepiandrosterone sulfate (DHEAs) on FL 
accumulation in IRPTs 
 
DHEAs has been demonstrated to be a substrate of OAT3 (Cha et al, 
2001).  To determine the contribution of OAT3 in the accumulation of FL in this 
model, 3 ml of IRPTs at 1 mg protein/ml were incubated for 2 min at 37ºC in a 
shaking water  bath (100 rpm) with 4 µM FL alone or in the presence of 1 mM 
DHEAs.   At the end of the 2 min incubation period, samples were assayed for FL 
content as described in section 3.7.1. 
  
 3.7.1.7 The effect of 4-acetamidophenyl-β-D-glucuronide (AG) on FL 
accumulation in IPRTs 
 
To determine the ability of AG to interact at the site of FL transport in this 
model (presumably OAT1 and/or OAT3), 3 ml of IRPTs at 1 mg protein/ml were 
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incubated for 2 min at 37ºC in a shaking water  bath (100 rpm) with 4 µM FL 
alone or in the presence of 500 µM AG.  At the end of the 2 min incubation 
period, samples were assayed for FL content as described in section 3.7.1. 
 
3.7.2 Accumulation and quantification of radioisotopes (14C and 3H) in IRPTs 
 
To further characterize the uptake of typical OAT substrates in IPRTs, 14C 
and 3H radiolabeled substrates were used.  The general method of test 
compound incubation and determination of isotope content of IRPTs following 
treatment is discussed in this section.  Specific details of each uptake experiment 
are given in subsequent sections, but all analysis of radioisotope accumulation 
follow the same method as described in this section. Briefly, 25 ml polycarbonate 
flasks with 4 ml of 1 mg protein/ml PT suspension were preincubated for 5 min. A 
1 ml aliquot was then removed for protein determination before addition of 
isotope.  14C-p-Aminohippuric acid (PAH), 3H-estrone-3-sulfate (ES), or 14C-
acetamidophenyl-β-D-glucuronide (AG), (approximately 0.1 - 0.2 µCi/ml) was 
added to each flask containing 3.0 ml of 1mg protein/ml IRPT suspension (see 
appendix for composition of stock and working solutions of radioisotopes). In 
each individual experiment, isotope concentrations vary slightly due to variation 
in the mixing of new working isotope solutions.  Each working solution was made 
from stock isotope solutions and counted for radioactivity, and concentration 
calculated before use in each experiment.  Tubules were incubated at 37º C in a 
shaking water  bath (180 rpm) (specific time points given in experiment 
description).  At the end of each time point, 5.0 ml ice cold transport buffer was 
added to each flask to stop uptake.  Flasks were decanted into 15 ml centrifuge 
tubes and each flask was rinsed with an additional 5 ml cold buffer, and this rinse 
was added to initial 8.0 ml before centrifugation.  PT suspensions were then 
centrifuged for 1 min at 7500 rpm in a IEC Centra CL2 Centrifuge.  Tubule pellets 
were rinsed 2x in 5 ml ice cold transport buffer, resuspended in 1.0 ml of distilled 
H2O and homogenized with a Teckmar Tissuemizer.  Radioactivity of the total 1 
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ml IRPT homogenate (in two 0.5 ml aliquots) was then determined by liquid 
scintillation counting on a Wallac 1409 Liquid Scintillation Counter (LSC).  Each 
0.5 ml aliquot was placed in a 5 ml plastic scintillation vial, to which 5 ml of 
Scintiverse II were added.  Each vial was labeled and mixed on a vortex before 
being analyzed.  Untreated tubules were used to correct for background activity.  
Untreated tubules were prepared in the same manner as those treated with 
radioisotopes.  Untreated tubules (1 ml) were homogenized and two 0.5 ml 
aliquots were used for “blank” measurements on the LSC for each experiment.   
 
3.7.2.1 The effect of probenecid on PAH accumulation and the 
determination of the IC50 for probenecid on PAH accumulation in IRPTs 
 
Accumulation of 14C-PAH by IRPTs was used as a marker for basolateral 
OAT1 and OAT3 uptake in this model.  Three milliliters of tubule suspension 
were incubated at 37ºC for 2 min with 73.8 µM 14C-PAH (0.2 µCi/ml) alone, or in 
the presence of 1 mM probenecid.  IRPT samples were then prepared and 
analyzed for 14C-PAH content as described in section 3.7.2.    
  To determine the IC50 value for probenecid inhibition of PAH in this model, 
3 ml of tubule suspension were incubated at 37ºC for 2 min with 4.5 µM 14C-PAH 
(0.24 µCi/ml) in the presence of increasing concentrations of probenecid; 25, 50, 
100, 150, and 250 uM.  IRPT samples were then prepared and analyzed for 14C-
PAH content as described in section 3.7.2 
 
 3.7.2.2 The effect of AG on PAH accumulation in IRPTs 
 
Inhibition of 14C-PAH accumulation by AG was evaluated to assess the 
interaction of AG at the site of basolateral PAH transport (OAT1 and OAT3) in 
this model.  Three milliliters of tubule suspension were incubated for 30 seconds 
with 2.5 µM 14C-PAH (0.13 µCi/ml) alone, or in the presence of 1 mM AG.  The 
concentration of PAH used in this experiment was minimized to maximize the 
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potential for reaction at the transport site for PAH.  Since PAH is such a good 
substrate for OAT1 and OAT3, to determine whether AG could interfere with PAH 
at the site of transport, the minimum amount of PAH was used so as to maximize 
the effect of AG in competing for potential transport sites.  IRPT samples were 
then prepared and analyzed for 14C-PAH content as described in section 3.7.2. 
 
3.7.2.3 The effect of testosterone glucuronide (TG) and methylumbelliferyl  
glucuronide (MUG) and AG on PAH accumulation in IRPTs 
 
Inhibition of 14C-PAH accumulation in IRPTs by TG and MUG was 
investigated to evaluate the interaction of additional glucuronide metabolites at 
the site of basolateral PAH transport (OAT 1 and 3) in this model.  The effect of 
AG on14C-PAH accumulation was also determined in this experiment as an 
additional control for the effects of TG and MUG (i.e. do all three glucuronides 
appear to have the same or different effects on PAH accumulation). Tubule 
suspensions (3 ml at 1 mg protein/ml) were incubated at 37ºC for 30 seconds 
with 4.4 µM 14C-PAH (0.23 µCi/ml) alone, or in the presence of 500 µM TC, MUG 
or AG.  A higher concentration of PAH was used in this experiment to assure 
consistant counting results on the LSC. Lower concenterations used in previous 
experiments often resulted in less consistant LSC results. IRPT samples were 
prepared and analyzed for 14C-PAH content as described in section 3.7.2.    
 
3.7.2.4 The effect of temperature on ES accumulation in IRPTs 
 
Temperature dependent accumulation of 3H-ES by IRPTs was used as a 
marker for active, protein-mediated OAT3 uptake in this model (Sweet et al., 
2003).   Cellular transport of molecules requires temperatures closer to 
physiological levels (37ºC); accumulation of ES at cold temperatures (4ºC) will 
allow distinction between basolateral protein-mediated transport, and non 
specific binding to tubular proteins or passive diffusion. Three milliliters of tubule 
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suspension were incubated at 4ºC or 37ºC for 60 seconds with 4 pM 3H-ES (0.2 
µCi/ml).  IRPT samples were then prepared and analyzed for 3H-ES content as 
described in section 3.7.2.    
 
3.7.2.5 The effect of probenecid on ES accumulation in IRPTs 
  
Accumulation of 3H-ES by IRPTs was used as a marker for OAT 3 uptake 
along the basolateral membrane in this model.  Three milliliters of tubule 
suspension were incubated at 37ºC for 30 seconds with 4 pM 3H-ES (0.18 
µCi/ml) alone or in the presence of 1mM probenecid.  IRPT samples were then 
prepared and analyzed for 3H-ES content as described in section 3.7.2 
    
 3.7.2.6 The effect of self-inhibition on ES accumulation in IRPTs 
 
Inhibition of 3H-ES accumulation by unlabeled (cold) ES was examined to 
assess whether basolateral uptake was a carrier protein-mediated transport 
process in this model, versus passive diffusion or other means of cellular 
accumulation.  Ability of a compound to “self inhibit” accumulation indicates that 
the compound is taken into the tubules by carrier-mediated transport 
mechanisms.   Three milliliters tubule suspension were incubated at 37ºC for 60 
seconds with 4 pM 3H-ES (0.2 µCi/ml) alone, or in the presence of 500 µM ES.  
IRPT samples were then prepared and analyzed for 3H-ES content as described 
in section 3.7.2 
    
 3.7.2.7 The effect of AG on ES accumulation in IRPTs 
 
Inhibition of 3H-ES accumulation by AG was explored to assess the 
interaction of AG at the site of ES transport (OAT3) in this model.  Three 
milliliters of tubule suspension were incubated at 37ºC for 60 seconds with 4 pM 
3H-ES (0.18 µCi/ml) alone or in the presence of 1 mM AG.  The concentration of 
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ES used in this experiment was minimized to maximize the potential for reacting 
at the transport site for ES.  IRPT samples were then prepared and analyzed for 
3H-ES content as described in section 3.7.2.   
 
3.8 14C-Acetamidophenyl-β-d-glucuronide (AG) 
accumulation studies in IRPTs 
  
 AG was selected as a model glucuronide to determine whether IRPTs 
demonstrated accumulation of glucuronide metabolites.  Due to its commercial 
availability, and because it was available in a radiolabeled form, AG was selected 
as a model glucuronide.  To determine whether IRPTs facilitate glucuronide 
accumulation, various experiments, as described in subsequent sections, were 
conducted to determine the role of the basolateral membrane in the renal 
secretion of AG.  Experiments were designed to determine whether the 
basolateral membrane demonstrated carrier protein-mediated transport of AG, 
and more importantly, whether AG interacts with OAT proteins along the 
basolateral membrane.      
 
 
 3.8.1 Time-dependent accumulation of AG in IRPTs 
 
To determine if there was a temporal factor for the accumulation of 14C-AG 
in this model, 3 ml of tubule suspension were incubated at 37ºC for 15, 30, 45, 
60, 120 or 300 seconds with 4.5 µM 14C-AG (0.22 µCi/ml).  IRPT samples were 
then prepared and analyzed for 14C-AG content as described in section 3.7.2.  
Temporal studies also allowed for the determination of the best time points for 
further uptake and inhibition studies to be conducted using 14C-AG.    
 
 3.8.2 The effect of temperature on AG accumulation in IRPTs 
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Temperature dependent accumulation of 14C-AG was used as a marker 
for active, carrier protein-mediated uptake of AG along the tubular basolateral 
membrane in this model. Accumulation of 14C-AG at cold temperatures (4ºC) will 
allow distinction between basolateral carrier protein-mediated transport, and non-
specific binding to tubular proteins or passive diffusion.  Three milliliters of tubule 
suspension were incubated at 4ºC or 37ºC for 30 seconds with 2 µM 14C-AG (0.1 
µCi/ml).  IRPT samples were then prepared and analyzed for 14C-AG content as 
described in section 3.7.2.   
    
 3.8.3 The effect of probenecid on AG accumulation on IRPTs 
 
To determine whether basolateral OAT proteins played a role in AG 
accumulation in this model, probenecid, the classical OAT inhibitor, was used to 
determine whether accumulation of AG could be inhibited.  Three milliliters of 
tubule suspension were incubated for 30 seconds with 2 µM 14C-AG (0.1 µCi/ml) 
(30 µl of 14C-AG at 10 µCi/ml) alone or in the presence of 1mM probenecid.  
Probenecid was added at the same time as AG, or added 5 min prior to the 
addition of AG.  IRPT samples were then prepared and analyzed for 14C-AG 
content as described in section 3.7.2.   
  
3.8.4 The effect of self-inhibition on AG accumulation in IRPTs 
 
To determine whether basolateral carrier-mediated transport mechanisms 
played a role in 14C-AG accumulation in this model, self-inhibition studies were 
conducted to determine whether unlabeled (cold) AG could inhibit the uptake of 
14C-AG by IRPTs.  Three milliliters of tubule suspension were incubated for 30 
seconds with 4.5 µM 14C-AG (0.22 µCi/ml) alone, or in the presence of 5 mM AG.  
IRPT samples were then prepared and analyzed for 14C-AG content as described 
in section 3.7.2 
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 3.8.5 The effect of ES on AG accumulation in IRPTs 
 
Inhibition of 14C-AG accumulation by ES in this model was examined to 
determine whether a known substrate of OAT3 could effectively act as an 
inhibitor of AG accumulation in this model.  This study was used to elucidate the 
role of OAT3 in AG uptake in this model.  Three milliliters of tubule suspension 
were incubated for 30 seconds with 4.5 µM 14C-AG (0.22 µCi/ml) alone, or in the 
presence of 100 µM ES. IRPT samples were then prepared and analyzed for 
14C-AG content as described in section 3.7.2.   
 
 3.8.6 The effect of D-saccharic acid 1,4-lactone on AG accumulation  
in IRPTs  
 
 Since IRPTs still have metabolic capabilities, including the deconjugation 
of glucuronide metabolites by β-glucuronidase, it was important to determine 
whether accumulation of 14C-AG was being affected by the presence of β-
glucuronidase in the tubule preparation.  To assure that accumulation of AG was 
due to the conjugate, D-saccharic acid 1,4-lactone (SL) was used as an inhibitor 
of β-glucuronidase activity.  Three milliliters of tubule suspension were incubated 
for 2 min with 4.5 µM 14C-AG (0.21 µCi/ml) alone, or in the presence of 10 or 20 
mM SL.  Tubules were pre-incubated with SL for 5 min prior to the addition of 
14C-AG.  IRPT samples were then prepared and analyzed for 14C-AG content as 
described in section 3.7.2.   
 
3.9 Western blot analysis for OAT1 and OAT3 in IRPTs and HK2 cells 
 
3.9.1 Cell Fractionation 
Plasma membrane fractions of immortalized human kidney (HK-2) cells were 
prepared from 7 day old monolayers scraped from T75 flasks or from Transwell 
membranes, pelleted at 270 x g and frozen.  Cell pellets (HK-2 and F344 rat PTC) 
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were resuspended in homogenization buffer (HB; see appendix for composition), 
homogenized (15 slow strokes) and centrifuged (100 x g, 2 min) to remove intact 
cells. To separate membrane from cytosolic fractions, three different methods were 
used.  The supernatants (whole cell lystes) were centrifuged at 100,000 x g for 1 
hour at 4oC (procedure provided by Dr. Mary Vore) to isolate crude membrane 
fractions or at 15,000 x g for 30 minute at 4oC (Kikuchi et al., 2003) to isolate 
plasma membrane fractions.  Proteins from the membrane pellets were extracted 
in HB containing 1% Triton-X 100 by frequent mixing on a vortex for 1 hour then 
tumbling overnight at 4oC.  The extracts were centrifuged for 30 minutes at 14,000 
x g at 4oC and the supernatants (membrane proteins) were assayed for protein 
content. 
3.9.2 SDS-PAGE and Western Blot Procedure 
Each sample was solubilized in loading buffer (4% sodium dodecyl sulfate, 
62.6 mM Tris, 10% glycerol) with or without 5% 2-mercaptoethanol, loaded at 200-
250 µg HK-2 protein/lane and 100 µg F344 rat or human protein/lane and 
separated by polyacrylamide gel electrophoresis on a 12.5% or 8% gel overnight 
at 4oC (12.5% gel for 15 hours at 70 V; 8% gel for 15 hours at 74V).  Proteins were 
transferred onto a nitrocellulose membrane, blocked with 5% nonfat dry milk in 
Tris-buffered saline containing 0.3% Tween 20 for 1 hour at 25oC and incubated 
overnight at 4oC with anti-ratOAT1 or OAT3 antibodies reported by the 
manufacturer to be specific for respective OATs and cross-reactive with the 
respective human orthologues (1:333, Alpha Diagnostics International).  The 
bound antibody was detected on x-ray film by enhanced chemiluminescence with 
horseradish peroxidase-conjugated anti-rabbit IgG antibody.  Buffer and gel 
formulations are recorded in the appendix.  
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3.10 Accumulation studies with OAT substrates in  
renal cortical slices (RCS) 
 
 Since IRPT isolation involves enzymatic digestion to release the tubules 
from the cortical tissue, there is the potential that this digestion could also 
damage the transport proteins along the basolateral membrane of the tubules.  
To determine whether enzymatic digestion had any consequence in the ability of 
IRPTs to demonstrate transport of both known OAT substrates and AG, renal 
cortical slices were used to study the accumulation of PAH, ES, and AG.  
Transport of these compounds was then compared to the findings in IRPTs to 
determine whether accumulation results were altered by enzymatic digestion of 
the basolateral membrane of the IRPTs. 
 
3.10.1 Preparation of RCSs. 
 
Rats were anesthetized with diethyl ether and tested for surgical 
anesthesia with toe pinch and corneal reflex.  The abdomen was opened with a 
midline incision and the animal exsanguinated by rupturing the diaphragm and 
cutting the vena cava.  The kidneys were removed, decapsulated and cut into 
quarters.  Each quartered kidney was then placed in a 30 ml beaker containing 
10 ml ice cold oxygenated Transport buffer #2 (see appendix for composition). 
The kidneys were kept on ice for the remainder of the slice preparation.  Renal 
cortical slices were prepared free hand as previously described (Valentovic et. al. 
1992) and placed in a clean 30 ml beaker containing 10 ml ice cold Transport 
buffer #2.  To conduct uptake studies, slices were transferred with forceps into a 
12 well cell culture plate in a shaking water bath incubator.  Each well contained 
3-4 slices (30-60 mg) in 1.0 ml of oxygenated Transport buffer #2 at 37ºC.  Slices 
were allowed 5 min to equilibrate at 37º C at 100 rpm before the addition of test 
compound.  Assays were conducted in duplicate at each concentration and time 
point.  
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3.10.2 Accumulation and quantification of radioisotopes (14C and 3H) in RCSs 
 
 This section describes the general method for analyzing uptake of 
radiolabeled substrates in RCSs.  Details of specific experiments (time points 
and isotope concentrations) are provided in subsequent sections.  This section 
also describes the method used in all experiments to determine the isotope 
content of treated slices. 
 At the end of each incubation period with a selected radioisotope, slices 
were removed from each assay well with forceps and placed in 2.0 ml of ice cold 
Transport buffer #2 in the corresponding well of a clean 12 well cell culture plate.  
This was done to both stop uptake of the radioisotope and to rinse excess 
radioisotope from the slices.  After all slices were removed from the assay wells 
and transferred to rinse wells, the slices from each rinse well were removed and 
placed on a disk of heavy filter paper.  Excess buffer was then removed from the 
slices by pressing slices between several discs of filter paper.  The slices were 
removed from the filter paper and then weighed.  Following weight determination 
the slices were transferred to labeled 13 x 100 mm glass tubes containing 1 ml 
H2O and homogenized using a Teckmar Tissuemizer.  Homogenates were 
divided into two 0.5 ml aliquots in 5 ml scintillation vials to count the total slice 
sample for each assay.  Five milliliters of scintillation fluid (Scintiverse II) were 
added to each vial, mixed and analyzed for radioisotope content using a Wallac 
1409 Liquid Scintillation Counter.   
 
 
3.10.2.1 Time-dependent 3H-Mannitol accumulation in RCS 
 
 Mannitol (MN) is not actively transported by any portion of the renal 
cortical slice. Thus, MN accumulation can be used to assess the amount of 
diffusion into interstitial spaces in the RCSs.  Slices (30-60 mg) were incubated 
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at 37ºC for 10, 15, 30 or 60 min in the presence of 176 pM MN (0.3 µCi/ml).  
Slices were then prepared and analyzed for 3H-MN content as described in 
section 3.10.2.        
 
 3.10.2.2 The effect of probenecid on PAH accumulation in RCSs 
 
 Inhibition of PAH accumulation by probenecid was studied to characterize 
the ability of this model to transport a classical OAT substrate, with inhibition by a 
the classical OAT transport inhibitor.  Slices (30-60 mg) were incubated at 37ºC 
for 30 min with 4.7 µM 14C-PAH (0.25 µCi/ml) alone or in the presence of 1 mM 
probenecid.   Slices were then prepared and analyzed for 14C-PAH content as 
described in section 3.10.2. 
    
3.10.2.3 The effect of testosterone glucuronide (TG), methylumbelliferyl 
glucuronide (MUG) and acetaminophen glucuronide (AG) on PAH 
accumulation in RCSs 
 
The ability of TG, MUG and AG to inhibit the accumulation of 14C-PAH in 
renal cortical slices was evaluated to explore the interaction of glucuronide 
metabolites at the site of basolateral PAH transport (OAT1 and 3) in this model.  
Slices (30-60 mg in 1 ml Transport buffer #2) were incubated for 30 min with 4.7 
µM 14C-PAH (0.25 µCi/ml) alone or in the presence of 500 µM TG, MUG or AG.  
Slices were then prepared and analyzed for 14C-PAH content as described in 
section 3.10.2. 
 
3.10.2.4 Time-dependent accumulation of ES in RCSs 
 
To determine the presence and function of OAT3 along the basolateral 
membrane of PTs in RCS, ES was chosen as the substrate for transport (Sweet 
et al, 2003).  Time-dependent accumulation also allowed for assessment of OAT 
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transport function over time to determine the best time points for subsequent 
assays.  Slices (30-60 mg) were incubated at 37ºC for 5, 10, 15, 30 and 60 min in 
the presence of 4 pM 3H-ES (0.2 µCi/ml).  Slices were then prepared and 
analyzed for 3H-ES content as described in section 3.10.2. 
 
3.10.2.5 The effect of temperature on ES accumulation in RCSs 
 
 To demonstrate that accumulation of ES in RCSs is via a carrier protein-
mediated mechanism, temperature-dependent accumulation of 3H-ES was 
assessed.  Slices (30-60 mg) were incubated at 4ºC or 37ºC for 10 min with 4 pM 
3H-ES (0.2 µCi/ml).  Slices were then prepared and analyzed for 3H-ES content 
as described in section 3.10.2. 
    
 3.10.2.6 The effect of probenecid on ES accumulation in RCSs 
 
Inhibition of 3H-ES accumulation in RCS by probenecid was used to 
evaluate further the function of basolateral OAT3 transport in this model.  Slices 
(30-60 mg) were incubated at 37ºC for 10 min with 4 pM 3H-ES (0.2 µCi/ml) 
alone or in the presence of 1 mM probenecid. Slices were then prepared and 
analyzed for 3H-ES content as described in section 3.10.2. 
 
3.11 14C-acetamidophenyl-β-D-glucuronide (AG)  
accumulation studies in RCS 
 
 3.11.1 Time-dependent accumulation of AG in RCSs 
 
To determine if there was a temporal factor for the accumulation of 14C-AG 
in this model, slices (30-60 mg) were incubated at 37ºC for 2.5, 5, 15, 30, 45 or 
60 min with 4.7 µM 14C-AG (0.23 µCi/ml). Slices were then prepared and 
analyzed for 14C-AG content as described in section 3.10.2. 
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 3.11.2 The effect of temperature on AG accumulation in RCSs 
 
Temperature-dependent accumulation of 14C-AG was used as an indicator 
for active, protein-mediated uptake of AG along the tubular basolateral 
membrane in this model. Accumulation of 14C-AG at cold temperatures (4ºC) will 
allow distinction between basolateral protein-mediated transport, and non-
specific binding to tissue or passive diffusion.  Slices (30-60 mg) were incubated 
at 4ºC or 37ºC for 30 min with 4.7 µM 14C-AG (0.23 µCi/ml).  Slices were then 
prepared and analyzed for 14C-AG content as described in section 3.10.2. 
 
 3.11.3 The effect of probenecid on AG accumulation in RCSs 
  
To determine whether OAT proteins along the basolateral membrane of 
RCS played a role in AG accumulation in this model, probenecid was used to 
determine whether accumulation of AG could be inhibited by a classical OAT 
inhibitor.  Slices (30-60 mg) were incubated at 37ºC for 30 min with 4.7 µM 14C-
AG (0.23 µCi/ml) alone or in the presence of 1 mM probenecid.  Slices were then 
prepared and analyzed for 14C-AG content as described in section 3.10.2. 
 
3.11.4 The effect of self-inhibition on AG accumulation in RCSs 
 
To determine whether basolateral transport mechanisms played a role in 
14C-AG accumulation in this model, self-inhibition studies were conducted to 
determine whether unlabeled (cold) AG could inhibit the uptake of 14C-AG.  
Slices (30-60 mg) were incubated at 37ºC for 30 min with 4.7 µM 14C-AG (0.23 
µCi/ml) alone or in the presence of 500 µM AG.  Slices were then prepared and 
analyzed for 14C-AG content as described in section 3.10.2. 
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3.11.5 The effect of PAH and ES on AG accumulation in RCSs 
 
To explore further whether OAT plays a role in the accumulation of AG 
along the basolateral membrane of the PT in this model, known organic anion 
substrates of OAT1 and OAT3 were used as potential inhibitors of AG 
accumulation.  Slices (30-60 mg) were incubated at 37ºC for 30 min with 4.7 µM 
14C-AG (0.23 µCi/ml) alone or in the presence of 1mM PAH or 500 µM ES. Slices 
were then prepared and analyzed for 14C-AG content as described in section 
3.10.2. 
 
3.12 14C-AG accumulation studies in RCSs from male Sprague-Dawley rat 
 
 Several studies have reported contradicting results regarding the ability of 
the kidney to secrete glucuronide conjugates, namely AG (Duggin and Mudge, 
1975, Galinsky and Levy, 1981, Watari et al, 1983, Morris and Levy, 1984 
Heckman et al. 1986).  Since these studies have been conducted in different 
animal models and strains, it was important to determine whether genetic strain 
had any influence in the ability to show basolateral transport of AG by the renal 
PT.  The renal cortical slice model was chosen to assess renal transport of AG in 
the male SD rat.  SD rats were chosen as an alternate rat strain because it was 
demonstrated by Galinsky and Levy (1981) that the SD strain appears to renally 
secrete AG.   
The following studies were conducted and carried out as previously 
described for the corresponding studies conducted in RCSs from F344 rat  at 4.3 
µM 14C-AG (0.21 µCi/ml):   
  
3.12.1 The effect of temperature on AG accumulation in RCSs from SD rat 
(see section 3.11.2 for details on assay methods) 
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3.12.2 The effect of probenecid on AG accumulation in RCSs from SD rat 
(see section 3.11.3 for details on assay methods) 
 
3.12.3 The effect of self-inhibition on AG accumulation in RCSs from S-D 
rat (see section 3.11.4 for details on assay methods)  
 
3.12.4 The effect of PAH on AG accumulation in RCSs from S-D rat (see 
section 3.11.5 for details on assay methods) 
 
 
3.13 Statistics 
 
Values are expressed as the mean ± SE for 3-4 experiments.  Values from 
each rat represent n=1.  Data were analyzed using Non-linear Regression 
Analysis, Student t-test or One-Way Repeated Measures Analysis of Variance 
(ANOVA) followed by a Dunnett or Student-Newman-Keuls analysis.  All 
statistical tests were run at 95% confidence interval, significance at P<0.05.  
Statistics were analyzed using Sigma Stat ® 2.03 statistical software (SPSS Inc., 
1992-1997).   
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CHAPTER IV 
 
Results 
 
4.1 Studies Using Isolated Renal Proximal Tubules (IRPTs) 
 
4.1.1 Characterization of Isolated Proximal Tubules 
 
 Since the renal PT is the primary site of drug transport and metabolism in 
the kidney, the first step of this study was to isolate renal PT segments from male 
F344 rats.  Before the initiation of any toxicity or transport studies, it was 
necessary to characterize the isolated renal material to ensure that the tissue 
population that was isolated consisted primarily of PT fragments.  
Characterization of the PT fraction was carried out through enzymatic analysis 
and visual assessment.    HK activity, AP activity, protein content and LDH 
release assays were conducted on the initial sample of digested cortical tissue 
containing tubules (pool sample) and on the enriched sample of tubules collected 
after Percoll separation (PT sample).  HK and AP enzyme assays were used to 
assess the enrichment of the tubule sample.  AP, which is a brush-border 
enzyme, was used as a marker for PT content.  HK, a cytosolic enzyme with 
greatest activity in distal tubular cells was used as a marker for distal tubule 
contamination. Lash and Tokarz (1989) have reported PT fractions to have AP 
and HK activities of 403 ± 113 and 111 ± 48 nmol/min/mg protein respectively. 
Based on this information and assay results it was determined that the enriched 
proximal tubule (PT) samples isolated in these studies are of proximal tubular 
origin (Table 6).  Viability was evaluated by measuring lactate dehydrogenase 
(LDH) release into the media and reported as a percent of total.  LDH is a 
cytosolic enzyme and leakage from cells into the media can be correlated to 
sample viability (as percent LDH release increases, percent viability decreases).  
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Tubule viability for samples following Percoll separation was found to be 
approximately 89%, reported by percent LDH release in the range of 11.73 ± 
0.91 (Table 6). These results indicated that the Percoll isolation procedure did 
not cause excessive damage to the tubule segments and they are adequate for 
toxicity and uptake studies.  While it did not appear that the enzyme values 
changed significantly, the Percoll separation did effectively separate out any 
glomeruli and blood vessel tissue present in the pooled sample.  Percoll density 
centrifugation provided a final PT sample that consisted primarily of proximal 
tubules with minimal distal tubule contamination. PT content was also observed 
microscopically as PTs were identified by their large diameter and unbranched 
morphology (Fig. 4.1).  Based on morphological examination, there were a few 
distal tubules or collecting ducts (thin, straighter tubule segments) present in the 
sample and the major portion of the sample appeared to consist of PTs.  Tubules 
appeared largely undamaged, although segments were shorter following Percoll 
separation and rinsing.  No glomerular contamination was present in the PT 
sample based on microscopic examination.   
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Table 6.  Biochemical characteristics of IRPTs from male F344 rata. 
 
Parameter                                             Pool Sample                        PT Sample                            
 
Protein content (mg protein/ml)              7.80 ± 0.23                         7.62 ± 0.39     
 
Cell viability 
 LDH release (%)                        4.84 ± 0.63                        11.7 ± 0.91 
Enzymesb 
 Alkaline Phosphatase                 521 ± 30.9                         542 ± 26.9 
               
 Hexokinase                              24.8 ± 1.94                         22.6 ± 1.91 
 
Note: a.  All values are means ± SE of measurements from 8 rat preparations.   
           b.  Enzyme results are total activity in nmol product per min, per mg protein.   
 
 
Figure 4.1.  Freshly isolated renal proximal tubules from Fischer 344 rat.  
Tubules were isolated by collagenase digestion and enriched through Percoll density gradient 
centrifugation.  The resulting isolated material consisted primarily of PT fragments as noted by 
their large diameter and unbranched morphology.  Distal tubular contamination was minimal and 
no glomerular contamination was noted. Magnification 100x, Nikon inverted Diaphot-TMD phase 
contrast microscope. 
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4.1.2 Toxicity studies 
 
 Prior to conducting uptake studies it was necessary to ensure that the 
model compound (AG) was not toxic in this study system (IRPTs).  
Acetaminophen (APAP), the parent compound of AG, and diclofenac (DC) were 
also studied for toxicity since both of these compounds have been associated 
with nephrotoxicity. Additionally, DC is known to form an acyl-glucuronide 
metabolite.  Toxicity was measured by LDH release from tubules incubated with 
200 or 500 µM AG (Fig. 4.2), APAP (Fig 4.3) or DC (Fig 4.4).  Incubations were 
carried out for 30 and 60 min for AG and APAP.  DC studies were carried out for 
15 and 30 min, as toxicity was already noted (by LDH release) by 30 min. These 
studies indicate that AG and APAP are not toxic at these concentrations or time 
points, and are therefore suitable for use in uptake studies in IRPTs.  Since DC 
was found to be slightly toxic by 30 min it was not used in any future studies. 
In addition to LDH release, nucleotide levels were also used to assess 
toxicity of AG, APAP and DC.  Nucleotide levels were measured to determine 
whether tubules were not showing signs of toxicity at an earlier stage than could 
be detected by LDH release.   Treatment with some chemicals may not trigger 
LDH release, but they may have a profound effect on the ability of a cell to 
produce energy in the form of ATP.  To determine whether AG, APAP or DC had 
any intracellular toxic effects, following incubation of 3 ml of tubule suspension 
with 200 or 500 µM AG (Fig 4.5), and APAP (Fig. 4.6) for 30 or 60 min, or DC 
(Fig. 4.7) for 15 or 30 min, 1 ml of the tubule suspension was assayed for ATP, 
ADP, and AMP content. These studies indicate that AG and APAP do not show 
any early, toxic events at these concentrations or time points (i.e., no depressed 
production of nucleotides), and are therefore suitable for using in uptake studies 
in IRPTs.  DC, however, was again found to be slightly toxic by 30 min as seen 
by depressed nucleotide levels.  Toxicity studies at 15 min were also conducted 
with DC to determine whether depression of nucleotide levels might occur on an 
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earlier time frame than LDH release.  Studies at 15 min demonstrate that while 
LDH release is not at significantly different levels than control, by this time point, 
ATP levels are already significantly decreased below control.  This finding 
indicates that DC toxicity includes early cellular effects that occur before 
significant LDH release.   
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Figure 4.2.  Percent LDH release from IRPTs treated with AG.  To determine the 
toxicity of AG in IRPTs, 3 ml of tubule suspension (at 1 mg protein/ml) were incubated in the 
absence or presence of either 200 or 500 µM AG for 30 or 60 min.  Separate flasks were used for 
each time point, and each concentration/time point was determined in duplicate.  At the end of 
each time point, 1 ml of PT suspension was removed and assayed for LDH content.  Each bar 
represents LDH release from the tubules into the incubation medium, and expressed as percent 
of total LDH ± SE for n=4.  Percent LDH release by tubules treated with 200 or 500 µM AG was 
not significantly different from water treated tubules at either time point.  LDH release was also 
not significantly different between time points for each concentration.  Data were analyzed by 
Repeated Measures ANOVA.  
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Figure 4.3.  Percent LDH release from IRPTs treated with APAP.  To determine 
the toxicity of APAP in IRPTs, 3 ml of tubule suspension (at 1 mg protein/ml) were incubated in 
the absence or presence of either 200 or 500 µM APAP for 30 or 60 min.  Separate flasks were 
used for each time point, and each concentration/time point was determined in duplicate.  At the 
end of each time point, 1 ml of PT suspension was removed and assayed for LDH content.  Each 
bar represents LDH release from the tubules into the incubation medium, and expressed as 
percent of total LDH ± SE for n=4.  Percent LDH release by tubules treated with 200 or 500 µM 
AG was not significantly different from water treated tubules at either time point.  LDH release 
was also not significantly different between time points for each concentration.  Data were 
analyzed by Repeated Measures ANOVA.   
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Figure 4.4.  Percent LDH release from IRPTs treated with DC.  To determine the 
toxicity of DC in IRPTs, 3 ml of tubule suspension (at 1 mg protein/ml) were incubated in the 
absence or presence of either 200 or 500 µM DC for 15 and 30 min.  Separate flasks were used 
for each time point, and each concentration/time point was determined in duplicate.  At the end of 
each time point, 1 ml of PT suspension was removed and assayed for LDH content.  Each bar 
represents LDH release from the tubules into the incubation medium, and is expressed as 
percent of total LDH release ± SE for n=4 or 5.  (* Percent LDH release significantly different from 
the appropriate control value (P<0.05)).  Percent LDH release was significantly higher following 
DC treatment at 30 min. There was not a significant difference in LDH release between 200 and 
500 µM DC at either time point.  Data were analyzed by Repeated Measures ANOVA followed by 
Dunnett’s analysis with a 95% confidence interval. 
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Figure 4.5.  Effect of AG on nucleotide levels in IRPTs.   To determine whether 
there may be earlier toxic events than LDH release associated with treatment of IRPTs with AG, 
nucleotide levels were determined after 30 and 60 min and used as a marker for tubular 
sensitivity to AG.  Tubules (3 ml at 1 mg protein/ml) were treated in the absence or presence of 
200 or 500 µM AG for 30 or 60 min.   Separate flasks were use for each time point and each 
concentration/time point was measured in duplicate.  At the end of each time point, each flask 
was sampled and ATP, ADP and AMP levels determined by HPLC for each sample. Each bar 
represents the mean nucleotide level (nmol/mg protein) ± SE for n=10 (30 min H2O treatment), 
n=4  (60 min H2O treatment) and n=4 (30 and 60 min AG treatments).   No significant difference 
in nucleotide levels was determined for any AG concentration or time point for ATP, ADP or AMP 
as compared to control values.  Data were analyzed by Repeated Measures ANOVA.  
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Figure 4.6.  Effect of APAP on nucleotide levels in IRPTs.   To determine whether 
there may be earlier toxic events than LDH release associated with treatment of IRPTs with 
APAP, nucleotide levels were determined after 30 and 60 min and used as a marker for tubular 
sensitivity to AG.  Tubules (3 ml at 1 mg protein/ml) were treated in the absence or presence of 
200 or 500 µM APAP for 30 or 60 min.   Separate flasks were use for each time point and each 
concentration/time point was determined in duplicate. At the end of each time point, each flask 
was sampled and ATP, ADP and AMP levels determined by HPLC for each sample. Each bar 
represents the mean nucleotide level (nmol/mg protein) ± SE for n=10 (30 min H2O treatment), 
n=4 (60 min H2O treatment) and n=4 (30 and 60 min APAP treatments).   No significant 
difference in nucleotide levels was determined for any APAP concentration or time point for ATP, 
ADP or AMP as compared to control values. Data were analyzed by Repeated Measures 
ANOVA. 
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Figure 4.7.  Effect of DC on nucleotide levels in IRPTs.  To determine whether 
there may be earlier toxic events than LDH release associated with treatment of IRPTs with DC, 
nucleotide levels were determined after 15 and 30 min and used as a marker for tubular 
sensitivity to DC.  Tubules (3 ml at 1 mg protein/ml) were treated in the absence or presence of 
200 or 500 µM DC for 15 or 30 min.   Separate flasks were use for each time point and each 
concentration/time point was determined in duplicate. At the end of each time point, each flask 
was sampled and ATP, ADP and AMP levels determined by HPLC analysis. Each bar represents 
the mean nucleotide level (nmol/mg protein) ± SE for n=4 (all 15 min treatments) n=10 (30 min 
H2O treatment), and n=3 or 4 (30 min DC treatment). (* Significantly different from 15 min control 
(H2O) levels P< 0.05)).  ATP levels following DC treatment for 15 min were significantly lower 
than control ATP levels.  ADP and AMP levels did not show a significant difference between 
control and DC treatment at 15 min.  (# Signifncantly different from 30 min control (H2O) levels 
(P<0.05)).  ADP and ATP levels were both significantly lower than control levels following 30 min 
treatment with DC.   AMP levels are not significantly different between control and DC treated.   
Data were analyzed by Repeated Measures ANOVA, followed by Dunnett’s analysis with a 95% 
confidence interval.      
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4.1.3 Uptake studies 
 
4.1.3.1 Fluorescein accumulation in IRPTs 
 
 Transport of organic anions by renal PTs of F344 rats has not been 
previously characterized.  FL, a typical OAT1 and OAT3 substrate, has been 
used in numerous studies to assess the function of OAT transporters in various 
models.  Thus, FL was used to study OAT function along the basolateral 
membrane of freshly isolated renal PTs from F344 rats. Based on studies 
conducted by Groves and Morales (1999) in suspensions of rabbit renal PTs, 4 
µM was selected as the concentration of FL for uptake studies in this rat IRPT 
model.  Temporal studies using IRPTs in the presence of 4µM FL revealed that 
FL is accumulated in IRPTs in a time-dependent manner (Fig. 4.8).  
Accumulation of FL appears steady up to 120 seconds. Time-dependent uptake, 
however, does not solely indicate uptake of FL by OAT proteins along the 
basolateral membrane.  To characterize further OAT function in this model, 
various inhibition studies were conducted to determine whether accumulation of 
FL was a protein carrier-mediated process, and to further elucidate the 
contribution of OAT1 and OAT3 to FL accumulation. 
  
To determine whether accumulation of FL along the basolateral 
membrane was via a protein carrier-mediated process, temperature dependent 
transport of FL was assessed.  IRPTs were incubated with 4 µM FL at either 
37ºC to allow protein-mediated transport, or at 4ºC to minimize protein-mediated 
transport.  Tubules incubated with FL for 2 min revealed that at 4ºC, 
accumulation of FL was significantly lower than at 37ºC by approximately 93 % 
(Fig. 4.9).  This reduction in basolateral uptake at 4ºC is consistent with transport 
mediated by a protein such as an organic anion transporter.  
  
To characterize further the contribution of OAT along the basolateral 
membrane in IRPTs, inhibition of FL accumulation by probenecid was assessed.  
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Probenecid is the prototypical inhibitor of renal OAT (Insel, 1996), and should 
therefore inhibit FL uptake into IRPTs.  To study the effect of probenecid on FL 
accumulation, tubules were incubated with 4µM FL in the presence or absence of 
1 mM probenecid for 2 min (Fig. 4.10).  Probenecid significantly inhibited FL 
accumulation along the basolateral membrane of IPRTs by approximately 86%.   
This reduction in basolateral uptake in the presence of probenecid is consistent 
with transport mediated by OAT proteins.  To determine the IC50 value of 
probenecid for FL transport in the IRPT model, tubules were incubated with 4 µM 
FL for 2 min in the presence of increasing concentrations of probenecid (Fig. 
4.11).  The IC50 value was calculated from the non-linear regression equation to 
be approximately 67 µM in this model, with 250 µM probenecid yielding nearly 
maximal inhibition of FL accumulation (approximately 80%) in IRPTs.    
  
Additional studies were conducted to further characterize FL accumulation 
in the F344 IRPT model.  To help elucidate the role of OAT1 vs. OAT3 in FL 
accumulation along the basolateral membrane, various inhibitors were used that 
were selective for either OAT1 or OAT3.  The first inhibitor used was the cardiac 
glycoside, ouabain.  Ouabain directly inhibits the Na+/K+ ATPase which is known 
to drive OAT1 transport (Kelly and Smith, 1996).  Tubules were incubated with 4 
µM FL alone, or preincubated in the dark for 10 min with 100 µM ouabain, and 
then coincubated for 2 min with 4 µM FL, (Fig. 4.12).  Ouabain significantly 
inhibited the basolateral accumulation of FL in IRPTs by approximately 51% 
suggesting a role for OAT1 in FL accumulation.   
  
The effect of benzylpenicillin (penicillin G, PG) on FL accumulation along 
the basolateral membrane was assessed to elucidate the role of OAT3 in FL 
accumulation.  PG is an OAT3-selective substrate for rOAT3 (Hasegawa et al., 
2002). Tubules were incubated for 2 min with 4 µM FL in the presence or 
absence of 1mM PG (Fig. 4.13).  PG significantly inhibited basolateral FL 
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accumulation in IRPTs by approximately 40%.  The effect of PG on FL 
accumulation indicates that OAT3 also plays a role in FL transport in this model.  
 
 The effect of dehydroepiandrosterone sulfate (DHEAs) on FL 
accumulation along the basolateral membrane was also used to assess the 
potential role of OAT3 in FL accumulation.  DHEAs is a substrate of OAT3 (Cha 
et al., 2000) and has been used in many models to study the function of OAT3 
transport. To assess its value as a potential OAT3 inhibitor in this model, tubules 
were incubated with 4 µM FL in the presence or absence of 1 mM DHEAs (Fig. 
4.14).  DHEAs significantly inhibited basolateral FL accumulation in IRPTs by 
approximately 82%.  The effect of DHEAs at this concentration indicates 
interaction with OAT1 and OAT3 as inhibition is comparable to that found for 
probenecid (86%).  
  
To determine whether glucuronide metabolites interact with OAT 
transporters along the basolateral membrane of IRPTs, acetamidophenyl 
glucuronide (AG) was selected as a model glucuronide metabolite to assess 
whether it interacted with OAT proteins in this model.  To determine whether AG 
interacted with OAT1 and OAT3, AG was used as a potential inhibitor of FL 
accumulation.  If AG interacts with OAT proteins, it would cause inhibition of FL 
uptake by competition for the site of transport.  Tubules were incubated for 2 min 
with 4 µM FL in the presence or absence of 1 mM AG (Fig. 4.15).  AG did not 
cause significant inhibition (< 7%) of basolateral FL accumulation. This result 
indicates that AG does not appear to undergo transport via the same 
mechanisms (OAT1 and OAT3) as FL in this model.  It may also indicate that AG 
is such a weak substrate for OAT that it does not have the ability to displace FL 
from the transporter protein (competitively inhibit FL binding).          
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Figure 4.8. Time-dependent accumulation of FL in IRPTs.   IRPTs were incubated 
at 1mg protein/ml in the presence of 4µM FL for 15, 30, 45, 60 and 120 sec.  FL was added to 
each flask containing 3ml of tubule suspension (at 1 mg protein/ml) and incubated at 37ºC in a 
shaking water  bath (100 rpm) under 95% O2/5% CO2. At the end of each assay, 1 ml of tubule 
suspension was removed from each flask and analyzed for tubular FL accumulation.  Each point 
represents mean FL accumulation in nmol FL/mg protein ± SE for n=4.  Data were analyzed by 
Nonlinear Regression analysis [(f=a*x/(b*x) ; a= 4.44, b= 436.73; r2=0.96]. 
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Figure 4.9. The effect of temperature on FL accumulation in IRPTs. To 
determine the effect of temperature on FL uptake in IPRTs, 3 ml of tubules (at 1 mg protein/ml) 
were incubated at 37ºC and 4ºC in the presence of 4 µM FL.  FL was added to each flask of IRPT 
suspension and incubated for 2 min in a shaking water  bath (100 rpm) under 95% O2/5% CO2.  
At the end of the assay, 1 ml of tubular suspension was removed from each flask and tubular FL 
accumulation determined.  Each assay was run in triplicate.  Bars represent mean FL content 
(nmol/mg protein) ± SE for n=4.    (* Significantly different from control (37ºC) value). FL 
accumulation was significantly inhibited by incubation at 4ºC (P<0.001).   Data were analyzed by 
Student’s t-test, with a 95% confidence interval. 
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Figure 4.10. The effect of probenecid on FL accumulation in IRPTs. To 
determine the effect of probenecid on FL uptake in IPRTs, 3 ml of tubules (at 1 mg protein/ml) 
were incubated at 37ºC with 4 µM FL in the presence or absence of 1mM probenecid.  Each flask 
containing IRPT suspension was incubated for 2 min in a shaking water  bath (100 rpm) under 
95% O2/5% CO2.  At the end of the assay, 1 ml of tubular suspension was removed from each 
flask and tubular FL accumulation determined.   Each assay was run in triplicate.  Bars represent 
mean FL content (nmol/mg protein) ± SE for n=4.    (* Significantly different from control (FL 
alone) treatment).  FL accumulation in IRPTs was significantly inhibited by probenecid (P<0.001).   
Data were analyzed by Student’s t-test, with a 95% confidence interval 
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Figure 4.11.  IC50 determination of probenecid for FL uptake in IRPTs. To 
determine the IC50 value of probenecid for FL uptake in IRPTs, 3 ml tubules (at 1 mg protein/ml) 
were incubated with 4 µM FL in the presence of increasing concentrations of probenecid.  Each 
flask was incubated at       37 º C for 2 min in a shaking water bath (100 rpm). All assays were run 
in duplicate.  At the end of each assay, 1 ml of tubular suspension was removed from each flask, 
and tubular FL accumulation determined.    Probenecid concentrations used were 5, 25, 50, 100 
or 250 µM.  Each point represents mean FL content (nmol/mg protein) ± SE for n=3. Data were 
analyzed by Nonlinear Regression analysis.  The IC50 value of probenecid for FL uptake in IPRTs 
was calculated from the nonlinear regression equation [(f=a*x/(b*x); r2=0.94] to be 67.4 µM.   
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Figure 4.12. The effect of ouabain on FL accumulation in IRPTs. To determine 
the effect of ouabain on FL uptake in IPRTs, 3 ml of tubules (at 1 mg protein/ml) were incubated 
at 37ºC  with 4 µM FL in the presence or absence of 100 µM ouabain.  Each flask containing 
IRPT suspension was incubated for 2 min in a shaking water bath (100 rpm) under 95% O2/5% 
CO2.  At the end of the assay, 1 ml of tubule suspension was removed from each flask and 
tubular FL accumulation determined.  Each assay was run in triplicate.  Bars represent mean FL 
content (nmol/mg protein) ± SE for n=4.    (* Significantly different from control (FL alone) value). 
FL accumulation in IPRTs was significantly inhibited by ouabain (P<0.05). Data were analyzed by 
Student’s t-test, with a 95% confidence interval.    
 
 
 
 
 
105 
Treatment
Fl
uo
re
sc
ei
n 
(n
m
ol
/m
g 
pr
ot
ei
n)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
   FL       FL+benzylpenicillin
 *
 
 
Figure 4.13. The effect of benzylpenicilin on FL accumulation in IRPTs. To 
determine the effect of benzylpenicillin on FL uptake in IPRTs, 3 ml of tubules (at 1 mg protein/ml) 
were incubated at 37ºC  with 4 µM FL in the presence or absence of 1 mM benzylpenicillin.  Each 
flask containing IRPT suspension was incubated for 2 min in a shaking water bath (100 rpm).  At 
the end of the assay, 1 ml of tubule suspension was removed from each flask and tubular FL 
accumulation determined.   Each assay was run in triplicate.  Bars represent mean FL content 
(nmol/mg protein) ± SE. n=4. (* Significantly different form control (FL alone) values).  FL 
accumulation in IPRTs was significantly inhibited by benzylpenicillin (P<0.05).   Data were 
analyzed by Student’s t-test, with a 95% confidence interval. 
 
 
 
 
 
 
 
106 
Treatment
Fl
uo
re
sc
ei
n 
(n
m
ol
e/
m
g 
pr
ot
ei
n)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
   FL FL + DHEAs
 *
 
 
Figure 4.14. The effect of dehydroepiandrosterone sulfate on FL 
accumulation in IRPTs. To determine the effect of DHEAs on FL uptake in IPRTs, 3 ml of 
tubules (at 1 mg protein/ml) were incubated at 37ºC with 4 µM FL in the presence or absence of 1 
mM DHEAs.  Each flask containing IRPT suspension was incubated for 2 min in a shaking water  
bath (100 rpm) under 95% O2/5% CO2. At the end of the assay, 1 ml of tubule suspension was 
removed from each flask and tubular FL accumulation determined.  Each assay was run in 
triplicate.  Bars represent mean FL content (nmol/mg protein) ± SE for n=4.    (* Significantly 
different from control (FL alone) values).  FL accumulation in IPRTs was significantly inhibited by 
DHEAs (P<0.05).  Data were analyzed by Student’s t-test, with a 95% confidence interval.    
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Figure 4.15. The effect of acetamidophenyl glucuronide on FL accumulation 
in IRPTs. To determine the effect of AG on FL uptake in IPRTs, 3 ml of tubules (at 1 mg 
protein/ml) were incubated at 37ºC with 4 µM FL in the presence or absence of 1 mM AG.  Each 
flask containing IRPT suspension was incubated for 2 min in a shaking water  bath (100 rpm) 
under 95% O2/5% CO2.  At the end of the assay, 1 ml of tubule suspension was removed from 
each flask and tubular FL accumulation determined.   All assays were run in triplicate.  Bars 
represent mean FL content (nmol/mg protein) ± SE for n=4.  FL accumulation was not 
significantly inhibited by incubation with AG.  Data were analyzed by Student’s t-test, with a 95% 
confidence interval. 
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4.1.3.2 PAH accumulation in IRPTs 
 
 PAH, a typical substrate of OAT1 and OAT3 proteins, has been used 
widely to study OAT uptake in various renal models.  14C-PAH was used to 
further study and characterize the presence of OAT transporters along the 
basolateral membrane of the PT of F344 rats.  Since PAH is readily available 
radiolabeled, and there is great deal of information available about this OAT 
substrate, PAH is useful for assessing OAT function in this model.  Since PAH is 
a substrate for both OAT1 and OAT3, it provides an indication of OAT function in 
this model.   
 
 To determine first whether PAH uptake in this model was due to OAT 
transport across the basolateral membrane, the effect of probenecid on PAH 
uptake was assessed.  Since probenecid is the typical inhibitor of OAT transport, 
and PAH is the typical OAT substrate, treatment with probenecid should block 
PAH uptake in this system if PAH uptake is OAT-mediated.  To study the effects 
of probenecid on PAH accumulation, IRPTs (1mg protein/ml) were incubated with 
73.8 µM PAH in the absence or presence of 1mM probenecid for 2 min (Fig. 
4.16).  This concentration of PAH was originally selected as the value that 
provided the Km concentration of PAH at 0.2 µCi/ml (Sweet et al., 1997; Kushara 
et al., 1999)   Probenecid significantly inhibited PAH uptake in IPRTs by 
approximately 87%. This reduction in basolateral uptake in the presence of 
probenecid is consistent with transport mediated by OAT proteins.  To determine 
the IC50 value of probenecid for PAH transport in the IRPT model, tubules were 
incubated with 4.5 µM PAH for 2 min in the presence of increasing 
concentrations of probenecid (Fig. 4.17).  The IC50 value was calculated from the 
nonlinear regression equation to be approximately 106 µM in this model, with 250 
µM probenecid yielding approximately 73% inhibition of PAH accumulation in 
IRPTs.    
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 To assess further the contribution of OAT in glucuronide metabolite 
transport, AG was again used as a potential inhibitor of uptake of a known 
substrate of OATs.  To determine the effect of AG on OAT protein transport, PAH 
was used as the known substrate, since PAH was shown to interact with OAT 
proteins in this IRPT model.  In this study, IRPTs (1mg protein/ml) were 
incubated with 2.5 µM PAH in the absence or presence of 1 mM AG for 30 
seconds (Fig. 4.18). This concentration of PAH is equivalent to .13 uCi/ml, and 
was used to try to minimize the amount of PAH in the incubation, thus 
maximizing the potential for interaction of AG with OAT.  Incubation with AG did 
not significantly inhibit PAH uptake (approximately 9%), indicating either that AG 
does not interact with the same transporters responsible for PAH accumulation in 
this model or that AG is such a weak substrate for OAT (very low affinity for OAT) 
that it does not have the ability to displace PAH from the transport (OAT) 
proteins. 
 
 To determine whether other glucuronide metabolites may interact with 
PAH transport in this model, testosterone glucuronide (TG) and 
methylumbelliferyl glucuronide (MUG) were used as alternate potential inhibitors 
of PAH accumulation in IRPTs.   AG inhibition was also studied again as a 
second control for TG and MUG inhibition.  If inhibition with TG and MUG 
produced different results than inhibition with AG, it would indicate that various 
glucuronides may have different substrate specificities for basolateral OAT 
transporters.  To study the effects of TG and MUG on renal OAT, IPRTs were 
incubated with 4.4 µM PAH in the absence or presence of 500 µM TG, MUG, or 
AG for 30 seconds (Fig. 4.19). Due to increased variability in the results obtained 
in the previous experiment, the concentration of PAH was increased to 0.25 
µCi/ml to minimize the variability in 14C-PAH counting. Significant inhibition of 
PAH accumulation was not seen in the presence of TG, MUG or AG.  These 
results suggest that these glucuronide metabolites do not interact strongly with 
PAH transporters (OATs) along the basolateral membrane of IRPTs or again, TG 
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and MUG also have such weak affinity for the PAH transporter that they cannot 
displace PAH and thus inhibit PAH transport.    
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Figure 4.16.  The effect of probenecid on PAH accumulation in IRPTs. 
To determine the effect of probenecid on PAH accumulation in IRPTs, 3 ml of tubules (at 1 mg 
protein/ml) were incubated for 2 min with 73.8 µM 14C-PAH in the absence or presence of 1 mM 
probenecid.  Each flask was incubated at 37ºC in a shaking water  bath (180rpm) under 95% 
O2/5% CO2.  At the end of two min the total IRPT sample in each flask was analyzed for tubular 
PAH accumulation.   All assays were run in duplicate.  Bars represent mean PAH content 
(pmol/mg protein) ± SE for n=3.  (*Significantly different from control (PAH alone) values).  
Probenecid significantly inhibited PAH accumulation in IRPTs from Fischer 344 rat (P<0.05).  
Data were analyzed by Student’s t-test, with a 95% confidence interval.      
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Figure 4.17.  IC50 determination of probenecid for PAH uptake in IRPTs.    
To determine the IC50 value of probenecid for 14C-PAH uptake in IRPTs, 3 ml tubules (at 1 mg 
protein/ml) were incubated with 4.5 µM PAH in the presence of increasing concentrations of 
probenecid.  Each flask was incubated at 37 º C for 2 min in a shaking water  bath (180 rpm) 
under 95% O2/5% CO2. Assays were run in duplicate at each concentration.  At the end of each 
assay the total IRPT sample in each flask was analyzed for tubular PAH accumulation.    
Probenecid concentrations used were 25, 50, 100, 150 or 250 µM.  Each point represents mean 
PAH content (pmol/mg protein) ± SE for n=8 (PAH) or n=4 (+probenecid). Data were analyzed by 
Nonlinear Regression analysis. The IC50 value of probenecid for PAH uptake in IPRTs was 
calculated from the nonlinear equation (f=a*x/(b+x); r2=0.97) to be 106.5 µM.   
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Figure 4.18.  Effect of acetamidophenyl glucuronide on PAH accumulation 
in IRPTs.  To determine the effect of AG on PAH accumulation along the basolateral 
membrane in IRPTs, 3 ml of tubules (at 1 mg protein/ml) were incubated at 37ºC with 2.5 µM 14C-
PAH in the presence or absence of 1 mM AG.  Each flask containing IRPT suspension was 
incubated for 30 seconds in a shaking water  bath (180 rpm) under 95% O2/5% CO2.  At the end 
of the assay, the total IRPT sample in each flask was analyzed for tubular PAH accumulation.  All 
assays were run in duplicate.  Bars represent mean PAH content (pmol/mg protein) ± SE for n=4.  
PAH accumulation was not significantly inhibited by incubation with AG.  Data were analyzed by 
Student’s t-test, with a 95% confidence interval. 
 
 
 
 
 
113 
Treatment
PA
H
 (p
m
ol
/m
g 
pr
ot
ei
n)
0
10
20
30
40
50
  P
AH
  P
AH
 + 
TG
PA
H 
+ M
UG
  P
AH
 + 
AG
 
 
Figure 4.19. Effect of testosterone glucuronide (TG), methylumbelliferyl 
glucuronide (MUG), and acetamidophenyl glucuronide (AG) on PAH 
accumulation in IRPTs.   To determine the effect of TG, MUG, and AG on PAH 
accumulation in IRPTs, 3 ml of tubule suspension (1mg protein/ml) were incubated with 4.4µM 
14C-PAH in the absence or presence of 500 µM TG, MUG, or AG. Tubules were incubated at 
37ºC for 30 seconds in a shaking water  bath (180 rpm) under 95% O2/5% CO2.  At the end of 
each assay, the total IRPT sample in each flask was analyzed for tubular PAH accumulation.  All 
assays were run in duplicate.  Bars represent mean PAH content (pmol/mg protein) ± SE for n=4 
(PAH + TG) or n=5 (PAH + MUG, AG).  Incubation with PAH in the presence of TG, MUG or AG 
did not cause significant inhibition of PAH accumulation in IRPTs.  Data were analyzed by 
Repeated Measures ANOVA. 
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4.1.3.3  Estrone sulfate accumulation in IRPTs. 
  
Estrone sulfate (ES) has been used as the typical substrate of OAT3 in 
numerous OAT transport studies.  Since ES is selective for OAT3 rather than 
OAT1, it allows for direct study of the interaction of compounds with the OAT3 
protein.  Therefore, ES was used to characterize the contribution of OAT3 in 
transport along the basolateral membrane of IRPTs from F344 rat, and to 
determine also the potential role of OAT3 in glucuronide metabolite uptake.   
 
 To characterize OAT3 transport in this IRPT model, it was first necessary 
to determine whether accumulation of ES in this model was a carrier protein-
mediated process.  To determine this, temperature dependent uptake of ES was 
studied.  Tubules (1 mg protein/ml) were incubated with 3H-ES in a shaking water  
bath (180 rpm) at 37 or 4ºC (Fig. 4.20).  Incubation at 4ºC significantly inhibited 
ES uptake in IRPTs by approximately 38%.  This temperature dependent 
inhibition is consistent with the presence of carrier protein-mediated transport. 
 
 To further characterize ES transport in this model, probenecid was used 
as the classical OAT inhibitor to determine whether ES transport in this model 
was probenecid sensitive.  Probenecid sensitivity would give additional 
supporting evidence for the presence and function of OAT3 in this model.  For 
this study, tubules (1 mg protein/ml) were incubated with 4 pM 3H-ES in the 
absence or presence of 1 mM probenecid (Fig. 4.21).  Incubation with ES in the 
presence of probenecid caused significant inhibition of ES uptake in IRPTs by 
approximately 41%. This indicates that OAT transport (as demonstrated by ES 
accumulation) is in part carried out by OAT3 in this model.  These results 
combined with those found for temperature sensitivity of ES uptake, also suggest 
that there may be other transporters involved in ES transport in this model, or 
potentially another transporter involved in the transport of OAT3 substrates. 
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 Self-inhibition of ES accumulation in IRPTs was also used to characterize 
ES transport and OAT3 function in this model.  Self-inhibition, or the inhibition of 
radiolabeled substrate uptake by addition of excess amounts of unlabeled 
substrate, is commonly used as an indicator of true carrier-mediated “transport” 
of a compound vs. other forms of entry into a cell (i.e. diffusion).  To determine 
whether ES is subject to self-inhibition, IRPTs (1 mg protein/ml) were incubated 
with 4 pM 3H-ES, in the absence or presence of 500 µM unlabeled ES (Fig 4.22).  
Incubation of IRPTs with 3H-ES in the presence of excess unlabeled ES showed 
significant inhibition of ES accumulation by approximately 63%. This 
demonstrates that ES transport in IRPTs from Fischer 344 rat is a carrier-
mediated transport process, and also demonstrates the presence and function of 
OAT3 along the tubular basolateral membrane.  
 
 To assess the potential interaction between AG and OAT3, AG was used 
as a potential inhibitor of uptake of ES, a known OAT3 substrate.  In this study 
IRPTs (1 mg protein/ml) were incubated with 4 pM 3H-ES in the absence or 
presence of 1 mM AG for 60 seconds (Fig. 4.23).  Incubation of IRPTs with ES in 
the presence of AG did not demonstrate significant inhibition of ES accumulation. 
This indicates that AG does not interfere with ES transport, further demonstrating 
that AG either does not interact with OAT3 transporters along the basolateral 
membrane of the PT, or is such a weak substrate that it can not displace ES (a 
high-affinity OAT3 substrate) from the protein. 
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Figure 4.20.  The effect of temperature on estrone sulfate accumulation in 
IRPTs.  To determine the effect of temperature on ES uptake in IPRTs, 3 ml of tubules (at 1 mg 
protein/ml) were incubated at 37ºC or 4ºC in the presence of 4 pM 3H-ES.  ES was added to each 
flask of IRPT suspension and incubated for 60 seconds in a shaking water  bath (180 rpm) under 
95% O2/5% CO2.   At the end of each assay, the total IRPT sample in each flask was analyzed for 
tubular ES accumulation.  All assays were run in duplicate.  Bars represent mean ES content 
(fmol/mg protein) ± SE for n=5,   * Significantly different from control (37) values (P<0.05).   Data 
were analyzed by Student’s t-test, with a 95% confidence interval. 
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Figure 4.21. The effect of probenecid on ES accumulation in IRPTs. 
To determine the effect of probenecid on ES accumulation in IRPTs, 3 ml of tubules (at 1mg 
protein/ml) were incubated for 30 seconds with 4 pM 3H-ES in the absence or presence of 1 mM 
probenecid.  Each flask was incubated at 37ºC in a shaking water  bath (180rpm) under 95% 
O2/5% CO2.  At the end of each assay the total IRPT sample in each flask was analyzed for 
tubular ES accumulation.   All assays were run in duplicate.  Bars represent mean ES content 
(fmol/mg protein) ± SE, n=3.   * Significantly different from control (ES) values (P<0.05).  Data 
were analyzed by Student’s t-test, with a 95% confidence interval.      
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Figure 4.22. The effect of self-inhibition on estrone sulfate accumulation in 
IRPTs.  To determine the effect of self-inhibition on ES uptake in IRPTs, 3 ml tubules (at 1 mg 
protein/ml) were incubated for 60 seconds with 4 pM 3H-ES in the absence or presence of 500 
µM unlabeled ES.  Each flask was incubated at 37ºC in a shaking water  bath (180rpm) under 
95% O2/5% CO2.  At the end of each assay the total IRPT sample in each flask was analyzed for 
tubular ES accumulation.   All assays were run in duplicate.  Bars represent mean ES content 
(fmol/mg protein) ± SE for n=4.  * Significantly different from control (3H-ES) values (P<0.05).  
Data were analyzed by Student’s t-test, with a 95% confidence interval.    
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Figure 4.23. The effect of acetamidophenyl glucuronide on estrone sulfate 
accumulation in IRPTs.   To determine the effect of AG on ES accumulation along the 
basolateral membrane in IRPTs, 3 ml of tubules (at 1 mg protein/ml) were incubated for 60 
seconds with 4 pM 3H-ES in the presence or absence of 1 mM AG.  Each flask containing IRPT 
suspension was incubated for 37 ºC in a shaking water  bath (180 rpm) under 95% O2/5% CO2.  
At the end of the assay, the total IRPT sample in each flask was analyzed for tubular ES 
accumulation.  All assays were run in duplicate.  Bars represent mean ES content (fmol/mg 
protein) ± SE for n=3.  ES accumulation was not significantly inhibited by incubation with AG.  
Data were analyzed by Student’s t-test, with a 95% confidence interval. 
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4.1.3.4 Acetamidophenyl glucuronide (AG) accumulation in IRPTs 
 
 AG was selected as a model glucuronide for the study of glucuronide 
transport along the basolateral membrane of the renal PT.  This compound was 
available radiolabeled, and previous studies suggest that AG has the ability to be 
secreted by the kidney (Duggin and Mudge, 1975; Galinsky and Levy, 1981; 
Watari et al., 1983).  To elucidate whether OAT proteins contribute to AG 
secretion (and possibly glucuronide metabolites in general) across the 
basolateral membrane of the PT, various aspects of AG accumulation by IRPTs 
were studied.   Temporal studies revealed that when IRPTs are incubated with 
4.5 µM AG, AG appears to demonstrate time-dependent accumulation within the 
tubule fragments (Fig. 4.24).  Accumulation appeared gradual over time with AG 
tubular content doubling between 15 and 300 seconds.  
 
 To elucidate further the mechanism of uptake of AG in IRPTs, temperature 
dependent studies were used to determine whether accumulation of AG 
appeared to be via a carrier protein-mediated process (such as OAT).  IRPTs 
incubated with 2 µM 14C-AG at either 37ºC or 4ºC did not reveal significant 
decrease in AG accumulation across the basolateral membrane of IRPTs (Fig. 
4.25).  Decreased temperature generated only approximately 18% inhibition.  
These results indicate that AG entry into IRPTs across the basolateral membrane 
may, in large part, be due to mechanisms other than a carrier protein-mediated 
pathway.  
 
 To determine whether AG interacts with OAT transporters, probenecid 
was used as the typical OAT transport inhibitor.  Since probenecid has been 
demonstrated to inhibit the uptake of organic anions in this model, if AG 
accumulation is due in any part to transport by OAT proteins, treatment with 
probenecid should yield inhibition of AG accumulation.  IRPTs pretreated with 
probenecid or coincubated with probenecid in the presence of 2 µM 14C-AG did 
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not demonstrate inhibition of AG accumulation (Fig. 4.26).  Lack of inhibition of 
AG accumulation in IRPTs by probenecid demonstrates that AG accumulation 
may by via a different mechanism than OAT transport. 
 
 Since the previous experiments raise question as to whether transport of 
AG across the basolateral membrane is due to a protein-mediated transport 
process, self-inhibition studies were used to characterize further the mechanism 
of AG transport into IRPTs.  IRPTs incubated with 14C-AG in the presence of 
excess unlabeled AG did not demonstrate inhibition of labeled AG accumulation 
(Fig. 4.27).  This provides further evidence that AG entry across the basolateral 
membrane in this IRPT model may be due to other mechanisms than carrier-
mediated transport.   
 
 To characterize further whether AG interacts with OAT transporters along 
the basolateral membrane, potential transport by OAT3 was specifically 
examined.  Since AG is a bulky, charged molecule (as are glucuronides in 
general), AG is more likely to interact with OAT3 than other OATs should AG 
have any interaction with OAT proteins along the basolateral membrane of renal 
PTs.  IRPTs incubated with 4.5 µM AG in the presence of 100 µM ES did not 
demonstrate inhibition of AG accumulation (Fig. 4.28).  Since the presence of ES 
(a high affinity substrate for OAT3) did not interfere with AG accumulation in this 
model, this finding further supports that AG accumulation into IRPTs is not due to 
OAT proteins along the basolateral membrane, and more specifically, AG does 
not appear to interact with OAT3 proteins.    
 
 In the previous studies, the mechanism of AG uptake across the 
basolateral membrane of IRPTs does not appear to be due to a carrier protein-
mediated process such as OAT.  With concern that these results may have been 
affected by metabolism of the AG metabolite by β-glucuronidase during 
incubation, AG accumulation studies were conducted in the presence of D-
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saccharic acid 1,4-lactone (SL), a β-glucuronidase inhibitor (Soars et al., 2001).  
Since deconjugation of AG would have yielded a glucuronic acid moiety, and a 
labeled acetaminophen (APAP) molecule, it was necessary to determine whether 
what was documented as AG uptake was due to AG or APAP, since APAP does 
have the ability to diffuse through the cell membrane.  If uptake was due to 
diffusion of APAP into the IRPTs rather than AG, treatment with SL should 
completely inhibit accumulation of labeled substrate (AG).  IRPTs treated with 4.5 
µM AG in the presence of SL demonstrated no inhibition of AG accumulation 
(Fig. 4.29).  This indicates that the demonstrated accumulation of AG in previous 
studies is in fact due to the AG molecule, and not deconjugation to APAP with 
subsequent entry of APAP into the tubules.     
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Figure 4.24.  Time-dependent accumulation of acetamidophenyl 
glucuronide in IRPTs. To determine the time-dependent accumulation of AG in IRPTs, 3 ml 
tubules (at 1 mg protein/ml) were incubated with 4.5 µM 14C-AG for 15, 30, 45, 60,120 or 300 
seconds.  Tubules were incubated at 37 ºC in a shaking water  bath (180 rpm) under 95% O2/5% 
CO2. All assay was run in duplicate.  At the end of each time point, the total tubule suspension 
from each flask was analyzed for tubular AG accumulation.  Each point represent mean tubular 
AG content (pmol/mg protein) ± SE for n=3.  Data were analyzed by Nonlinear Regression 
analysis [(f=a*x/(b+x)+c*x); r2=0.994].     
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Figure 4.25.  The effect of temperature on acetamidophenyl glucuronide 
accumulation in IRPTs.  To determine the effect of temperature on AG uptake in IPRTs, 3 
ml of tubules (at 1 mg protein/ml) were incubated at 37ºC or 4ºC in the presence of 2 µM 14C-AG.  
AG was added to each flask of IRPT suspension and incubated for 30 seconds in a shaking water  
bath (180 rpm) under 95% O2/5% CO2.   At the end of each assay, the total IRPT sample in each 
flask was analyzed for tubular AG accumulation.  All assays were run in duplicate.  Bars 
represent mean AG content (pmol/mg protein) ± SE for n=4,   AG accumulation was not 
significantly inhibited by incubation at 4ºC.   Data were analyzed by Student’s t-test, with a 95% 
confidence interval. 
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Figure 4.26. The effect of probenecid on acetamidophenyl glucuronide 
accumulation in IRPTs.  To determine the effect of probenecid on AG accumulation in 
IRPTs, 3 ml of tubules (at 1mg protein/ml) were either incubated for 30 seconds with 2 µM 14C-
AG in the absence or presence of 1 mM probenecid or preincubated with 1mM probenecid before 
the addition of 2 µM 14C-AG.  Each flask was incubated at 37ºC in a shaking water  bath (180rpm) 
under 95% O2/5% CO2.  At the end of each assay the total IRPT sample in each flask was 
analyzed for tubular AG accumulation.   All assays were run in duplicate.  Bars represent mean 
AG content (pmol/mg protein) ± SE for n=4.   Probenecid did not significantly inhibited AG 
accumulation in IRPTs from Fischer 344 rat.  Data were analyzed by Student’s t-test, with a 95% 
confidence interval.      
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Figure 4.27. The effect of self-inhibition on acetamidophenyl glucuronide 
accumulation in IRPTs.  To determine the effect of self-inhibition on AG uptake in IRPTs, 3 
ml tubules (at 1 mg protein/ml) were incubated for 30 seconds with 4.5 µM 14C-AG in the absence 
or presence of 5 mM unlabeled AG.  Each flask was incubated at 37ºC in a shaking water  bath 
(180rpm) under 95% O2/5% CO2.  At the end of each assay the total IRPT sample in each flask 
was analyzed for tubular AG accumulation.   All assays were run in duplicate.  Bars represent 
mean AG content (pmol/mg protein) ± SE for n=3.  The presence of unlabeled AG did not 
significantly inhibit the accumulation of 14C-AG in IRPTs.  Data were analyzed by Student’s t-test, 
with a 95% confidence interval 
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Figure 4.28. The effect of estrone sulfate on acetamidophenyl glucuronide 
accumulation in IRPTs.  To determine the effect of ES on AG accumulation in IRPTs, 3 ml 
of tubules (at 1mg protein/ml) were incubated for 30 seconds with 4.5 µM 14C-AG in the absence 
or presence of 100 µM ES.   Each flask was incubated at 37ºC in a shaking water  bath (180rpm) 
under 95% O2/5% CO2.  At the end of each assay the total IRPT sample in each flask was 
analyzed for tubular AG accumulation.   All assays were run in duplicate.  Bars represent mean 
AG content (pMole/mg protein) ± SE for n=3.   Incubation with ES did not significantly inhibited 
AG accumulation in IRPTs.  Data were analyzed by Student’s t-test, with a 95% confidence 
interval.      
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Figure 4.29. The effect of D-saccharic acid 1,4-lactone on acetamidophenyl 
glucuronide accumulation in IRPTs.  To determine the effect of SL on AG 
accumulation in IRPTs, 3 ml of tubules (at 1mg protein/ml) were incubated for two min with 4.5 
µM 14C-AG in the absence or presence of either 10mM or 20 mM SL following 5 min 
preincubation with SL.   Each flask was incubated at 37ºC in a shaking water  bath (180rpm) 
under 95% O2/5% CO2.  At the end of each assay the total IRPT sample in each flask was 
analyzed for tubular AG accumulation.   All assays were run in duplicate.  Bars represent mean 
AG content (pMole/mg protein) ± SE for n=3.   Incubation with SL at either concentration did not 
significantly inhibited AG accumulation in IRPTs.  Data were analyzed by Repeated Measures 
ANOVA, with a 95% confidence interval.      
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4.1.3.5 Western Blot Analysis of OAT1 and OAT3 in Fischer 344 IRPTs 
  
 Western blot analysis of the organic anion transporters, OAT1 and OAT3, 
was performed using crude membrane fractions isolated from Fischer 344 rat 
IRPTs (Fig. 4.30).  IRPTs were isolated as described in the Methods chapter and 
western blot analysis was carried out by Eliza Robertson.  Molecular weight is 
given for protein bands larger than 50 kD, as smaller bands are thought to be 
due to either incompletely formed proteins or breakdown products. Antibodies 
synthesized against peptides homologus to the amino-terminus were used and 
would therefore bind whole and partial proteins. The OAT1 band demonstrated 
for Fisher 344 IRPTs at 75 kD is comparable to the 77 kD band reported by Ji et 
al (2002) for OAT1, where the 61.3 kD band is likely the nonglycosylated protein 
form.  Faint bands for OAT3 were detected at 54 and 63 kD which is comparable 
to the 54 and 65 kD, bands reported by Hasegawa et al. (2002) for rOAT3. Heavier 
darker bands may potential represent breakdown products.  While western blot 
analysis can not show whether OAT1 and OAT3 are functional, it demonstrates 
that OAT1 appears to be present while raising question as to the presence of 
OAT3 in F344 IRPTs.   
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Figure 4.30. Western Blot Analysis for OAT1 and OAT3.  Crude membrane fractions 
(250 µg/lane) isolated from HK-2 cells, passage 29, scraped from T75 flasks and from Fisher 344 
(F344) rat IRPTs were separated on a 12% polyacrylamide gel, blotted onto nitrocellulose then 
exposed to antibodies against OAT1 or OAT3.  In freshly isolated F344 IRPTs, bands were 
detected at 61.3 and 75 kD for OAT1, and faint bands for OAT3 were detected at 54 and 63 kD. 
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4.2 Studies in Renal Cortical Slices (RCS) 
 
4.2.1 Uptake studies in renal cortical slices (RCSs) 
 
 
 The isolation of renal PTs used in the previously described studies 
involved the use of collagenase digestion.  Collagenase digestion, while 
providing healthy tubule fragments for uptake studies, may potentially cause 
partial digestion of some transporters along the basolateral membrane.  To 
determine whether the results for AG uptake in IRPTs are due to partial digestion 
of the transport mechanisms for the AG molecule  
(partial digestion of OAT transporters at a critical AG binding site) has occured, 
additional studies were conducted in renal cortical slices.  It is important to note 
that the IRPT model was able to demonstrate transport of known organic anions 
such as FL, PAH, and to a certain extent ES.  These compounds may have 
multiple recognition sites within the OAT proteins and transport of these OAs 
would be less sensitive to partial digestion by collagenase.  AG however, if it has 
extremely low substrate specificity for OAT, may be more susceptible to the 
effects of partial digestion of the OAT proteins by collagenase digestion.  RCSs 
have the same transport properties as IRPTs, but their isolation does not involve 
the use of collagenase.  Therefore, in the RCS model, OAT proteins along the 
proximal tubular basolateral membrane should remain fully intact.  If digestion of 
OAT proteins in the IRPT model caused decreased affinity of AG for the 
transporter proteins, this affinity should be unchanged in the RCS model.  
 
4.2.1.1 Mannitol accumulation in RCSs 
 
 Accumulation of 3H-mannitol was used to assess interstitial accumulation 
in the RCS model.    Mannitol does not undergo transport by any portion of the 
RCS.  Therefore, mannitol does not accumulate in RCSs by transport 
mechanisms but accumulation is due to movement (leak) of MN into interstitial 
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spaces between cells within the slices.  Thus, MN accumulation gives an 
indication as to the amount of interstitial space where compounds may collect by 
mechanisms other than cellular transport. RCSs incubated over time in the 
presence of 176 pM 3H-mannitol demonstrated accumulation of less than 7 
fmol/mg protein of mannitol over a 60 min incubation time (Fig. 4.31).  
Accumulation of mannitol was minimal over the entire time period (10-60 min), 
indicating that the slices were of good quality (no large interstitial spaces or gaps 
created during slicing) and could be used for uptake studies.  
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Figure 4.31.  Mannitol accumulation in RCSs.  To assess the quality of the RCS 
technique, RCSs (30-60 mg) were incubated for 10, 15, 30, and 60 min in the presence of 176 
pM 3H-mannitol.  Slices were incubated at 37ºC in a shaking water  bath (100 rpm).  At the end of 
each time point, the total slice content of each well was analyzed for mannitol accumulation.  
Each assay was run in duplicate.  Each point represents mean mannitol content (fmol/mg protein) 
± SE for n=4.  Mannitol accumulation appeared to reach a maximum of less than 7 fmol/mg 
protein.  Data were analyzed by Nonlinear Regression analysis [f=a*x/(b+x); r2=0.99]. 
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4.2.1.2 PAH accumulation in RCSs 
 
 Accumulation of PAH, the typical OAT1/OAT3 substrate, was used to 
assess the activity of OAT transporters along the basolateral membrane of PTs 
in the RCS model.  Since the tubular lumens collapse in the slice model, the only 
entry for PAH into the PT cells in RCSs is via tubular OAT transporters along the 
basolateral membrane.    
 
 To characterize best that PAH uptake in the RCS model is mediated by 
OAT proteins, probenecid, the typical OAT transport inhibitor, was used to 
demonstrate inhibition of PAH uptake.   RCSs incubated with 4.7 µM 14C-PAH in 
the presence of probenecid showed accumulation of PAH with significant 
inhibition of PAH accumulation in the presence of 1 mM probenecid (Fig. 4.32). 
Inhibition of PAH accumulation by probenecid was approximately 80%.  This 
result is similar to that found in IRPTs (86%; Fig. 4.16), indicating that OAT 
proteins are functional in this model and transport is probenecid sensitive.     
 
 To characterize the potential interaction of OAT transport with glucuronide 
metabolites in the RCS model, TG, MUG, and AG were used to assess their 
interaction with PAH transport.   RCSs incubated with 4.7 µM 14C-PAH in the 
presence of 500 µM TG, MUG, or AG demonstrated no inhibition of PAH 
transport (Fig. 4.33).  TG, MUG, and AG all failed to inhibit PAH accumulation in 
RCSs, indicating that these compounds do not interact with the same transport 
mechanisms as PAH in the RCS model.  This finding is also in agreement with 
that found in the IRPT model (Fig. 4.19). 
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Figure 4.32. The effect of probenecid on PAH accumulation in RCSs. To 
determine the effect of probenecid on PAH transport in RCS, RCSs (30-60 mg) were incubated 
for 30 min with 4.7 µM 14C-PAH in the absence or presence of 1mM probenecid.  RCSs were 
incubated at 37ºC in a shaking water  bath (100 rpm).  At the end of each assay, total slice 
content of each well was analyzed for PAH accumulation.  Each assay was run in duplicate.  Bars 
represent mean PAH content (pmol/mg protein) ± SE for n=4.  * Significantly different from control 
(PAH) values (P<0.05).  Data were analyzed by Student’s t-test with a 95% confidence interval. 
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Figure 4.33. The effect of testosterone glucuronide (TG), methylumbelliferyl 
glucuronide (MUG), and acetamidophenyl glucuronide (AG) on PAH 
accumulation in RCSs.   To determine the effect of TG, MUG and AG on PAH 
accumulation in RCSs., RCSs (30-60 mg) were incubated for 30 min with 4.7 µM PAH in the 
absence or presence of 500 µM TG, MUG or AG.  Slices were incubated at 37ºC in a shaking 
water  bath (100 rpm).  At the end of each assay, total slice content from each well was analyzed 
for PAH accumulation.  Each assay was run in duplicate.   Each bar represents mean PAH 
content (pmol/mg protein) ± SE for n=4.  Data were analyzed by One Way Repeated Measures 
ANOVA.   
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4.2.1.3 Estrone sulfate accumulation in RCSs. 
 
 To evaluate the activity and contribution of OAT3 to organic anion 
transport in RCSs, estrone sulfate was used as the typical substrate for OAT3.  
Since OAT3 is most likely responsible for the transport of bulky organic anions 
(and thus glucuronide conjugates), it was important to determine the presence of 
active OAT3 function in this model, and determine whether AG appeared to have 
any interaction at this transporter.  Temporal uptake studies in RCSs, show that 
when treated with 4 pM 3H-ES, RCSs accumulate ES in a time-dependent 
manner (Fig. 4.34).  Accumulation of ES increases steadily until 30 min, and by 
60 min uptake appears to be reaching equilibrium.   
 
 To characterize further ES transport, and thus OAT3, in the RCS model, 
the effects of probenecid and temperature on ES accumulation were assessed.  
Probenecid inhibition would indicate that ES is transported by an OAT protein in 
this model, and temperature sensitivity would indicate that transport is via a 
carrier protein-mediated process.  RCSs incubated with 4 pM 3H-ES in the 
presence of 1mM probenecid or at 4ºC demonstrated significantly decreased ES 
accumulation (Fig. 4.35).  Probenecid treatment caused a 33% reduction in ES 
accumulation, while incubation at 4ºC caused an 80% decrease in ES 
accumulation.  Since low temperature demonstrated a significantly greater 
decrease in ES accumulation than treatment with probenecid, this indicates that 
there may be another transport mechanism involved in ES accumulation. 
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Figure 4.34.  Time-dependent accumulation of estrone sulfate in RCSs.  
RCSs (30-60mg) were incubated for 10, 15, 20, 30 or 60 min in the presence of 4 pM 3H-ES.  
Slices were incubated at 37ºC in a shaking water  bath (100 rpm).  At the end of each time point, 
total slice content of each well was analyzed for ES accumulation.  Each assay was run in 
duplicate.  Each point represents mean ES content (fmol/mg protein) ± SE for n=4.  Data were 
analyzed by Nonlinear Regression analysis [f=a*x/(b+x); r2=0.99].  
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Figure 4.35. Effect of probenecid and temperature on ES accumulation in 
RCSs.  To determine the effect of probenecid and temperature on ES accumulation, RCSs (30-
60 mg) were incubated for 10 min with 4 pM  3H-ES in the absence or presence of 1mM 
probenecid at 37ºC, or with 4 pM  3H-ES alone at 4ºC.   At the end of each assay, total slice 
content from each well was analyzed for ES accumulation.  Assays were run in duplicate.  Each 
bar represents mean ES content (fmol/mg protein) ± SE, n=4.  * Significanlty different from 
control (ES) value (P<0.001).  # Significantly different from treatment with probenecid (P<0.001).  
Data were analyzed by One Way Repeated Measures ANOVA, followed by Student-Newman-
Keuls analysis with a 95% confidence interval. 
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4.2.1.4  Acetamidophenyl glucuronide accumulation in RCSs 
 
 Accumulation of AG in RCSs was studied in various experiments to 
determine whether the affinity of AG for OAT transporters may have been 
affected by the collagenase digestion treatment in the IRPT isolation procedure.  
If OAT proteins along the basolateral membrane had become partially digested, 
the tubule fragments may no longer be able to recognize AG as a potential 
substrate.  Accumulation studies in RCS allow for the study of glucuronide 
transport in a model that does not have enzymatically digested proteins, such as 
OAT.  If enzymatic digestion has destroyed a critical recognition site for 
glucuronide substrates in IRPTs, this may be a reason why the IRPT model 
appears to lack the ability to demonstrate AG accumulation via carrier protein-
mediated mechanisms.   If a critical binding site has been digested in the IRPT 
model, this site should be functional in the RCS model.  Therefore, the RCS 
model should demonstrate a protein carrier-mediated accumulation mechanism 
for AG, if AG or other glucuronide metabolites are transported across the 
basolateral membrane by carrier proteins such as OAT1 or OAT3.  To assess 
whether accumulation of AG in RCS differed from that seen in IRPTs, temporal 
studies were conducted.  RCSs incubated over time in the presence of 4.7 µM 
14C-AG demonstrates a slightly biphasic accumulation pattern (Fig. 4.36).  AG 
accumulation in RCS occurs rapidly during the first 5 min, and reaches an 
apparent equilibrium by 20 min.  At 45 min, accumulation appears to begin to 
increase, however this increase may be due to loss of slice integrity with 
increased accumulation within interstitial spaces, or increased binding to 
exposed intracellular proteins.   
 
 To determine whether AG accumulation in slices is due to carrier protein-
mediated process temperature sensitive studies were conducted.  At the same 
time studies were conducted to determine the effects of probenecid on AG 
accumulation.  Inhibition of AG accumulation by probenecid would give an 
indication of the role of OAT in AG accumulation in this model.  RCS incubated 
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with 4.7 µM 14C-AG at 4ºC demonstrated a significantly lower accumulation of AG 
than RCSs incubated at 37ºC (Fig. 4.37).   AG accumulation was inhibited at 4ºC 
by approximately 30%.  While this is not a large degree of inhibition, it indicates 
that there may be some protein-mediated process for AG accumulation in RCS.  
No inhibition was seen in the IRPT model.  When RCSs were incubated with 4.7 
µM 14C-AG in the absence or presence of 1mM probenecid, AG accumulation 
was significantly inihibited (Fig. 4.37).  Accumulation of AG was inhibited 
approximately 22%.  This probenecid sensitivity of AG accumulation in RCSs 
indicates that OAT may play a small role in AG accumulation in this model.  It is 
important to note, however, that there is a large amount of AG accumulation that 
is not accounted for by either a temperature-dependent, carrier protein-mediated 
mechanism, or by a probenecid-sensitive (OAT) mechanism (70% and 78%, 
respectively).   
 
 To study further whether AG interacts with OAT proteins along the tubular 
basolateral membrane in RCS, PAH and ES were used as potential competitive 
inhibitors of AG accumulation.  PAH was used to assess both OAT1 and OAT3, 
and ES used to assess primarily the OAT3 contribution.  RCSs incubated with 
4.7 µM 14C-AG in the absence or presence of either 1mM PAH or 500 µM ES did 
not demonstrate inhibition of AG accumulation in RCSs (Fig 4.38).  This finding is 
similar to that found in IRPTs for ES, and further indicates that OAT1 and OAT3 
may not be responsible for AG accumulation in this model.  
 
 Since AG accumulation did not appear to be due to OAT transport along 
the basolateral membrane, self-inhibition studies were conducted to further 
characterize the presence of a protein carrier-mediated uptake mechanism, as 
demonstrated by the temperature dependent studies.  While uptake does not 
appear to be via OAT proteins, there may be other protein carriers responsible 
for AG accumulation in the RCS model.  However, RCSs incubated with 4.7 µM 
14C-AG in the absence or presence of 500 µM unlabeled AG did not show 
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inhibition of AG accumulation (Fig. 4.39).  This indicates that AG accumulation in 
the RCS model is not due to a carrier protein-mediated process, supporting the 
results found in the IRPT model. Accumulation of AG must, therefore, be due to 
other mechanisms such as non-specific binding.     
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Figure 4.36 Time-dependent accumulation of acetamidophenyl glucuronide 
in RCSs. RCS (30-60 mg) were incubated for 2.5, 5, 15, 30, 45 or 60 min in the presence of  
4.7 µM 14C-AG.  Slices were incubated at 37ºC in a shaking water  bath (100 rpm).  At the end of 
each time point total slice content of each well was analyzed for AG accumulation.  Each assay 
was run in duplicate. Each point represents mean AG content (pmol/mg protein) ± SE for n=3. 
Data were analyzed by Nonlinear Regression analysis [(f=a*x/(b+x)+c*x); r2=0.96]. 
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Figure 4.37.  The effect of temperature and probenecid on AG accumulation 
in RCSs.  To determine the effects of temperature on AG accumulation, RCSs (30-60 mg) 
were incubated for 30 min with 4.7 µM 14C-AG at either 37ºC or at 4ºC.  To determine the effect of 
probenecid on AG accumulation, RCSs were incubated for 30 min with 4.7 µM 14C-AG at 37ºC in 
the absence or presence of 1 mM probenecid.  Slices were incubated in a shaking water  bath 
(100 rpm). At the end of each assay, total slice content from each well was analyzed for AG 
accumulation.  Each assay was run in duplicate.   Each bar represents mean AG content 
(pmol/mg protein) ± SE for n=4.  * Significantly different from control (AG) values (P<0.05).  
Temperature and probenecid treatments were not significantly different from each other.  Data 
were analyzed by One Way Repeated Measures ANOVA, followed by Student Newman-Keuls 
analysis at a 95% confidence interval.   
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Figure 4.38. The effect of p-aminohippuric acid and estrone sulfate on AG 
accumulation in RCSs.  To determine the effects of PAH and ES on AG accumulation, 
RCSs (30-60 mg) were incubated for 30 min with 4.7 µM 14C-AG in the absence or presence of 
either 1 mM PAH or 500 µM ES.  Slices were incubated at 37ºC in a shaking water  bath (100 
rpm).  At the end of each assay, total slice content from each well was analyzed for AG 
accumulation.  Each assay was run in duplicate.   Each bar represents mean AG content 
(pmol/mg protein) ± SE for n=5.  Incubation with PAH or ES did not significantly inhibit AG 
accumulation in RCSs.   Data were analyzed by One Way Repeated Measures ANOVA. 
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Figure 4.39. The effect of self-inhibition on AG accumulation in RCSs. To 
determine the effect of self-inhibition on AG accumulation, RCSs (30-60 mg) were incubated for 
30 min with 4.7 µM 14C-AG in the absence or presence 500 µM unlabeled AG.  Slices were 
incubated at 37ºC in a shaking water  bath (100 rpm).  At the end of each assay, total slice 
content from each well was analyzed for AG accumulation.  Each assay was run in duplicate.   
Each bar represents mean AG content (pmol/mg protein) ± SE for n=5 (14C-AG) or n=4 (14C-
AG+AG).  Incubation with excess AG did not significantly inhibit AG accumulation in RCSs.  Data 
were analyzed by Student’s t-test with a 95% confidence interval. 
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4.2.1.5 Acetamidophenyl glucuronide accumulation in RCSs from Sprague-
Dawley (SD) rat 
 
 Studies conducted in IRPTs and RCSs from male F344 rat provided 
evidence that these models are able to accumulate organic anions such as FL, 
PAH and ES.  Uptake of these molecules was carrier protein-mediated, and 
determined to be via OAT transport proteins. However, these models did not 
demonstrate that accumulation of AG was due to a protein-mediated process, 
and more importantly, accumulation does not appear to be via OAT mechanisms 
along the basolateral membrane of the PT.   Because studies that have indicated 
renal secretion of AG were conducted in other rat strains (SD; Galinsky and 
Levy, 1981) (Wistar; Watari et al. 1983), it was necessary to investigate whether 
studies in a different rat strain would produce different results.  Possibly the F344 
rat does not have the same renal OAT substrate specificities as other rat strains.  
To investigate whether AG accumulation can be documented in another rat 
strain, male SD rats were chosen for this study, and RCS selected as the model 
(to eliminate collagenase digestion issues). 
 
 To determine whether AG accumulation appeared to be via a carrier 
protein-mediated process, temperature-dependent studies were conducted.  
Probenecid sensitivity was used to determine whether AG accumulation across 
the basolateral membrane is an OAT-mediated process.    RCSs from male SD 
rats incubated with 4.3 µM 14C-AG at 4ºC demonstrated significantly reduced AG 
accumulation (Fig. 4.40). Incubation at 4ºC decreased AG accumulation 
approximately 29%. This finding is similar to that found in RCS from F344 rats 
(30%).  However, when RCSs were incubated with 4.3 µM 14C-AG in the 
presence of 1 mM probenecid, no reduction of AG accumulation was found (Fig 
4.40).  This finding differs from that found in F344 RCSs.  Most importantly, this 
indicates that AG accumulation, while it may have a small protein-mediated 
component, does not appear to be via OAT in SD RCSs. 
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 To document further any potential interaction of AG with OAT proteins 
along the basolateral membrane, PAH was selected as a competitive inhibitor of 
AG accumulation.  RCSs incubated with 4.3 µM 14C-AG in the presence of 1 mM 
PAH showed no inhibition of AG accumulation (Fig. 4.41).  This again indicates 
that AG uptake does not appear to be via OAT proteins along the basolateral 
membrane of the renal PT. 
 
 To verify whether apparent AG accumulation is truly via a carrier protein-
mediated process, self-inhibition studies were conducted in RCSs from male 
Sprague-Dawley rats as had been conducted in Fischer 344 models.  RCSs 
incubated with 4.3 µM 14C-AG in the presence of 500 µM unlabeled AG 
demonstrated no inhibition of AG accumulation in this model (Fig. 4.42).  This 
result again demonstrates that AG accumulation is via a mechanism(s) other 
than carrier protein-mediated process.   
 
 Together, these findings demonstrate that AG accumulation in SD rat is 
comparable to that found in models from F344 rat.  AG accumulation does not 
appear to be mediated by a carrier protein mechanism, and cannot be 
demonstrated to be due to OAT proteins at the basolateral membrane of the PT 
in either F344 or SD rat strains.  Accumulation of AG must, therefore, be due to 
other mechanisms.       
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Figure 4.40. The effect of temperature and probenecid on AG accumulation 
in RCSs from Sprague-Dawley rat. To determine the effects of temperature on AG 
accumulation, SD RCSs (30-60 mg) were incubated for 30 min with 4.3 µM 14C-AG at either 37ºC 
or at 4ºC.  To determine the effect of probenecid on AG accumulation, RCSs were incubated for 
30 min with 4.3 µM 14C-AG at 37ºC in the absence or presence of 1 mM probenecid.  Slices were 
incubated in a shaking water  bath (100 rpm). At the end of each assay, total slice content from 
each well was analyzed for AG accumulation.  Each assay was run in duplicate.   Each bar 
represents mean AG content (pmol/mg protein) ± SE for n=4.  *Significanlty different from control 
(AG at 37ºC) values (P<0.05).  Data were analyzed by One Way Repeated Measures ANOVA, 
followed by Dunnett’s analysis with a 95% confidence interval.   
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Figure 4.41. The effect of p-aminohippuric acid on AG accumulation in 
RCSs from Sprague-Dawley rat.  To determine the effects of PAH on AG accumulation, 
SD RCSs (30-60 mg) were incubated for 30 min with 4.3 µM 14C-AG in the absence or presence 
of 1 mM PAH.  Slices were incubated at 37ºC in a shaking water  bath (100 rpm).  At the end of 
each assay, total slice content from each well was analyzed for AG accumulation.  Each assay 
was run in duplicate.   Each bar represents mean AG content (pmol/mg protein) ± SE for n=4.  
Incubation with PAH did not significantly inhibit AG accumulation in RCSs.   Data were analyzed 
by Student’s t-test with a 95% confidence interval. 
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Figure 4.42. The effect of self-inhibition on AG accumulation in RCSs from 
Sprague-Dawley rat. To determine the effect of self-inhibition on AG accumulation, SD 
RCSs (30-60 mg) were incubated for 30 min with 4.3 µM 14C-AG in the absence or presence 500 
µM unlabeled AG.  Slices were incubated at 37ºC in a shaking water  bath (100 rpm).  At the end 
of each assay, total slice content from each well was analyzed for AG accumulation.  Each assay 
was run in duplicate.   Each bar represents mean AG content (pmol/mg protein) ± SE for n=4.  
Incubation with excess AG did not significantly inhibit AG accumulation in S-D RCSs.   Data were 
analyzed by Student’s t-test with a 95% confidence interval. 
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CHAPTER V 
 
Discussion 
 
5.1 Characterization of IRPTs 
 
 Characterization of IRPTs utilized for organic anion uptake in these 
studies involved enzymatic analysis and visual assessment.  Because the 
isolation technique for IRPTs from rat has been established previously, only 
minor characterization was necessary.  The main objective of this 
characterization was to establish that the population of renal tissue isolated from 
the male F344 kidney was enriched in proximal tubular segments.  Hexokinase 
(HK) and alkaline phosphatase (AP) enzyme assays demonstrated that the 
tubular samples isolated are of PT origin. Microscopic examination also revealed 
that the population of tubules isolated was primarily of proximal tubular origin, 
and there was no glomerular contamination.  Viability for IRPTs was found to be 
approximately 89%, indicating that the tubule fragments were not damaged in the 
isolation process.  Western blot analysis also demonstrated the presence of 
OAT1 and OAT3 proteins in IRPTs.  Enzymatic, microscopic and Western blot 
analysis demonstrated that IRPTs isolated from male F344 rat are greatly 
purified, intact, and contain both OAT1 and OAT3 proteins, demonstrating that 
the IRPTs isolated can be used to study OA transport.    
 
5.2 Toxicity Studies 
 
 Toxicity studies utilizing APAP and AG both demonstrated that these 
compounds are non-toxic in the IRPT model.  Both LDH release and nucleotide 
levels remained at control levels indicating that these compounds do not cause 
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any type of toxic reactions within the proximal tubular cells at the concentrations 
and time points studied.  This allowed for the study of transport of AG knowing 
that AG did not interfere with any cellular mechanisms (e.g., ATP production) that 
may be directly connected to the ability of the cells to transport the compound.    
 Studies with DC provided important new information on the toxicity of this 
compound in the IRPT model. Diclofenac had been associated with nephrotic 
syndrome and acute interstitial nephritis, however, the exact mechanism of DC 
toxicity in the kidney is not fully understood. Initial studies conducted at 30 min 
demonstrated that DC was mildly toxic at both concentrations.  LDH release was 
significantly increased over control LDH release values, and ATP and ADP levels 
were significantly depressed compared to control nucleotide values.  To 
determine whether this toxicity originated with an early toxicity event (e.g., 
depression of mitochondrial function and thus altered ATP production) or whether 
toxicity appeared to be a whole cell event, as demonstrated by cellular LDH 
release, studies were reduced to a 15 min time frame.  At 15 min, LDH release 
was not elevated compared to control values, however, ATP levels showed 
significant depression over control values.  This finding demonstrates that the 
early events in DC toxicity appear to result in the alteration of mitochondrial 
production of ATP, or, due to a toxic cellular reaction, the cellular needs for ATP 
exceed the ability of the cells to produce ATP.   This finding is in agreement with 
those of Bort et al. (1998), demonstrating that acute diclofenac-induced toxicity in 
hepatocytes was preceded by a decrease in ATP levels. Bort et al. (1998) 
concluded that the toxic effect of diclofenac on hepatocytes may have been 
caused by drug-induced mitochondrial impairment.  These results appear to be 
similar to those found in this study in the kidney.  Whether this toxic event is due 
to the diclofenac molecule or another metabolite (such as DC-acyl glucuronide) 
remains to be clarified.     
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5.3 OAT1 and OAT3 studies in IRPTs 
 
 Because the transport of organic anions across the basolateral membrane 
of renal PTs from F344 rats has not been studied previously, it was important to 
demonstrate the transport of known organic anions (FL, PAH, ES) by the IRPT 
model.  In studying transport of organic anions, inhibition of OA uptake by various 
mechanisms (low temperature, inhibitors, and self-inhibition) helped characterize 
the function of the transport proteins (primarily demonstrating the presence of 
OAT1 and OAT3) along the basolateral membrane of the IRPT model.  Time and 
temperature-dependent accumulation of FL demonstrated that FL accumulation 
is a protein-mediated process.  Further studies using competitive inhibition of FL, 
PAH and ES accumulation also demonstrated that accumulation of these OAs 
supported a protein-mediated process.  Since FL and PAH are the prototypical 
substrates for OAT1 and OAT3, this indicates that OAT1 and/or OAT3 
transporters are present and functional along the basolateral membrane in 
IRPTs.  
Additional evidence of the role of OAT1 and OAT3 in FL transport is the 
sensitivity of FL accumulation to probenecid, the prototypical OAT inhibitor.  
Accumulation of PAH and FL has been demonstrated in isolated proximal tubular 
cells from Wistar rat and additional studies concluded that in isolated cells, 
accumulation of FL and PAH was mediated by a carrier at the basolateral 
membrane (Masereeuw et al., 1994).  Findings of the present study are in 
agreement with these findings as accumulation of both FL and PAH appear to be 
carrier-mediated. Additionally, FL and PAH appear to undergo accumulation via 
similar or the same transport mechanisms along the basolateral membrane 
(OAT1 and OAT3).  Sensitivity of FL accumulation to ouabain additionally 
supports uptake of this compound by OAT1.  Treatment of IRPTs with ouabain 
resulted in approximately 51% inhibition of FL accumulation, providing indirect, 
supportive evidence that OAT1 is partially responsible for FL accumulation in 
IRPTs. These findings are in agreement with those found in isolated PTs from 
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rabbit by Sullivan et al. (1990), thus indicating the role for the classical organic 
anion system in FL accumulation in the IRPT model.    FL transport was also 
sensitive to inhibition by the OAT3 substrates benzylpenicillin (40%) and DHEA 
sulfate (82%), indicating a role for OAT3 in FL accumulation as well.  The degree 
of inhibition of DHEAs appears to indicate that at high concentrations (1 mM), 
DHEAs loses its specificity for OAT3 and appears to inhibit OAT1 transport as 
well.  This is supported by the fact that Hasegawa et al. (2003) demonstrated 
DHEAs inhibition of rOAT1 PAH uptake.  Hasegawa et al. (2003) also 
demonstrated inhibition of PAH accumulation by rOAT1 with benzylpenicillin, 
however, the concentrations of benzylpenicillin needed to inhibit FL transport 
appear to be higher to produce comparable inhibition of FL transport by DHEAs. 
Because there is overlap with FL and PAH for transport by OAT1 and 
OAT3, it is difficult to determine the exact contribution of each transporter in total 
accumulation of FL and PAH.  The potential role of other transporters besides 
OAT1 and OAT3 can also not be ruled out. Accumulation of ES, the prototypical 
OAT3 substrate, suggests that OAT3 transporters are also present and functional 
in the IRPT model, and provides a useful substrate to probe the contribution of 
OAT3 along the basolateral membrane.  Probenecid sensitivity for FL, PAH and 
ES also provided supporting evidence that accumulation of these compounds is 
via organic anion transport proteins along the basolateral membrane, as 
probenecid is the prototypical inhibitor of OAT transport.   
While the use of ES helped to identify the function of OAT3 in this model, 
it does not appear to demonstrate the expected inhibition by probenecid and 
temperature as would be expected with OAT3 transport. Very weak inhibition by 
probenecid (41%) and treatment at 4ºC (38%) indicates that there may be other 
mechanisms for ES accumulation in this model, be it via other non-OAT 
transporters, or nonspecific binding. Sweet et al. (2003) demonstrated nearly 
complete inhibition of ES via rOAT3 (~88%) in rOAT3 transfected oocytes. Self-
inhibition studies of ES accumulation further support that there may be other 
mechanisms than OAT transport for ES in this model as self-inhibition provided a 
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greater level of inhibition of ES than either probenecid treatment or reduction in 
temperature.  
It is important to note that recent studies have shown that OAT1 and 
OAT3 share similar mechanisms of action as dicarboxylate exchangers indirectly 
coupled to the sodium gradient (Sweet et al., 2003).  Since there is a great deal 
of overlap in substrate specificity with FL and PAH for OAT1 and OAT3, it cannot 
be definitively stated that both of these transporters are functional in this model 
based on data obtained for FL, PAH and ES accumulation by IRPTs.  Since both 
OAT1 and OAT3 may function via a similar mechanism (dicarboxylate exchange 
coupled to the sodium gradient), OAT1 and OAT3 may be sensitive not only to 
probenecid but also to ouabain as ouabain would affect the ability of the cells to 
maintain the sodium gradient necessary for transport via.  Whether ouabain 
interferes with OAT3 transport remains to be clarified in this model.  Cha et al. 
(2001) and Kusuhara et al. (1999) demonstrated that hOAT3 and rOAT3 
expressed in oocytes were not inhibited by ouabain.  This raises the question as 
to the driving force of OAT3 transport, whether OAT3 is also dependent on the 
Na+/K+ ATPase to maintain the sodium gradient for α-ketoglutarte, thus 
maintaining the α-ketoglutarte gradient to drive OAT3 transport.      
  
5.4 Acetamidophenyl glucuronide accumulation in IRPTs 
 
 OAT proteins, specifically OAT3, have been demonstrated to transport the 
glucuronide conjugate 17β-estradiol-d-17β-glucuronide.  In the IRPT model,  
OAT1 and OAT3 appear to be functional, transporting the known organic anions 
PAH (OAT1 and OAT3) and ES (OAT3).  Since glucuronide metabolites are 
organic anions at physiological pH, AG may be a substrate for the OAT 
transporters along the basolateral membrane of the renal PT.  This is the first 
time that IRPTs have been used to study the renal handling (secretory process) 
of a non-steroid glucuronide conjugate across the basolateral membrane of the 
renal PT.  While rOAT3 has been shown to transport estradiol glucuronide, it has 
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not been determined whether transport of estradiol glucuronide relies on the 
glucuronide moiety, or the steroid structure.  Previous studies that have 
assessed renal secretion of AG have used whole animal studies where the exact 
nature of the interaction of AG with renal OAT transporters cannot be 
determined.   Use of the IRPT model to study renal AG secretion allows for the 
assessment of the interaction of the AG molecule directly with the basolateral 
membrane, and thus, the transport proteins (OAT1 and OAT3 primarily) that are 
active along that membrane. 
 The accumulation of AG in IRPTs does not support protein-mediated 
uptake across the basolateral membrane.  While AG accumulation appears to 
have a time-dependent factor for accumulation, uptake can not be deminished by 
reduction of temperature to 4ºC.  Since uptake is not temperature dependent, it 
indicates that accumulation is not by a protein-mediated mechanism, and is more 
likely due to non-specific binding of the AG molecule to proteins along the tubule, 
or gradual accumulation into interstitial spaces between the proximal tubular 
cells, as rat PTs in general are noted to be significantly leaky.  In addition to not 
being temperature sensitive, self-inhibition studies using 1000-fold excess 
unlabeled AG did not show inhibition of AG accumulation as well.  This again 
demonstrates that apparent accumulation of AG is not due to a protein-mediated 
process.       
As it has been shown that AG accumulation does not appear to be a 
protein-mediated process, more specifically, it does not appear to be mediated 
by OAT proteins along the basolateral membrane of the IRPTs.  Cotreatment 
with AG was not able to inhibit the accumulation of the known OAs, FL, PAH or 
ES.  In addition, the accumulation of AG was not inhibited by the presence of ES. 
This demonstrates that AG does not appear to interact with the organic anion 
transporters OAT1 or OAT3 along the basolateral membrane in this model.  In 
addition, AG accumulation was also not found to be probenecid sensitive, again 
showing that AG does not appear to interact with OAT proteins in this model. 
This finding supports the finding by Duggin and Mudge (1975) that AG secretion 
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did not appear to be probenecid sensitive, while the secretion of the sulfate 
conjugate was.  Additionally, AG accumulation was not found to be influenced by 
metabolism (deconjugation) during incubation with IRPTs, as inhibition of β-
glucuronidase activity had no effect of AG accumulation.  The fact that inhibition 
of glucuronide deconjugation did not affect the results of AG accumulation in 
IRPTs shows that results obtained in these experiments are due directly to 
movement of the AG molecule and not deconjugation to the parent compound 
APAP.   
 
5.5 OAT1 and OAT3 studies in RCSs 
 
To assure that these studies were not compromised by inadequate activity 
of OAT proteins due to partial enzymatic digestion, a number of studies were 
also carried out in renal cortical slices.  Since AG appears to have extremely 
limited affinity for OAT transporters, it was necessary to demonstrate that 
collagenase digestion during the IRPT preparation did not have a detrimental 
effect on the activity of OAT transporters.  If the OAT transporters had become 
partially digested during the PT isolation procedure, their ability to interact with 
AG may have been greatly weakened, or collagenase digestion may have left 
fewer functional OAT transporters along the basolateral membrane of the 
tubules.  Partial digestion of membrane OAT proteins could potentially account 
for the apparent lack of AG transport by basolateral OAT proteins. 
Initial OAT transporting capabilities were tested with PAH and ES.  RCS 
demonstrated probenecid sensitive uptake of both PAH and ES, as well as time 
and temperature dependent accumulation of ES.  Time-dependent accumulation 
of ES by RCS follows a similar pattern as that determined by Sweet et al. (2003) 
and Hasegawa et al. (2003), with nearly linear uptake for the first 15 min and 
approaching steady state during the subsequent 45 min.  Additionally, uptake of 
ES was concentrative. These PAH and ES accumulation studies indicate that the 
OAT transporters are functional in this model and this model could be used to 
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study the interactions between OAT transporters and AG.  Probenecid inhibition 
of PAH uptake was approximately 80% which was very similar to inhibition in 
IRPTs (86%).  ES accumulation also appeared to show similar results as those 
found in IRPTs.  Inhibition of ES with probenecid demonstrated a 33% inhibition 
in RCSs, which is similar to the 41% inhibition found in IRPTs, indicating that the 
same mechanisms for ES accumulation are in place in both models.  
Interestingly, Sweet et al. (2003) demonstrated nearly twice the amount of 
inhibition of ES accumulation by probenecid (66%) in their rat renal cortical slice 
model.  This indicates that in the F344 rat, there may be a lower level of 
expression of OAT3 compared to other rat strains.  This was further supported by 
Western blot analysis, demonstrating only weak labeling for OAT3 in the F344 
kidney.   
 Temperature-sensitive uptake of ES in RCSs however, appeared quite 
different than in IRPTs.  In RCSs, reduction of temperature to 4ºC caused an 
80% reduction in ES accumulation, whereas in IRPTs, it only inhibited ES uptake 
by 38%.  This seems to indicate that there are also mechanisms of ES 
accumulation other than OAT3 in the RCS model, as in the IRPT model, that may 
be more sensitive to the effects of collagenase digestion.  While non-specific 
binding appears to be less in the RCS than in the IRPT model, the amount of ES 
accumulation accounted for by OAT3 (probenecid sensitive) appears to be 
similar.   Since these results in general appear similar to those found in IRPTs, 
the similarity of results in both RCS and IRPT models indicates that in the IRPT 
model, the digestion of proteins did not appear to affect OAT transporting 
capabilities.  Additionally, both the RCS and IRPT models appear to show similar 
capabilities for OAT transport and both are useful models for studying the effects 
of OAT transport on AG accumulation in the renal PT.   
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5.6 Acetamidophenyl glucuronide accumulation in RCSs 
 
 In renal cortical slices, AG accumulation appears to demonstrate possible 
protein-mediated transport.  Temperature-dependent uptake showed only a 30% 
decrease in AG accumulation, indicating that while it appears there may be some 
type of protein-mediated transport, there is still a large amount of AG 
accumulation that cannot be accounted for by a protein-mediated transport 
mechanism (e.g., non-specific binding).  However, while temperature and 
probenecid sensitivity can indicate a carrier-mediated OAT mechanism lack of 
self-inhibiton of AG accumulation is a more accurate determination of whether a 
carrier-mediated mechanism exists for AG accumulation. Self-inhibition studies 
did not demonstrate any inhibition of AG accumulation.  Lack of self-inhibition in 
AG accumulation provides a conflicting result to the temperature-dependent 
study.  Since self-inhibition failed to demonstrate inhibition of AG accumulation, 
this suggests that AG accumulation is actually not a protein-mediated process in 
this model and provides additional new in vitro data that may help to clarify in 
vivo results found by other investigators. 
 OAT proteins in RCSs do not appear to play a major role in AG 
accumulation at the basolateral membrane.   AG accumulation in RCSs was only 
weakly inhibited (22%) by treatment with probenecid, indicating a very weak 
interaction at OAT proteins.  More importantly, however, is the finding that 
cotreatment of AG with PAH or ES was not able to inhibit the accumulation of AG 
in RCSs.  This strongly suggests that AG does not interact with OAT1 and OAT3 
along the basolateral membrane.   These findings are similar to those found in 
IRPTs.   
 To assure that the results found in male F344 rats were not a strain-
dependent phenomenon (i.e., this strain may show a lower expression of OAT 
transporters than another strain), AG accumulation was also studied in RCSs 
from male SD rats.  AG has been suggested to undergo renal secretion in SD 
rats (Galinsky and Levy, 1981) as well as Wistar rats (Watari et al. 1983).  
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Findings in SD rats, however, did not support the findings of Galinsky and Levy 
(1981), and rather supported those found in this lab in F344 rats.  Decreasing the 
incubation temperature inhibited AG accumulation by only 29%, similar to that 
found in RCSs from F344 rats. Self-inhibition studies however, did not 
demonstrate any inhibition of AG accumulation.  This finding is also the same as 
the findings in F344 rat and reconfirms that AG accumulation is not via a protein-
mediated process.  AG accumulation in RCSs from SD rats was also not 
probenecid sensitive, indicating that AG accumulation is not via OAT proteins.  
The finding that AG is not transported by OATs was further verified by the fact 
that AG accumulation was not inhibited by the presence of PAH, a known OAT 
substrate.   These findings demonstrate that the results found in F344 rats are 
not a rat strain-dependent phenomenon, and AG accumulation does not appear 
to undergo protein-mediated transport, and more specifically does not interact 
with OAT transporters along the basolateral membrane of the renal PT in rat 
models.  
While AG does not appear to undergo transport in this model, it does 
appear to accumulate via some mechanism.  It is possible that this accumulation 
is actually by non-specific binding.  The studies that examined mannitol uptake 
actually further suggest that AG accumulation may be due to protein binding, as 
AG accumulation is much greater than mannitol accumulation, as can be seen by 
the time-dependent accumulation of each compound. Mannitol uptake, which 
measures the amount of substrate accumulation into water filled spaces is much 
smaller than that of AG, indicating that while AG may also accumulate in spaces 
between the cells in both IRPTs and RCSs, there appers to be another factor to 
AG accumulation that is not accounted for by transport or accumulation into 
spaces.  This mechanism is quite possibly via protein binding within the tissue, or 
intercalation of the APAP portion of the AG molecule into the surface of the IRPT 
or RCS, since APAP is lipid soluble and can undergo diffusion through 
membranes.  
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5.7 Interaction of glucuronide metabolites with OAT1 and OAT3 
 in IRPTs and RCSs  
 
 While studies using AG have indicated that this glucuronide metabolite 
does not interact with OAT1 or OAT3 transporters along the basolateral 
membrane, it was important to determine whether other glucuronide metabolites 
may interact with transporters along the PT basolateral membrane.  To study the 
potential interaction of other glucuronide metabolites with OAT, PAH was used 
as the prototypical substrate to determine whether testosterone glucuronide (TG) 
or methylumbelliferyl glucuronide (MUG) demonstrated any interaction with the 
transport of PAH (OAT1 and OAT3).  Since TG is a steroid, studies with TG may 
potentially help to elucidate the role of the steroid portion of the molecule in 
transport across the basolateral membrane vs. the glucuronide portion of the 
moiety, helping determine whether there is a difference in transport of steroid 
glucuronides and non-steroid glucuronides.  MUG is a non-steroid glucuronide 
metabolite of a similar molecular weight as AG (352.3 and 349.3, respectively). 
Studies conducted in both IRPTs and RCSs from F344 rats showed that these 
glucuronide metabolites do not appear to inhibit the accumulation of PAH along 
the basolateral membrane.  In these studies AG was also used as a secondary 
control for the effects of TG and MUG.  Treatment with TG and MUG were not 
statistically different from AG treatment, suggesting that TG and MUG may 
possibly interact along the basolateral membrane in a similar manner as AG.  
The fact that TG and MUG do not interfere with PAH accumulation suggests that 
these glucuronide metabolites do not interact with OAT proteins along the 
basolateral membrane of rat PTs, and may be transported or enter the proximal 
tubular cells by other mechanisms. 
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5.8 Conclusion 
  
The present study provides some of the first characterization of organic 
anion transport in the F344 rat.  Several studies have been conducted in SD and 
Wistar rats, but to date, information in the F344 model is lacking.  With the vast 
amounts of toxicity data for various compounds available in the F344 rat, it is 
important to more fully understand the function of transport mechanisms for 
potentially toxic compounds in the F344 rat model.  With the information gained 
in this study, it can help to better understand the mechanisms of cellular entry of 
potentially toxic compounds.  Uptake of organic anions appears to follow similar 
patterns in both IRPT and RCS from Fisher 344 rats.  In the IRPT model, 
collagenase digestion does not appear to have a negative impact on the ability of 
this model to demonstrate OA transport, as compared to the RCS model.  In 
general, the RCS model has some benefits over the IRPT model, mainly in 
technical simplicity.  While the isolation procedure for IRPTs is time consuming, 
the IRPT model offers a highly purified population of PT fragments that are useful 
for studying the impact of OAT transport in the proximal tubules handling of 
xenobiotics without the interference of other cell populations.  
 In terms of glucuronide transport, studies in IRPTs and RCSs from both 
F344 and SD rats suggest that glucuronide metabolites are not transported by 
the OAT proteins along the basolateral membrane of rat PTs.  While 
glucuronides are organic anions at physiological pH, it appears that the 
specificity of these compounds for OAT is extremely low, and if they have the 
ability to cross the basolateral membrane, it is via another mechanism.  It is also 
important to note that the findings presented in these studies do not support the 
findings found in the literature.  The findings of Duggin and Mudge (dog; 1975), 
Galinsky and Levy (SD rat; 1981), and Watari et al. (Wistar rat; 1983) have all 
suggested that the kidneys possess the ability to secrete glucuronide 
metabolites, and demonstrate renal secretion with AG.  The conflicting findings 
with those of Duggin and Mudge (1975) may be accounted for by species 
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differences in transporters along the basolateral membrane of the renal PT (rat 
vs. dog).  However, similar results were expected in these studies as those found 
by Galinsky and Levy (1981) and Watari et al. (1983), who suggested renal 
secretion of AG in rat models.  
Upon thorough study of the findings in these papers, there were a number 
of mechanistic discrepancies that may account for the conflicting results between 
their studies and those found in this present study.  During studies on the renal 
clearance of AG in SD rats conducted by Galinsky and Levy (1981), control rats 
for renal CLCR were not the same rats used for studying AG clearance.  Since AG 
clearance values and CLCR values were not conducted in the same rats at the 
same time, the actual CLCR values determined do not reflect any potential effects 
that AG itself may have on renal clearance, and therefore CLCR values.  
Therefore, the clearance of AG may have appeared to be higher than control 
renal creatinine clearance, thus indicating secretion. To accurately determine the 
true AG clearance in the model, AG treatment and clearance should have been 
conducted on the same rats at the same time, and control values should not 
have been determined in a separate group of rats.  A similar discrepancy also 
occurs with the study conducted in Wistar rats by Watari et al. (1983).  In the 
study conducted by Watari et al. (1983) control CLCR values used for comparison 
with AG clearance values were those determined by Galinsky and Levy (1981) in 
SD rats.  Thus, the same control issues exist. CLCR values and AG clearance 
values in the study by Watari et al. (1983) were not only measured in separate 
rats at a separate time, but data was collected in a different rat strain as well. 
Making the comparison between CLCR in SD rats from one experiment to AG 
clearance in Wistar rats in a separate experiment, under likely different laboratory 
conditions, compromises the validity of the results.  Therefore, what Watari et 
al.(1983) demonstrate as secretion of AG, based on AG clearance values in 
Wistar rats being higher than CLCR in SD rats, cannot be accurate.   
   The current findings in the literature on the renal secretion of glucuronide 
metabolites remain limited.  AG has been used in a number of studies as it is a 
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common, renally excreted metabolite of acetaminophen.  While the studies 
mentioned above suggest that the kidney can secrete AG, other conflicting 
studies suggest that it is not secreted but rather is excreted in the urine solely via 
glomerular filtration (Heckman et al. 1986).  The findings in the present study 
support the role for glomerular filtration rather than secretion of this glucuronide 
metabolite (AG) along the basolateral membrane of the PT.  Specifically, AG 
does not appear to be a substrate for renal basolateral membrane OAT proteins 
in the F344 model.  The overall contribution of OAT in the basolateral membrane 
transport of AG (and potentially other glucuronide metabolites, as suggested by 
OAT inhibition studies with TG and MUG), is also minimal in the F344 rat.  
Furthermore, while there appears to be tubular accumulation of AG, the 
accumulation of AG does not appear to be due to a non-OAT, protein carrier-
mediated mechanism along the basolateral membrane.  Thus, rat renal 
basolateral proximal tubular cells do not appear to facilitate the transport of 
glucuronide conjugates, and thus do not appear to contribute to the renal 
secretion of glucuronide conjugates by transport mechanisms along the 
basolateral membrane. If uptake with subsequent secretion is occurring across 
the basolateral membrane, it is by a mechanism other than a protein-mediated or 
OAT transport and other mechanisms of flux of AG across the basolateral 
membrane need to be evaluated.  
 
5.9 Future Directions 
 
 To gain a more complete picture of the renal secretion of AG, and 
potentially other glucuronide metabolites, the other type of information that needs 
to be gathered is an accurate measurement of the renal secretion of AG in a rat 
model.  Because the papers mentioned in this discussion failed to accurately 
establish the values of AG clearance, it is difficult to determine whether the data 
truly reflect AG secretion.  Based on the findings of this current study, it is 
believed that their results do not reflect true AG secretion.  Accurate 
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determination of AG secretion by the rat kidney could be accomplished by 
repeating data collection for AG clearance in the whole animal with inulin 
clearance values being measured in the same animals at the same time as 
APAP or AG clearance.  These data would help to clarify the discrepancy 
between the studies discussed and this one.   
 As far as determining further the potential role for OAT transporters in the 
uptake of glucuronide conjugates, particularly AG, the simplest way to 
accomplish this would be to use rOAT1 and/or rOAT3 transfected cells (i.e., 
oocytes or LLC-PK1 cells).  Transfected cell models, used frequently in OA 
uptake studies, would allow for direct contact between the selected transporter 
without interference from other transport proteins that are present in the 
basolateral membrane of IRPT and RCS models.  By directly treating a cell 
expressing rOAT1 or rOAT3 with AG, the uptake of AG could be determined, 
assessing the contribution of each transporter in the renal handling (secretion) of 
AG. 
 Another potential for studying further glucuronide transport would be the 
use of cultured cells.  The use of primary cell culture could provide crucial 
evidence for the renal handling of these conjugates as cells grown on permeable 
membranes would allow for a dynamic system from which data could be obtained 
from both the basolateral and luminal membranes of the renal PT.  Where this 
study in IRPT and RCS demonstrated that there did not appear to be a secretory 
mechanism for AG, it does not address the potential for luminal uptake of the AG 
compound and potentially other glucuronide conjugates.  Primary cultures of 
renal PTs from F344 rat was the original aim of this study.  However, a number of 
contamination conditions led to the use of IRPTs and RCSs to study the 
basolateral uptake of AG.  Initial characterization of PT cells grown in culture 
demonstrated that they were of PT origin (based on enzymatic analysis as in the 
IRPT model) and should, therefore, have been capable of demonstrating OAT-
mediated transport.  In the right setting, primary cultures would have provided a 
system similar to the IRPT model (maintenance of cell-to-cell contact and 
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communication, maintained cellular metabolism and transport) with the benefit of 
being able to more completely study how the renal PT handles glucuronide 
conjugates.  Again, in addition to the basolateral membrane, the luminal 
membrane would have also been intact and functional, providing a much more 
dynamic model for studying the transport of AG. 
 Another important study that would greatly clarify the findings found in the 
present study would be to examine the nature of the apparent protein binding of 
AG.  Whether it could be done immunohistochemically or by other means of 
studying protein binding, it would allow for greater understanding as to the 
disposition of the AG molecule in the IRPT and RCS model.    
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Appendix 
 
 
        
         Perfusion Buffer A     
    
pH 
7.36    
  Chemical   Concentration      
 NaCl  115.0 mM    
 KCl  5.0 mM    
 NaHCO3 25.0 mM    
 NaH2PO4 2.0 mM    
 MgSO4●7H2O 1.0 mM    
 Alanine  1.0 mM    
 Glucose  5.0 mM    
 Deferoxamine 0.1 mM    
 Mannatol 25.0 mM    
 Lactate  4.0 mM    
 Dextran  0.6 % (w/v)    
 Penicillin G 100 units/ml    
  CaCl2   1.0 mM     
 bubble with 95% O2/ 5% CO2 for 30 min    
        
 
 
 
        
         Perfusion Buffer B     
        
  Chemical Concentration    
  Collagenase 130 units/ml     
  SBTI   0.01 % (w/v)     
        
 diluted in 25 ml Perfusion buffer A    
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          Incubation Buffer A    
    pH 7.36    
  Chemical Concentration    
 NaCl  115.0 mM    
 KCl  5.0 mM    
 NaHCO3 25.0 mM    
 NaH2PO4 2.0 mM    
 MgSO4●7H2O 1.0 mM    
 Alanine  1.0 mM    
 Glucose  5.0 mM    
 Deferoxamine 0.1 mM    
 Malic acid 5.0 mM    
 Butyric acid 2.0 mM    
 Lactate  5.0 mM    
 CaCl2  1.0 mM    
  Penicillin G 100 units/ml     
 bubble with 95% O2/ 5% CO2 for 30 min    
        
 
 
 
        
          Incubation Buffer B    
        
  Chemical   Concentration      
 Collagenase 150 units/ml    
 SBTI  0.02% (w/v)    
 BSA  0.2% (w/v)    
  Dnase   70 units/ml     
 diluted in 50 ml Incubation buffer A    
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        Krebs-Henseleit Concentrate (KHB) (10x)   
        
  Chemical    Concentration      
 NaCl  118.0 mM    
 KCl  4.8 mM    
 NaHCO3 0.12 mM    
 MgSO4●7H2O 25.0 mM    
  Hepes   25.0 mM     
 bubble with 95% O2/ 5% CO2 for 30 min    
 
 
 
 
 
 
 
        
 Krebs-Henseleit Buffer (1x)    
    pH 7.36    
  Chemical   Amount      
 KHB 10x 20.0 ml    
  dH2O   180.0 ml     
 bubble with 95% O2/ 5% CO2 for 30 min    
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 Transport Buffer #1 (tubules)    
295 ± 5 mOsm/kg  pH 7.4    
  Chemical   Concentration      
 NaCl  110.0 mM    
 NaHCO3 25.0 mM    
 KCl  5.0 mM    
 NaH2PO4 2.0 mM    
 MgSO4●7H2O 1.0 mM    
 CaCl2  1.8 mM    
 Sodium acetate 10.0 mM    
 Glucose  8.3 mM    
 Alanine  5.0 mM    
 Glycine  0.9 mM    
 Lactate  1.5 mM    
 Malic acid 1.0 mM    
  Sodium citrate 1.0 mM     
 bubble with 95% O2/ 5% CO2 for 30 min    
        
        
        
 
 
 
       
 Transport Buffer #2 (slices)    
    pH 7.5    
  Chemical   Concentration      
 NaCl  120.0 mM    
 KCl  16.2 mM    
 CaCl2  1.0 mM    
 MgSO4●7H2O 1.2 mM    
  NaH2PO4 10.0 mM     
 bubble with 95% O2/ 5% CO2 for 30 min    
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 45% Percoll Density Gradient    
    pH 7.36    
  Chemical Amount      
 KHB 10x 6.0 ml     
 dH2O  27.0 ml     
  Percoll   27.0 ml      
 bubble with 95% O2/ 5% CO2 for 30 min    
 mixed in exact order      
        
 
 
 
 
        
        
 Alkaline Phosphatase Assay    
  Procedure 104     
             
             
Stock substrate solution      
 40 mg capsule 10 ml H2O    
        
p-Nitrophenol standard solution     
 0.5 ml p-nitrophenol standard solution    
 QS to 100 ml with 0.02 N NaOH    
        
0.02 N NaOH       
  0.8g NaOH 1000 ml H2O    
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     Hexokinase Assay     
        
             
 Substrate solution (3.24x)     
 Glucose  0.88 g     
 MgCl2●6H2O 1.32 g     
 Na2EDTA 0.121 g     
 Tris/HCl   5.1 g     
  100.0 ml adjust pH to 7.6    
        
 NADP+  (3.24x)      
 8.1 mg/ 5.0 ml H2O     
        
 ATP   (3.24x)       
 0.267 g/ 3.0 ml H2O     
        
 G6PDH   (type VII, Sigma)     
 Stock = 350 units/mg; 332.5 units/ml   
        
   Assay:      
           
  Chemical   Concentration     
 Glucose  15.0 mM    
 MgCl2●6H2O 20.0 mM    
 Na2EDTA 10.0 µM    
 Tris/HCl  0.1 M    
 NADP+  0.67 mM    
 ATP  2 units/ml    
  G6PDH    50 mM    
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          Bradford Reagent     
        
  Chemical   Amount     
 Coomassie 100.0 g    
         Brilliant Blue     
 95% EtOH 50.0 ml    
 85% Phosphoric 100.0 ml    
          acid       
  QS to 1L with H2O      
 
 
 
 
 
 
        
  p-[glycyl-14C]-aminohippuric acid (PAH)  
        
Stock Solution 50 µCi           
1 add 375 µl dH2O to bottle (+ 2 drops 1 N NaOH)  
2 transfer to scintillation vial     
3 was bottle 1x with 375 µl H2O  and transfer to scintillation vial 
        
 1.25 ml = 50 µCi/1.25 ml= 40 µCi/ml   
        
Working solution 20µCi/ml   10µCi/ml   
        
 250 µl stock PAH solution  
100 µl stock PAH 
solution 
 250 µl H2O    
300 µl 
H2O   
 500 µl = 20 µCi/ml  400 µl = 10 µCi/ml 
        
        
Stock cold PAH        
 14 mM       
 27.188 mg / 10 ml H2O     
 several drops of 1N NaOH added    
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70 µM working solution      
 1.25 ml stock 14C-PAH     
 
1.25 ml stock 
cold PAH       
 2.5 ml 7 mM PAH @ 20 µCi/ml    
                
        
 
 
 
 
 
 
 
 
 
        
           4-acetamidophenyl-ring-UL14C β-D-glucuronide sodium salt (AG) 
        
Stock Solution 250 µCi           
1 add 3.95 µl dH2O to bottle     
 6.25 ml = 250 µCi/6.25 ml= 40 µCi/ml   
        
Working solution 20µCi/ml   10µCi/ml   
        
 250 µl stock AG solution  
100 µl stock AG 
solution 
 250 µl dH2O    
300 µl 
dH2O   
 500 µl = 20 µCi/ml  400 µl = 10 µCi/ml 
        
Assay concentration      
 1:100 dilution of working solution yields 0.1 or 0.2 µCi/ml 
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  D-[1-3H(N)]-mannitol (MN)    
        
Stock Solution 250 µCi           
1 add 0.25 ml dH2O to vial     
2 transfer to scintaillation vial labeled stock   
3 wash vial 4x with 0.5 ml dH2O and add to stock  
        
 250 µCi/ 2.5 ml = 100 µCi/ml    
        
Working solution 10µCi/ml      
        
 50 µl stock MN solution     
 450 µl dH2O       
 500 µl = 10 µCi/ml     
        
Assay concentration      
 1:100 dilution of working solution yields 0.1 or 0.2 µCi/ml 
                
        
        
        
        
     [6,7-3H(N)]-estrone sulfate, ammonium salt (ES)  
        
Stock Solution 50 µCi           
1 Stock solution at 50 µCi/ml    
        
        
        
Working solution 10µCi/ml      
        
 50 µl stock ES solution     
 2.450 ml dH2O       
 3 ml = 15 µCi/ml      
 ***standards of working soln.= actually at 20 µCi/ml  
Assay concentration      
 1:100 dilution of working solution yields 0.2 µCi/ml  
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Fluorescein 400uM       
        
 1.5 mg/ 10 ml H2O     
        
        
Probenecid 100mM       
        
 28.54 mg / 1.0 ml      
 add 1 N NaOH dropwise until in solution   
 QS to 1 ml with H2O     
        
p-aminohippuric acid (PAH) 100mM     
        
 19.42 mg/ 1 ml      
 add 1 N NaOH dropwise until in solution   
 QS to 1 ml with H2O     
        
Ouabain 10mM         
        
 1.82 mg/ 250 µl H2O (warmed)    
  protected from light     
        
        
Saccharic acid 1,4-lactone 2M     
        
 38.0 mg/ 100 µl H2O     
        
 20 mM :       
 30µl 2M stock/3 ml     
        
 10 mM :       
 15µl 2M stock/3 ml     
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4-acetamidophenyl-β-D-glucuronide sodium salt (AG)    
        
 500 mM       
 70 mg/ 400 µl H2O     
        
 100 mM       
 35 mg/ 1 ml H2O     
        
 50 mM       
 17.44 mg/ 1 ml H2O     
        
 20 mM       
 80 µl 50 mM AG + 180 µl H2O    
        
        
Estrone Sulfate (ES)        
  protected from light     
 40 mM       
 4.7 mg/ 360 µl 100% EtOH     
  warmed      
 25mM       
 18.6 mg/ 2 ml 100% EtOH     
  warmed      
 10 mM       
 3.7 mg/ 1 ml 100% EtOH     
  warmed      
        
        
Testosterone Glucuronide (TG) 16.7 mM    
        
 10 mg/ 1230 µl 66% EtOH     
        
        
Methylumbelliferyl-β-D-glucuronide 50 mM    
        
 8.8 mg/ 500 µl 50% EtOH     
  warmed      
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Dihydroxyepiandrosterone sulfate (DHEAs) 100 mM   
        
 3.9 mg/ 100 µl H2O     
  warmed      
        
Diclofenac (DC)          
         
 50 mM       
 15.8 mg/ 1 ml H2O     
        
 20 mM       
 80 µl 50 mM DC + 180 µl H2O    
        
        
4-Acetamidophenol (APAP)     
        
 50 mM       
 7.6 mg/ 1 ml H2O     
        
 20 mM       
 80 µl 50 mM APAP + 180 µl H2O    
        
        
Benzylpenicillin (PG) 100 mM     
        
 35.6 mg/ 1 ml H2O     
        
        
Pentobarbital Sodium 50 mg protein/ml     
        
 500 mg/ 10 ml H2O     
        
Heparin           
        
 22.7 mg/ 10 ml 0.9% saline    
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0.9% Saline         
        
 9 g NaCl/ 1L H2O     
        
        
3M Perchloric Acid       
        
 50 ml 70% perchloric acid     
 qs 250 ml with H2O     
        
Potassium Phosphate Buffer (KH2PO4)monobasic - HPLC   
        
 13.6 g/ 1.0 L H2O     
  pH 6.0,  filtered     
 
 
 
 
 
Solutions for Gel Preparation and Western Blot 
 
† Solutions were prepared by Dr. Kelley Kiningham 
Cell Fractionization 
Homogenization Buffer (25 ml)                                                                         
20 mM HEPES .........................................................................5 ml x 100 mM 
5 mM EGTA..............................................................................1.25 ml x 0.1M 
10 mM 2-mercaptoethanol (2ME)*...........................................................20 ul 
1 ug/1 ml pepstatin........................................................... 25 ul of (1 mg/1 ml) 
1 ug/1 ml leupeptin........................................................... 20 ul of (1 mg/1 ml) 
1 ug/1 ml aprotinin............................................................ 20 ul of (1 mg/1 ml) 
1 mM phenylmethylsufonyl fluoride (PMSF) .............................500 ul x10mM 
Diluted to 25 ml with deionized water 
 * 2ME was not included for nonreduced protein samples. 
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Gel Preparation 
 
30% Acrylamide, 0.8% Bisacrylamide†   (neurotoxic) 
60 g acrylamide  
1.6 g bisacrylamide 
dilute to 200 ml with water 
Use 37oC water bath to dissolve solids if necessary; sterile filter into foil 
wrapped or brown bottle and store at 4oC. 
 
5X Separation Buffer† 
56.76 g TRIS 
1.25 g sodium dodecyl sulfate (SDS) 
pH to 8.8 
Diluted to 250 ml with DI water 
 
5X Stacking Buffer†  
37.85 g TRIS 
2.5 g SDS 
pH to 6.8 
Diluted to 500 ml with DI water 
 
10% Ammonium Persulfate (APS)   (prepared fresh daily) 
0.1 g APS in 1 ml deionized water 
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2X Sample Buffer† 
0.76 g TRIS (125 mM) 
2 g SDS (13.9 mM or 4%) 
10 ml Glycerol (20%) 
5 ml 2-mercaptoethanol (2ME)* (10%) 
pH to 6.8 
Diluted to 50 ml with DI water 
Bromophenol blue (1-2 mg) added until deep blue color obtained 
Sample Buffer was prepared without 2-ME which was added just before use 
(1:10).  Note: If 2X sample buffer is prepared without 2ME, it can remain at 
room temperature. 
* 2ME was not included for nonreduced protein samples. DI water was 
substituted for 2ME. 
 
Separation Gel     8 % Gel (ml) 12.5% Gel  (ml) 
5X Separation Buffer  7.0   7.0  
30% Acrylamine, 0.8% Bis  9.3   14.6 
H2O  18.5  13.2 
10% Ammonium Persulfate*  0.15  0.15         
TEMED  0.025  0.025  
Total  35.0 ml  35.0 ml 
N-butanol  (~2 ml) 
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Stacking Gel   ml 
5X Separation Buffer   3.0     
30% Acrylamine, 0.8% Bis   1.5    
H2O   10.5    
10% Ammonium Persulfate*   0.075          
TEMED   0.015  
After rinsing n-butanol from the set separation gel with a large volume of 
water then carefully drying the mold, Stacking Gel was prepared and 
poured over the separation gel then left at room temperature for one hour to 
set. 
 
10X Electrode Buffer† (Dilute 1:10 prior to use) 
30.3 g TRIS (250 mM) 
144 g Glycine (1.92 M) 
10 g SDS (34.68 mM) 
pH to 8.3 
Diluted to 1 L with deionized water 
 
Solutions Needed for Western Analysis 
 
Transfer Buffer† 
12.12 g TRIS 
57.6 g glycine  
800 ml methanol 
3.2 L distilled water 
Solution should be precooled for high voltage transfers. 
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Ponceau S† 
g Ponceau S 
5 ml acetic acid 
diute to 100 ml with deionized water 
Solution is stored in a brown bottle and may be reused. 
 
10X TBS† (Dilute 1:10 prior to use) 
12.12 g TRIS  
87.66 g NaCl 
pH to 8.0 
Dilute to 1 L with deionized water 
 
1X TBST 
Add 500 µl Tween-20 to 1 L 1X TBS 
 
Blocking solution (Blotto A) 
5% non-fat dry milk in TBST (2.5 mg to 50 ml) 
Prepared fresh daily and refrigerated. 
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